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Abstract 
Background: Influenza is an important global cause of morbidity and mortality.  
Though some cardiac complications of influenza, such as myocarditis, are well-
recognised, its role as a trigger for acute cardiovascular events is less clear.  
Improved understanding of this relationship will add to evidence to support 
appropriate prevention and treatment strategies. 
Methods: I investigated evidence that influenza and acute respiratory infections 
could trigger acute myocardial infarction (AMI) through a systematic literature 
review and meta-analysis (chapter 2) and original research studies (chapters 3-
7).  These were an ecological weekly time series study using Poisson regression 
models adjusted for temporal and environmental confounders in England & 
Wales and Hong Kong (chapter 3); two self-controlled case series analyses using 
the General Practice Research Database linked to influenza surveillance data 
(chapter 4) and to cardiac disease registry and hospitalisation data (chapter 5); a 
case control study in AMI patients and surgical controls during the 2009 influenza 
pandemic in London (chapter 6); an exploratory mechanistic study (chapter 7).        
Key findings: 
 Acute respiratory infections, and seasonal influenza, triggered AMI  
 A triggering effect may be greater for influenza than for other respiratory 
infections (p=0.011) 
 AMI risk was highest in the first three days after acute infection – adjusted 
incidence ratio 4.19 (95% CI 3.18-5.53) – and persisted for around 28 days 
 The proportion of AMI deaths due to seasonal influenza ranged from 3-5%, 
rising to 13% in periods of highest influenza circulation 
 The relative risk of AMI after acute respiratory infection was highest in 
people aged ≥80 years 
 Influenza vaccination protected against some adverse cardiac outcomes in 
people with existing cardiovascular disease 
Conclusions: Reducing the burden of influenza would benefit cardiovascular 
health.  Questions remain about key groups to target, as well as the optimal 
type and delivery of interventions to reduce influenza-associated AMI risk. 
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1. Key features of influenza and acute myocardial infarction 
relevant to the research aims 
 
1.1 Description of chapter contents 
 
In this chapter I outline the background to the hypothesis that acute respiratory 
infections such as influenza can trigger acute myocardial infarction (AMI). 
Seasonality, epidemiology, clinical characteristics, diagnosis and control of 
influenza are described with an emphasis on cardiac complications.  The focus is 
on aspects of influenza relevant to the research rather than on providing a 
comprehensive overview of influenza.  The epidemiology of AMI is described 
including an introduction to ‘traditional’ vascular risk factors and their potential 
interaction with triggers of atherosclerotic plaque instability such as infections.  
Key points at which a relationship with influenza might be relevant for AMI 
management are highlighted.  The chapter ends with an overview of the thesis 
aims and objectives. 
 
1.2 Infection as a trigger for acute myocardial infarction  
 
1.2.1 Introduction to hypothesis 
 
Various socio-demographic, lifestyle and clinical risk factors for cardiovascular 
disease have been well-documented over recent decades1–3.  Nevertheless people 
without these traditional factors continue to experience AMI, which has prompted 
a search for novel risk factors4.  A relationship between infection and 
cardiovascular disease was first proposed over a hundred years ago; William 
Osler writing in 1908 suggested that acute infections were an important factor in 
the ‘causation’ of atherosclerosis5.  As atherosclerosis was considered to be a 
disorder primarily of lipid storage until the 1970s6, links with infection seemed 
biologically implausible.  Now there is widespread recognition of the central role 
played by inflammation in the pathogenesis of ischaemic heart disease at all 
stages from early atherogenesis to downstream thrombotic events7.  Infections 
such as influenza act as acute inflammatory stimuli8 so may plausibly interact 
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with ongoing systemic inflammatory processes to trigger acute cardiovascular 
events.  The increase in both influenza and AMI incidence during cold winter 
months combined with the recognition of cardiac complications among influenza 
patients stimulated interest in influenza infection as a potential AMI trigger. 
 
1.2.2 Importance 
 
Ischaemic heart disease, predominantly due to AMI, is the world’s leading cause 
of death.  It is projected to remain so in 20209: the decline in incidence and case 
fatality of AMI in many developed countries over recent decades10,11 is countered 
by the epidemiological transition occurring in some developing nations as well as 
by population ageing, rising obesity levels and persisting health inequalities.  
Each year a large number of non-respiratory deaths are attributed to influenza, 
for example from cardiovascular causes, and this merits further explanation.  If a 
causal association were demonstrated between influenza and AMI, this could 
have implications for vaccine and antiviral policies as well as on influenza 
pandemic preparedness.  The 2009 influenza A H1N1 pandemic was a timely 
reminder of the clinical and public health importance of this area and the need for 
informed policy and emergency planning decisions to be taken on a firm evidence 
base. 
 
1.3 Influenza epidemiology, clinical features, diagnosis & control 
 
1.3.1 Seasonality  
 
Seasonal epidemics of human influenza virus infection are caused either by 
influenza A (divided into subtypes H3N2 or H1N1 based on the composition of 
the two main surface glycoproteins haemagglutinin and neuraminidase) or 
influenza B12.  In temperate climates, outbreaks tend to be dominated by type A 
viruses with type B following later in the season13, which typically lasts from 
around November until March.  Epidemics recur annually because antigenic 
variation (or ‘drift’) in viral surface glycoproteins allows people who have been 
infected previously to become susceptible14.  In sub-tropical zones such as Hong 
Kong two influenza seasons rather than one have been reported and in some 
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equatorial regions such as Singapore viruses have been isolated all year round15.  
An influenza pandemic, characterised by worldwide spread of a previously 
unknown virus, may occur outside of the usual circulation period for influenza.  It 
usually requires antigenic shift in influenza A virus, which may result from 
genetic reassortment between several subtypes of influenza affecting one host, to 
produce a novel antigenic variant16. 
 
1.3.2 Clinical characteristics  
 
Estimates of the proportion of asymptomatic seasonal influenza infections vary 
widely from around 25-75% of infections17,18, although figures of 33-50% are 
typically used for mathematical modelling studies19.  Symptomatic infection is 
characterised by an abrupt onset of feverish illness associated with respiratory 
tract symptoms such as cough and sore throat as well as systemic features such as 
myalgia and fatigue.  While most cases of influenza are mild and self-limiting, 
complications such as secondary bacterial infections eg pneumonia or otitis 
media occur in a small proportion of people.  These are usually people at the 
extremes of age, pregnant women or those with chronic medical conditions20.  
The likelihood of residual cross-immunity from previous influenza infections is 
directly proportional to age (so attack rates are generally highest in children)21.   
Although children and the elderly have the highest rates of hospitalisations due to 
influenza, mortality from seasonal influenza in people aged over 60 years is 
approximately 10 times higher than in young children22.  Deaths and more severe 
complications tend to be associated with the influenza A H3N2 subtype23, while 
influenza B viruses sometimes produce clusters of unusual conditions such as 
myositis24.   
 
In a pandemic situation, profiles of those affected can change dramatically as 
there is little pre-existing immunity in a population.  For example in the 1918 
influenza A H1N1 ‘Spanish flu’ pandemic an unusually high case fatality was seen 
in young adults25.  People of a similar age distribution were affected, though much 
less severely, by the 2009 influenza A H1N1 pandemic.  In the other two modern 
day pandemics of 1957 and 1968, patterns of mortality were found to resemble 
more closely those seen with seasonal influenza25,26.  
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1.3.3 Cardiac effects  
 
In acute influenza infection, cardiac pathology is thought to result either from 
direct effects of the virus on the myocardium or through exacerbation of 
underlying cardiovascular disease27.  Influenza-associated myocarditis, 
characterised by focal infiltration of inflammatory cells, interstitial oedema and 
cardiac necrosis, may be present in up to 10% of patients infected with influenza 
28.  It is, however, frequently undiagnosed and may be masked by respiratory 
symptoms.  While the majority of cases are mild and resolve spontaneously, 
influenza-associated myocarditis can precipitate congestive cardiac failure and 
even death in some cases28.  The fact that excess hospital admissions and deaths 
occur during the influenza season due to cardiovascular (rather than respiratory) 
causes is also well documented29,30.  New cardiac arrhythmias, incipient cardiac 
failure and acute coronary syndromes have been demonstrated in studies of 
patients with community-acquired pneumonia31.  Nonetheless the relationship 
between influenza infection and AMI is less clear and provides the focus for the 
following systematic literature review (chapter 2) and research studies (chapters 
3-7).  Though other acute cardiovascular events such as thrombotic stroke or 
acute limb ischaemia might also be triggered by influenza this thesis focussed on 
AMI, to allow in-depth study of one important outcome. 
 
1.3.4 Diagnosis and treatment  
 
The majority of influenza cases are not formally diagnosed, either due to their 
asymptomatic nature or failure to seek medical attention.  Patients who do 
present to primary care are most likely to be diagnosed using a clinical algorithm.  
For example general practitioners would have a high index of suspicion if a 
patient presented with an influenza-like illness (ILI – defined by the World Health 
Organization as acute fever>38˚C and cough or sore throat in the absence of 
another diagnosis) during time periods when influenza is circulating.  This 
definition has modest sensitivity (around 65%) and specificity (67%) for 
diagnosing true influenza infections32.  Clinical symptoms of influenza are 
mimicked by many other respiratory viruses including rhinovirus, coronavirus, 
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respiratory syncytial virus and parainfluenza virus33.  The positive predictive 
value of an ILI diagnosis varies markedly depending on prevalence of circulating 
influenza, and can be up to 70-80% at times of peak circulation34.  Other factors 
affecting the accuracy of ILI for diagnosing influenza are discussed in chapter 6, 
section 6.2.4, p153.  Laboratory testing of respiratory or serum specimens tends 
to be done on hospitalised cases and is commoner as symptom severity increases 
or complications develop.  It is described in chapter 6, sections 6.2.5-6, p153-154.  
 
Most treatment for influenza is supportive, involving for example rest, 
rehydration and symptomatic relief such as use of antipyretics.  Antiviral drugs 
(which may be of two classes – neuraminidase inhibitors such as oseltamivir and 
adamantanes such as amantadine12) – tend to be reserved for patients at high risk 
of complications from seasonal influenza.  In a pandemic situation they may be 
used more widely for both prophylaxis and treatment to limit transmission.     
 
1.3.5 Impact on population morbidity and mortality 
 
In England & Wales estimates from mathematical models suggest that there are 
18,500-24,800 deaths, 19,000-31,200 hospital admissions and 779,000-1,164,000 
general practice consultations attributable to seasonal influenza each year35.  
Worldwide, there may be up to 3 to 5 million cases of severe illness and 250,000 
to 500,000 deaths annually12, mainly among high risk groups.  Direct costs to 
health services (estimated as $10.4billion USD annually in the USA36) represent 
only part of the economic impact of influenza.  Loss of life and days of work or 
school lost to illness lead to substantial indirect costs through projected loss of 
earnings (amounting to an average of $16.3 billion USD annually in the USA36).  
The impact of influenza is due in part to its global nature: it affects all age groups, 
occurs worldwide and recurs in individuals37.  The effect of a pandemic is more 
variable depending on strain type and illness severity but the potential for 
overwhelming of clinical services, large numbers of deaths and widespread 
disruption to services and infrastructure necessitates contingency planning at 
local, national and international levels. 
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1.3.6 Transmission and prevention 
 
Influenza is a highly contagious disease37.  Transmission occurs through several 
routes including direct physical transfer of micro-organisms from infected 
individuals to others, indirect transfer via an intermediate object such as 
contaminated hands or surfaces, transmission via large droplets (≥5μm diameter) 
generated through coughing, sneezing or talking and airborne transmission via 
small aerosolised particles38.  Interventions to prevent or reduce influenza spread 
may be non-pharmaceutical or pharmaceutical such as vaccine and antiviral 
drugs.  Non-pharmaceutical measures, which include hand and respiratory 
hygiene, facemask use, social distancing, school closures and screening at entry 
ports, will not be discussed further here. 
 
Influenza vaccination (using trivalent inactivated vaccine or live attenuated 
influenza vaccine) is currently an effective way to prevent disease and reduce the 
incidence of severe complications.  A new vaccine is formulated every year whose 
composition is based upon the three most representative influenza strains 
circulating in humans identified through the World Health Organization (WHO) 
Global Influenza Surveillance Network12.  Vaccine effectiveness ranges from 60 to 
80% in healthy adults39 and is highest when circulating strains are well-matched 
with those in the vaccine.  Protection against infection is lower in the elderly but 
immunisation has been shown to reduce the incidence of severe complications, 
hospitalisations and deaths in this group40.  In England, the Department of Health 
recommends that for the 2012/13 influenza season vaccination is offered to the 
following groups: all people aged 65 years and over; patients aged six months or 
older with chronic respiratory, cardiac, renal, liver or neurological disease, 
diabetes or immunosuppression, all pregnant women, all residents of long-stay 
residential care homes, carers and health and social care workers40. 
 
1.3.7 Current relevant issues in vaccine research and policy  
 
Active areas of influenza vaccine research include the search for the ‘holy grail’ of 
a universal influenza vaccine that provides lasting protection against all strains as 
well as finding optimum methods to formulate and deliver existing vaccines eg 
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intra-nasally rather than by needle-based injection.  Aside from debates about 
vaccine effectiveness, influenza vaccine uptake in people with chronic diseases in 
England tends to be low – it was 51.6% in the 2011/12 influenza season41 – 
limiting its potential to prevent influenza and its complications.  The Department 
of Health has set an ambitious target of increasing vaccine uptake in people aged 
under 65 years with chronic diseases to 75% by 2013/1442.  It is hoped that 
vulnerable unvaccinated people in the community will also be protected 
indirectly by the introduction of a vaccination programme for healthy children in 
England from 2014, following recommendations by the Joint Committee on 
Vaccination and Immunisation (an expert advisory committee to the 
Government).  The evidence that influenza vaccine may offer protection against 
acute cardiovascular events (hypothesised to occur either directly through 
reducing the risk of influenza, or indirectly through reducing influenza 
complications such as dehydration or bacterial super-infection43) will be critically 
reviewed in chapter 2.  
 
1.4 Acute myocardial infarction epidemiology, risk factors, definition 
& management 
 
1.4.1 Epidemiology  
  
Acute myocardial infarction is a major cause of morbidity and mortality 
worldwide, with >7 million people experiencing an AMI each year44.  In general 
AMI incidence increases with age and it is more common in men.  Substantial 
geographic variation is found in both age and gender distributions of AMI: in the 
global INTERHEART study the median age of onset of first AMI was 51 years in 
the Middle East and 63 years in China; the proportion of male cases ranged from 
68% in Central and Eastern Europe to 85% in South Asia3.  Around 80% of the 
global burden of cardiovascular disease occurs in low- and middle-income 
countries where healthcare infrastructures are less developed3.  Progressive 
urbanisation in these settings has led to increasing rates of obesity and diabetes 
and an emerging epidemic of atherosclerotic coronary artery disease44.  Any 
intervention to prevent influenza that indirectly protects against AMI might 
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feasibly have a greater impact in the developing world where access to cardiac 
catheter laboratories and specialist cardiac services is limited. 
 
1.4.2 Risk factors for atherosclerosis and acute myocardial infarction 
 
‘Traditional’ cardiovascular risk factors were first investigated comprehensively 
through a landmark population-based cohort study, founded in Framingham, 
Massachusetts in 194945.  Hypertension, hypercholesterolaemia, cigarette 
smoking and overweight/ obesity were clearly established as risk factors for 
development of atherosclerosis.  Other factors including diabetes mellitus, 
psychosocial stress, physical inactivity, lack of fruit and vegetable consumption 
and extremes of alcohol intake have since been added to this list supported by 
evidence from various prominent studies2,3,46,47.  Estimates of the population 
attributable risk of AMI for these combined modifiable risk factors range from 
70% to 90%3.  There are various risk prediction scores48,49 based on 
combinations of risk factors which are designed to identify people at highest risk 
from cardiovascular disease as targets for individual interventions.  Nonetheless 
many acute cardiovascular events occur in people with low risk scores.  Despite 
the identification of several promising novel risk factors or markers, such as 
carotid intima-media thickness, high sensitivity CRP, coronary artery calcium 
score and genetic risk scores50, AMI risk is still incompletely explained. 
 
1.4.3 Transition from stable to unstable atherosclerotic disease 
 
Almost all AMIs occur against a background of atherosclerotic coronary artery 
disease, whether or not this has been diagnosed.  A detailed description of the 
pathogenesis of atherosclerosis, particularly focussing on the potential for 
interaction with influenza is given in chapter 7.  The widespread presence of 
coronary atherosclerosis at autopsy (eg >80% in US adults with a mean age of 36 
years who died of non-natural causes) far exceeds the annual incidence of AMI 
and sudden cardiac death (estimated in the United States to be between 0.2 and 
1%)51.  This suggests that factors other than the presence of atherosclerosis need 
to be present for an AMI – characterised by partial of complete epicardial 
coronary artery occlusion – to occur51.  Certain features of plaque morphology 
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combined with the concept of ‘vulnerable blood’ or a ‘prothrombotic state’ 
predispose to AMI.  Systemic inflammation is thought to play a key role in 
development of coronary instability, with or without plaque rupture52.  This is 
based on clinical and autopsy reports of widespread coronary and myocardial 
inflammation in patients with severe unstable angina or infarction53,54.  Figure 1.1 
shows a schematic drawing of the interaction between vascular risk factors and 
local and systemic conditions necessary for an AMI to occur.
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Figure 1.1 Interaction between cardiovascular risk factors and local and systemic systems necessary for AMI 
Adapted from Arbab-Zadeh A, et al51 
Cardiovascular risk factors (shown in green) interact with 
each other and at multiple points in the pathogenesis of local 
thrombogenicity and systemic blood vulnerability. 
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1.4.4 Acute triggers of AMI 
 
As well as studies of traditional cardiovascular risk factors, there is a body of 
literature focussed on acute triggers of cardiovascular events55,56.  These may be 
physical, chemical or psychological factors that represent the final step in the 
pathophysiological process from chronic atherosclerotic disease to plaque 
disruption and thrombosis55.  In vulnerable individuals these factors, which 
include infection, air pollution, heavy exercise, sexual activity and emotional 
stress56, are thought to precipitate acute cardiovascular events through their 
transient vasoconstrictive and prothrombotic effects55.  Figure 1.2 (adapted from 
Mittleman and Mostofsky55) is a schematic diagram of some proposed 
mechanisms linking various acute triggers to AMI in vulnerable individuals.  
Molecular level inflammatory and haemostatic changes associated with influenza 
and potential interactions with the final common pathway towards AMI are 
described further in chapter 7. 
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Figure 1.2 Proposed mechanisms through which acute triggers of AMI might act in vulnerable individuals 
Adapted from Mittleman and Mostofsky55 
31 
 
1.4.5 Definition of AMI 
 
A universal definition of AMI was first developed by an international taskforce in 
200057 and updated in 200758 and 201259.  This superseded the previous World 
Health Organization definition based on symptoms, ECG changes and enzymes to 
reflect the development of newer sensitive troponin assays for detection of 
myocardial necrosis44.  The universal definition of myocardial infarction from 
2007 (which was current during the time period of this PhD) is shown is box 1, 
reproduced from the European Society of Cardiology, American College of 
Cardiology Foundation, American Heart Association and the World Heart 
Federation expert consensus document58. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Criteria for acute myocardial infarction (Universal definition 200758, current 
during this PhD) 
 
The term ‘myocardial infarction should be used when there is evidence of myocardial 
necrosis in a clinical setting consistent with myocardial ischaemia.  Under these 
conditions any one of the following criteria meets the diagnosis for myocardial infarction: 
 
1. Detection of a rise in cardiac biomarkers (preferably troponin) with at least one value 
above the 99th percentile of the upper reference limit together with evidence of 
myocardial ischaemia with at least one of the following: 
 Symptoms of ischaemia 
 ECG changes indicative of new ischaemia (new ST-T changes or new left 
bundle branch block) 
 Development of pathological Q waves in the ECG 
 Imaging evidence of new loss of viable myocardium or new regional wall 
motion abnormality 
2. Sudden unexpected cardiac death involving cardiac arrest, often with symptoms 
suggestive of myocardial ischaemia and accompanied by presumably new ST 
elevation, or new LBBB and/or evidence of fresh thrombus by coronary angiography 
and/ or at autopsy, but death occurring before blood samples could be obtained or at 
a time before appearance of cardiac biomarkers in blood 
3. Pathological findings of an acute myocardial infarction 
 
In this definition criteria are also set out for percutaneous coronary intervention-related 
AMI and coronary artery bypass grafting-associated AMI but these are less relevant to 
studies included in this PhD so are not described here. 
 
In 2012, the definition was updated again to recognise development of even more 
sensitive assays for myocardial necrosis especially when such necrosis occurs in the 
setting of critical illness, cardiac surgery or percutaneous coronary procedures.  As 
changes to the definition were minor and post-dated studies in this thesis, they have not 
been included in this summary. 
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1.4.6 Management of AMI 
 
Briefly, the immediate management of AMI depends upon using pharmacological 
and cardiac catheter-based treatments to restore epicardial and microvascular 
blood flow, while optimising antithrombotic therapies to suppress recurrent 
ischaemic events and delivering treatments to mitigate the effect of myocardial 
necrosis44.  These will not be discussed further here.  Subsequent in-hospital care 
aims to initiate therapies or lifestyle changes to improve long-term outcome and 
act as secondary prevention of future events60.  Key points at which a relationship 
with influenza might theoretically be relevant for AMI management are prior to 
first AMI (eg using influenza vaccine for primary prevention), after an AMI (eg 
using influenza vaccine for secondary prevention) or during an influenza-like 
illness (eg using antiviral or other medications to lessen symptom severity and 
reduce cardiovascular risk).  These themes will be discussed in chapter 8 
(sections on policy implications and future research directions) in light of 
research findings from this thesis.   
 
1.5 Thesis rationale and aims  
 
Both influenza and AMI are common and contribute to a substantial burden of 
morbidity and mortality worldwide.  AMI remains a key challenge in the clinical 
management of ischaemic heart disease, especially as it can occur in individuals 
not previously identified to be at high cardiovascular risk.  Improved 
understanding of the role of inflammatory triggers such as influenza and their 
contribution to AMI disease burden will both inform strategies for prevention and 
enhance seasonal and pandemic influenza planning.     
 
1.5.1 Aims and objectives 
 
The overall aim of this thesis is to generate evidence to improve understanding of 
the relationship between acute respiratory infections, specifically influenza, and 
acute myocardial infarction and thereby inform policy and practice. 
 
 
33 
 
Specific objectives (outlined in more detail in the relevant chapters) are: 
1) To investigate and synthesise the evidence from previous studies for a 
relationship between influenza and AMI or death from cardiovascular 
disease (chapter 2). 
2) To compare population-level associations between seasonal influenza 
circulation and AMI under different climatic and environmental conditions 
in two discrete geographical settings (chapter 3). 
3) To investigate temporal associations between GP consultations for acute 
respiratory infections and AMI using a range of linked data sources 
(chapters 4 and 5). 
4) To perform a primary case control study investigating the experience of 
recent influenza or acute respiratory infection in hospitalised AMI patients 
and controls during the 2009 influenza A H1N1 pandemic (chapter 6). 
5) To examine potential biological mechanisms for an association between 
influenza and AMI in the literature and through an exploratory study in 
AMI patients (chapter 7). 
6) To discuss research findings, strengths and weaknesses as well as clinical 
and policy implications (chapter 8). 
 
 
 
 
 
 
 
 
 
 Something about AMI 
 Something about the relationship between the two 
 Something about the thesis 
 To be completed later 
 
 
 
 
 
 
  
SUMMARY 
 
 Influenza infection may lead to cardiovascular complications and 
deaths among vulnerable people 
 AMI risk is incompletely explained by traditional vascular risk factors 
 The contribution of inflammatory triggers such as influenza to AMI 
disease burden is not well understood 
 This thesis will investigate the relationship between acute respiratory 
infections, specifically influenza, and AMI through review of existing 
literature and by presenting original research to generate evidence to 
inform influenza prevention, treatment and planning   
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2.  Systematic literature review of the relationship between 
influenza and acute myocardial infarction or death from 
cardiovascular disease 
 
2.1 Description of chapter contents 
 
In this chapter I describe a systematic literature review of the evidence that 
influenza (including influenza-like illness and acute respiratory infection) might 
trigger AMI or cardiovascular death.  I also examine the effectiveness of influenza 
vaccine at protecting against cardiac events through performing a meta-analysis 
of data from randomised controlled trials.  Systematic searches are done of 
electronic databases and hand-searches of reference lists from relevant articles 
for original research articles matching inclusion criteria in any language.  Results 
from included studies are grouped by study design and by influenza classification.  
The quality of evidence is assessed by first considering flaws common to each 
study design and then by examining studies individually.  Conclusions are drawn 
from available evidence and outstanding questions are highlighted.  Updated 
evidence from recent searches is provided in an appendix to this chapter. 
 
2.2 Study rationale 
 
Although some cardiac complications of influenza infection such as myocarditis 
are well-recognised, the nature of any relationship between influenza and AMI is 
less clear.  Before embarking on original research studies, a systematic review 
was needed to identify whether existing studies provided evidence to support the 
hypothesis that AMI can be triggered by influenza infection and to identify gaps in 
the literature. 
 
2.3 Aims and objectives 
 
Aim: to perform a systematic review of the evidence for a relationship between 
influenza and AMI or death from cardiovascular disease. 
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Objectives: 
1) To design and perform systematic searches to identify original studies 
examining the link between influenza (including laboratory-confirmed 
influenza, influenza-like illness and acute respiratory infection in the 
absence of other aetiological information) or influenza vaccine and AMI or 
death from cardiovascular disease. 
2) To extract data from studies meeting inclusion criteria using a purpose-
designed data extraction tool. 
3) To synthesise findings by study design and influenza classification. 
4) To perform a meta-analysis of data from randomised controlled trials. 
5) To critically appraise quality of evidence. 
 
2.4 Methods 
 
2.4.1 Search strategy 
 
Searches were originally carried out using Pubmed (up to Feb 2009) and Embase 
(1980 – Feb 2009) to describe the literature at the beginning of this PhD.  I used 
the following MeSH search terms: “influenza human” OR “influenza vaccines” OR 
“viruses”[Majr] OR “respiratory tract infections”[Majr] AND “myocardial 
infarction”. The search was repeated with the MeSH terms “influenza human” OR 
“influenza vaccines” AND “cardiovascular diseases”[Majr].  Keyword searches 
were performed in both databases using all possible combinations of terms from 
the following lists: 1) “influenza”, “flu”, “vaccine” and “respiratory infection” and 
2) “myocardial infarction”, “cardiovascular”, “coronary”, “atherosclerosis” and 
“atherogenesis”.  Bibliographies of relevant articles were searched for additional 
references.  Findings were updated in October 2012 with additional results 
presented in an appendix to this chapter (appendix 2a, p65). 
 
2.4.2 Inclusion and exclusion criteria 
 
I included original studies with the outcomes ‘myocardial infarction’ or ‘death 
from cardiovascular disease’ (or death from a more specific cause such as 
coronary heart disease, or ischaemic heart disease).  I classed relevant exposures 
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as a) influenza, b) influenza-like illness, c) acute respiratory infection (where this 
was not subdivided into causes), and d) influenza vaccination.  I included 
ecological, case control, cohort, case only studies (eg self-controlled case series or 
case crossover) and randomised controlled trials but excluded case reports, 
review articles, editorials, clinical guidelines and information articles for patients.  
Studies that examined intermediate outcomes such as inflammatory markers, 
cardiac enzyme levels or ECG changes (outside the context of AMI) were rejected.  
Studies where methods were insufficiently described were also rejected.  All case 
control and cohort studies were required to have a comparison group to enable 
relative measures of the effect of influenza to be generated.  Similarly, all case 
only studies needed to have a comparison time period.  I considered studies from 
any time period, any country and in any language for inclusion.  For potentially 
relevant studies published in languages other than English, French and Italian, I 
advertised for PhD students to translate articles for a small payment.  Translators 
assisted with articles published in Russian, German and Polish.   
 
2.4.3 Data extraction and synthesis 
 
I collected data on study populations, settings, exposure definitions, outcome 
definitions, outcome measures, effect sizes, confidence intervals, and results of 
significance testing, using a data extraction sheet that I had designed.  Studies 
were categorised by study design and by definitions of influenza (confirmed 
influenza, influenza-like illness, and acute respiratory infection).  For 
observational studies no formal meta-analysis was done, as factors such as study 
design, exposure definitions, likelihood of bias and the extent to which authors 
controlled for confounding were too heterogeneous across studies.  Where 
possible, though, I compared effect sizes within categories of study type.  For 
randomised controlled trials of the effect of influenza vaccination on cardiac 
outcomes, I performed a meta-analysis using the user written ‘metan’ suite of 
commands61 in Stata version 10, which produced summary effects using both 
fixed- and random-effects models.  The likelihood of bias for individual studies 
was assessed against criteria defined in the STROBE statement62, tailored to the 
study question.  General quality issues were reported by study type to reflect 
flaws common to certain study designs. 
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2.5 Results 
 
2.5.1 Search results 
 
The search yielded 1,869 articles, of which 99 were deemed relevant and 37 
fulfilled inclusion criteria (figure 2.1).  An additional five articles were identified 
by scanning reference lists of included studies and relevant reviews.  My analysis 
included 42 papers published between 1932 and 2008.  Of these, 17 described 
ecological studies, 15 reported case control studies, three were prospective 
cohort studies, two were case only studies (incorporating one self-controlled case 
series study and one case crossover), and five papers described randomised 
controlled trials (including four papers describing outcomes of the same trial at 
different time points).  16 papers included the outcome ‘myocardial infarction’ 
alone, six incorporated AMI as part of a composite outcome and 20 used the 
outcome ‘cardiovascular death’ (with variants including ‘death from coronary 
heart disease’, ‘death from ischaemic heart disease’, ‘death from organic heart 
disease’, and ‘death from arteriosclerotic heart disease’).   
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Figure 2.1Study flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.5.2 Overview of study designs 
Various study designs have been used to study the relationship between influenza 
and cardiovascular disease.  Analytical ecological studies attempting to correlate 
population measures of influenza exposure with population level data on 
cardiovascular mortality typically generated correlation coefficients.  Case control 
99 potentially relevant publications 
retrieved for full-text review 
62 publications excluded: 
3 reviews 
4 commentary/ editorial/ letter to editor 
40 ineligible outcomes (eg platelet 
activation, ECG changes, all cause mortality) 
3 ineligible exposures 
10 no control/ comparison groups 
1 used overall annual flu rates for 
correlation 
1 full text not available (from a 1971 Italian 
journal unobtainable in any UK library/ 
online)  37 publications identified for inclusion 
5 additional publications identified for 
inclusion through hand-searching references of 
identified studies and relevant review articles 
42 publications included in analysis, 
describing 39 studies 
1869 publications identified in Pubmed/ EMBASE searches 
1655 publications excluded because not 
relevant (eg studies of other infections or 
other vascular disorders, case reports, 
articles for patients, opinion pieces) 
214 potentially relevant publications 
identified and abstracts reviewed 
115 publications excluded:  
39 not relevant 
2 case reports 
42 reviews 
24 letters to editor/ editorials 
7 clinical guidelines 
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studies, usually comprising AMI patients and controls sampled from a similar 
underlying population, yielded estimates of the relative effect of influenza on AMI.  
Case only studies, such as self-controlled case series or case crossover studies, 
compared the relative incidence of AMI occurring in different time periods after 
influenza infection using cases as their own controls.  This review did not include 
any cohort studies used directly to study the relationship between influenza and 
AMI.  Several prospective cohort studies were included, however, that 
investigated any relative protective effect of influenza vaccination against AMI in 
individuals who had received influenza vaccine compared to an unvaccinated 
comparison group.  Similarly, randomised controlled trials enabled the 
occurrence of AMI or cardiovascular death to be compared between groups 
randomised to receive either influenza vaccine or no vaccine/placebo.  
Characteristics of ecological studies, individual observational studies and 
randomised controlled trials are described in tables 2.1, 2.2 and 2.5 respectively.   
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Authors Study 
location 
Study 
years 
Exposure(s) Definition of exposure(s) Outcome(s) Definition of outcome(s)  
Collins (1932)29  
 
 
USA  1917 - 1929 Influenza 
epidemics 
Weekly mortality rates from 
influenza & pneumonia  
Organic heart disease 
mortality 
Weekly excess mortality 
rates from organic heart 
disease 
Azambuja & 
Duncan (2002)63 
 
USA 1918 and 
1920 - 1985 
Influenza 
circulation  
Influenza mortality rates in 
1918 
Coronary heart disease 
mortality 
Annual mortality rates 
from coronary heart 
disease in 1920 - 1985 
Bainton, Jones & 
Hole (1978)64 
 
 
London, UK 1953 - 1973 Influenza 
circulation  
a) Weekly mortality rates 
from influenza, pneumonia, 
bronchitis & all causes  
b) Weekly ILI incidence seen 
in General Practice 
c) Laboratory influenza 
surveillance data 
d) New sickness benefits 
Arteriosclerotic and 
ischemic heart disease 
mortality 
Weekly mortality rates 
from arteriosclerotic or 
ischaemic heart disease  
 
Eickhoff, 
Sherman & 
Serfling (1961)65  
 
 
USA 1957 – 
1960 
Influenza 
epidemics 
Weekly mortality rates from 
influenza & pneumonia  
Cardiovascular- renal 
disease mortality (with 
subcategory 
arteriosclerotic heart 
disease mortality) 
Weekly excess mortality 
rates from cardiovascular 
& renal disease  
Housworth & 
Langmuir 
(1974)66 
 
 
USA 1957 – 
1966 
Influenza 
circulation  
Influenza surveillance data – 
surveillance method unclear. 
Heart, circulatory & 
nervous system 
mortality (with 
subcategory 
arteriosclerotic heart 
disease mortality) 
Monthly excess mortality 
rates from heart, 
circulatory & nervous 
system disease 
Duda et al 
(1974)67  
 
Romania 1956 - 1971 Influenza 
circulation  
Monthly and annual 
influenza morbidity – 
surveillance method unclear 
Cardiovascular disease 
mortality 
Monthly and annual 
mortality rates from 
cardiovascular disease 
Reichert et al 
(2004)68 
 
 
USA 1959 - 1999 Influenza 
circulation  
a) Monthly mortality rates 
from influenza  
b) Laboratory influenza 
surveillance data 
Ischaemic heart 
disease mortality 
Monthly excess mortality 
rates from ischaemic heart 
disease 
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Scragg R 
(1985)69 
 
 
Australia 1967 - 1977 Influenza 
epidemics 
Monthly and annual 
mortality rates from 
influenza   
Ischaemic heart 
disease mortality 
Monthly and annual excess 
mortality rates from 
ischaemic heart disease 
Cooper et al 
(1980)70 
 
 
USA 1968 - 1976 Influenza 
circulation  
Monthly and annual 
mortality rates from 
influenza  
 
Coronary heart disease 
mortality 
Monthly and annual 
mortality rates from 
coronary heart disease 
Tillett, Smith & 
Gooch (1983)71  
 
 
UK 1968 - 1978 Influenza 
circulation  
a) Weekly mortality rates 
from respiratory disease  
b) Weekly ILI incidence seen 
in General Practice 
Circulatory disease 
mortality (with 
subcategory ischaemic 
heart disease 
mortality) 
Weekly excess mortality 
rates from circulatory 
disease 
Alling, 
Blackwelder & 
Stuart-Harris 
(1981)72 
 
USA 1968 - 1976 Influenza 
circulation  
a) Monthly mortality rates 
from influenza  
b) Laboratory influenza 
surveillance data 
Cardiovascular disease 
mortality 
Monthly and annual excess 
mortality rates from 
cardiovascular disease  
Marshall, Scragg 
& Bourke 
(1988)73  
 
 
New Zealand 1970 - 1983 Influenza 
circulation  
Monthly mortality rates from 
respiratory disease  
Coronary heart disease 
mortality 
Monthly mortality rates 
from coronary heart 
disease  
Dvorakova & 
Poledne (2004)74 
 
 
Czech 
Republic 
1973 - 1997 Influenza 
circulation  
Influenza surveillance data – 
surveillance method unclear  
AMI incidence Hospitalisations for AMI 
identified from disease-
specific register in regional 
hospital of Central 
Bohemia.  AMI definition 
unclear. 
Mackenbach, 
Kunst & Looman 
(1992)75 
 
 
Holland 1979 - 1987 Influenza 
circulation 
National mortality rates from 
respiratory disease  
Cardiovascular disease 
mortality (with 
subcategory ischaemic 
heart disease 
mortality) 
Daily mortality rates from 
cardiovascular disease 
Madjid et al Russia 1993 - 2000 Respiratory a)Weekly incidence of acute Coronary heart disease Weekly incidence of 
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(2007)76 
 
 
disease and 
influenza 
epidemics 
respiratory disease  
b) Laboratory influenza 
surveillance data 
mortality autopsy-confirmed AMI or 
chronic IHD deaths 
Fleming, Cross & 
Pannell (2005)30 
 
 
UK 1994 - 2000 Influenza 
circulation  
a) Weekly ILI incidence seen 
in General Practice 
b) Laboratory influenza 
surveillance data 
Circulatory disease 
mortality (with 
subcategory ischaemic 
heart disease 
mortality) 
Weekly mortality rates 
from circulatory disease 
 
 
Saltykova et al 
(2008)77 
 
Russia 1999 - 2005 Influenza 
circulation  
National mortality rates from 
influenza 
Cardiovascular disease 
mortality (with 
subcategory AMI 
mortality) 
National mortality rates 
from cardiovascular 
disease 
Table 2.1 Characteristics of ecological studies, n=17  
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Authors Study 
location 
Study design  Study population Exposure(s) Definition of 
exposure(s) 
Outcome(s) Definition of 
outcome(s) 
Sample size  
Spodick, 
Flessas & 
Johnson 
(1984)78 
USA Matched case 
control 
 
Cases - AMI patients 
Controls - matched for 
age, sex & date of  
hospital admission 
Respiratory 
infection 
Clinical history of 
respiratory 
symptoms  
AMI AMI definition not 
stated 
150 cases 
150 controls  
 
Penttinen & 
Valonen 
(1996)79 
Finland Nested case 
control  
 
 
Cases - AMI patients 
Controls - from within a 
community cohort of 
farmers, matched on 
dob, SES and smoking 
status 
Respiratory 
infection 
GP presentation 
with respiratory 
symptoms 
AMI AMI diagnosis 
obtained from 
hospital discharge 
register, death 
certificates, and 
medical records 
83 cases 
249 controls  
Meier et al 
(1998)80 
UK Matched case 
control 
 
Cases - AMI patients in 
GPRD 
Controls - patients 
without cardiac risk 
factors matched on age, 
sex & GP 
Respiratory 
infection 
GP presentation 
with systemic 
respiratory 
infection  
AMI AMI Read codes in 
primary care records  
1922 cases   
7649 controls  
Meyers et al 
(2004)81  
USA Case control 
 
Cases - hospitalised 
AMI patients 
Controls - hospitalised 
fracture patients 
a) 
Respiratory 
infection 
b) Influenza 
vaccine 
a) Clinical 
symptoms  
 
b) Self-reported 
vaccination status 
AMI At least two of: 
- Typical chest pain 
- ECG changes 
- Rise in troponin/ 
CK-MB/ myoglobin 
- Occluded coronary 
artery on angiography 
335 cases  
199 controls 
Clayton et al 
(2005)82 
UK Matched case 
control 
 
Cases - hospitalised 
AMI patients 
Controls - from 
community, matched 
on age, sex & 
deprivation 
Respiratory 
infection 
Clinical history of 
respiratory 
symptoms 
AMI Clinical diagnosis of 
AMI (made in a 
coronary care unit)  
119 cases 
214 controls  
Clayton et al 
(2008)83 
UK Matched case 
control 
Cases - Patients with a 
first AMI in the ‘IMS 
Disease Analyzer 
Mediplus Primary Care 
Respiratory 
infection 
 
GP presentation 
with systemic 
respiratory 
infection (using 
AMI AMI Read codes in 
primary care records  
 
11, 155 cases 
11, 155 
controls 
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Database’. 
Controls - from same 
database matched on 
age, sex, GP and time  
primary care 
records) 
Smeeth et al 
(2004)84 
UK Self-
controlled 
case series 
Cases - GPRD patients 
with a history of AMI 
and respiratory 
infection or flu 
vaccination 
a) 
Respiratory 
infection 
 
b) Influenza 
vaccination 
a) GP presentation 
with systemic 
respiratory 
infection  
b) Flu vaccination 
status  
using primary care 
records 
AMI AMI Read codes in 
primary care records  
 
 
20, 486 cases 
Zheng et al 
(1998)85 
  
USA Case 
crossover 
Cases - identified from 
a research database of 
AMI patients 
Influenza-like 
illness 
Clinical symptoms 
(fever and sore 
throat) 
AMI AMI definition not 
stated 
2,264 cases 
Pesonen et al 
(2008)86 
Sweden Matched case 
control 
 
Cases - AMI patients 
Controls - from 
community, matched 
on age, sex, parish, 
residence, season & flu 
circulation 
Influenza-like 
illness 
 
 
Clinical symptoms  
 
AMI At least two of: 
- typical ECG changes 
- chest pain lasting 
>20 minutes 
- raised CK-MB  
110 cases  
 
323 controls  
Nicholls & 
Thomas 
(1977)87 
UK Case control 
 
Cases - AMI patients in 
coronary care unit 
Controls - patients 
admitted to coronary 
care unit without AMI 
a) Influenza-
like illness 
b) Influenza 
 
a) Clinical 
symptoms 
 
b) Antibodies to 
influenza A 
infection 
(complement 
fixation tests on 
paired sera) 
AMI According to WHO 
definition 1959 
38 cases 
 
21 controls  
Ponka et al 
(1981)88 
Finland Case control  
 
Cases - AMI patients 
Controls - acute 
admissions for non-
cardiac reason 
a) Influenza-
like illness 
b) Influenza  
a) Clinical 
symptoms  
 
b) Antibodies to 
influenza A in 
AMI Clinical history, ECG 
changes, and elevated 
CK-MB levels 
49 cases 
 
37 controls  
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serum 
Mattila 
(1989)89 
Finland Case control 
 
Cases - AMI patients 
Controls - group 1: 
random patients; group 
2: patients with chronic 
CHD 
a) Influenza-
like illness 
b) Influenza 
a) Clinical 
symptoms 
 
b) IgM and IgG 
antibodies to 
influenza in serum  
AMI Ischaemic symptoms, 
ECG changes, and 
elevated CK-MB 
40 cases  
41 controls 
(group 1) 
30 controls 
(group 2) 
Porter & Porter 
(1999)90 
USA Case control 
 
Cases - patients dying 
of cancer  
Controls - patients 
dying of AMI (autopsy-
confirmed) 
Influenza  Influenza virus 
antigens in lung 
tissue  
Cancer death  Diagnosed by autopsy 
 
118 cases  
 
20 controls  
Guan et al 
(2008)91 
China Case control 
 
Cases - hospitalised 
AMI patients 
Controls - patients 
attending occupational 
health  
Influenza IgG antibodies to 
influenza in serum 
AMI Ischaemic symptoms, 
ECG changes, and 
raised cardiac 
enzymes 
99 cases 
 
110 controls  
Naghavi et al 
(2000)92 
USA Case control 
 
Cases - hospitalised 
AMI patients 
Controls - CHD patients 
admitted with no AMI 
Influenza 
vaccination 
Influenza 
vaccination status 
AMI At least two of: 
- ECG changes 
- enzyme changes 
- typical chest pain 
109 cases  
 
109 controls 
 
Siscovick et al 
(2000)93 
USA Case control 
 
Cases - patients dying 
of primary cardiac 
arrest 
Controls - randomly 
selected from 
community 
Influenza 
vaccination 
Self-reported 
influenza 
vaccination status 
Primary 
cardiac arrest 
Clinical diagnosis 342 cases 
 
549 controls  
Heffelfinger et 
al (2006)94 
USA Nested 
matched case 
control 
 
 
Cases - AMI patients 
Controls - from a cohort 
of patients attending a 
group health co-
operative matched for 
age, sex, year and BP 
Influenza 
vaccination 
Vaccination status 
obtained from 
medical records 
AMI From medical 
records.  Confirmed 
by symptoms, cardiac 
enzymes, ECG 
findings, provider 
notes & discharge 
summaries 
 
750 cases 
 
1735 controls  
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Jackson et al 
(2002)95 
USA Cohort  Cohort - patients with a 
first AMI 
Influenza 
vaccination 
From medical 
records and 
administrative 
data systems 
a) Nonfatal 
AMI + CVD 
death 
b) Fatal and 
nonfatal AMI 
AMI = chest pain, ECG 
changes and cardiac 
enzyme rise.   
 
1,378 patients   
(127 events 
from Aug ’92 -
Dec 96. Median 
follow up = 2.3 
years) 
Armstrong et al 
(2004)96 
UK Cohort Cohort - elderly people 
registered with general 
practices 
Influenza 
vaccination 
Medical record of 
vaccination 
Mortality 
from CVD 
CVD mortality rates 
from Office for 
National Statistics 
24,535 
patients (2,193 
events from 
Jan ’96 - Aug 
’00) 
Wang et al 
(2007)97 
Taiwan Cohort Community cohort of 
elderly people 
Influenza 
vaccination 
Vaccination status 
from 
administrative 
records  
Mortality 
from CVD 
Mortality data from 
death certificates  
102,698 
patients (484 
events from 
Jan 1st ’01 - Oct 
31st  01) 
Table 2.2 Characteristics of individual observational studies, n=20 
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2.5.3 Ecological studies 
 
2.5.3.i Results of ecological studies 
17 ecological studies examined the association between timing of influenza 
circulation and either mortality from cardiovascular disease (CVD)29,30,63–73,75–77 
or incidence of AMI74 using regression modelling (seven studies) or  comparing 
numbers or rates of deaths in influenza and non-influenza circulation periods (ten 
studies).  Studies were carried out in various temperate climates worldwide 
including the USA(7), UK(3), Russia(2), Australia(1), Czech Republic(1), 
Holland(1), New Zealand(1), and Romania(1).  All 17 reported an increase in CVD 
mortality or AMI incidence during time periods when influenza was circulating.  
Six studies generated correlation coefficients for associations between weekly or 
monthly rates of influenza circulation and death rates from CVD using methods 
such as Spearman’s rank correlation test and time series cross correlation 
analysis.  These ranged from 0·61 - 0·77 in five studies63,67,72,73,77.  The final study 
reported age-specific correlation coefficients of 0·77 (for those aged 45-64), 0·87 
(for those aged 65-75) and 0·98 (for the over 75s)30.  Overall these suggest a 
medium to strong correlation.  Another two studies found that significantly more 
deaths from ischaemic heart disease occurred during influenza epidemic weeks 
compared to non-epidemic weeks64,76.  Two studies reported correlation 
coefficients between influenza circulation and death from AMI of 0·38 and 
0·576,77. 
 
Some ecological studies estimated the overall excess mortality secondary to 
influenza (or influenza-like illness), for example by using national surveillance 
systems to calculate numbers of deaths in periods when influenza was circulating 
that exceeded a baseline number of expected deaths in time periods when 
influenza activity was absent.  Overall excess influenza mortality was then divided 
into causes.  Nine studies reported a percentage of excess influenza deaths that 
were due to CVD29,30,65,66,68,69,71,72,75; these ranged from 18% (in the 1918 
pandemic in the USA)29 to 57% (in 1968/69 in the USA)68.  Generally the 
proportion of excess influenza deaths due to CVD averaged around 35-50% but 
changing definitions of CVD made figures difficult to compare across studies.   
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2.5.3.ii Limitations of ecological studies 
A major limitation to such studies is ecological bias or failure of ecological 
associations to reflect biological effects at an individual patient level.  The 
assumption that those individuals dying of cardiovascular disease have been 
exposed to influenza may be an example of this ecological fallacy.  Many 
ecological studies were designed to investigate overall influenza mortality rather 
than cardiovascular mortality specifically; several studies were excluded for using 
overly broad definitions of CVD death eg ‘respiratory and circulatory deaths’98–100 
which would have introduced bias.  Another substantial problem with ecological 
studies is the difficulty controlling for potential population level confounding 
factors such as low temperature and humidity.  In one study daily minimum 
temperature averaged across 4-week periods was included as a covariate in 
multivariable regression models71; in another study, time periods when influenza 
was and was not circulating were matched for temperature and numbers of 
excess CVD deaths compared64; in both studies the effect remained evident after 
controlling for temperature.  The remaining studies, however, did not control 
appropriately for temperature.  In analysing correlations between influenza 
circulation and CVD mortality, it may also be necessary to allow a time lag of eg 1-
2 weeks during which an effect can take place. Nevertheless few studies included 
a lag period, which itself may be difficult to determine accurately: surveillance 
data may also lag behind true community incidence of infection101.  Despite this, 
ecological studies are useful for generating hypotheses to examine in further 
detail using individual level data, as well as for estimating public health burden 
(using measures such as excess mortality). 
 
2.5.4 Individual observational studies – case only, case control and cohort 
 
2.5.4.i Acute respiratory infections 
Seven observational studies (six case control studies78–83 and one self-controlled 
case series study84) examined the experience of recent acute respiratory infection 
in AMI patients by self-reported symptoms or from GP records.  Five reported 
statistically significant associations between occurrence of recent respiratory 
symptoms and AMI, with effect estimates ranging from 2·1 (95% CI 1·4 - 3·2)83 to 
4·95 (95% CI 4·4 - 5·5)84.  One study showed no effect of recent respiratory 
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infection (OR 1·0 (95% CI 0·5 - 1·9), p=0·98) but demonstrated a significantly 
greater chance of recent fever in cases compared to controls (OR 5·9 (95% CI 2·0 
- 16·8), p<0·0001)82.  The final study suggested that two or more GP attendances 
with upper respiratory tract infection were associated with AMI, but this 
association did not hold true when comparing one GP visit with no visits (OR 1·4 
(95% CI 0·8 - 2·3), p=0·19)79.  Three of these studies also described a higher risk 
of AMI in the days immediately following acute respiratory infection80,83,84.  The 
largest of these - a self-controlled case series study of over 20,000 UK patients 
with a first AMI in the General Practice Research Database - reported an incidence 
ratio of 4·95 for AMI occurring in the first 1-3 days after acute respiratory 
infection, which fell to 3·2 on days 4-7, 2·8 on days 8-14 and 1·4 on days 15-2884.  
A similar gradient of effect sizes was reported for two case control studies 
performed in primary care databases, with OR 2·1 (95% CI 1·4 - 3·2) on days 1-7 
in one study83 and OR 3·6 (95% CI 2·2 - 5·7) on days 1-5 in the other80.  
 
2.5.4.ii Influenza-like illness 
A further five studies (four case control studies86–89 and one case crossover 
study85) used the more specific exposure of influenza-like illness (ILI), defined 
using syndromes of clinical symptoms such as fever plus sore throat (though 
definitions varied across studies).  Of the case control studies, two reported a 
statistically significant positive association between recent ILI and AMI, with odds 
ratios of 3·8 (95% CI 1·4 - 10·8), p=0·01186 and 3·0 (95% CI 1·1 - 8·2), p=0·0389.  
The other two case control studies showed a slight positive but non-significant 
association, with odds ratios of 1·7 (95% CI 0·5 - 5·6), p=0·41 and 1·2 (95% CI 0·3 
- 4·4), p=0·8487,88.  In a case crossover study of 2,264 patients with AMI, 19% 
reported a recent ILI85.  In these patients, the relative probability that an AMI 
occurred on the first day after ILI onset compared to seven days afterwards was 
2·4 (95% CI 1·7 - 3·4).   
 
2.5.4.iii Influenza (laboratory-confirmed) 
Four case control studies examined influenza exposure by testing either single 
serum samples for IgG antibodies using ELISA91 or by using complement fixation 
assays to detect influenza antibodies in paired acute and convalescent samples87–
89.  Only the first of these reported a highly significant odds ratio, for IgG 
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antibodies to influenza A (OR 7·5 (95% CI 1·3 - 47·0), p=0·023) and influenza B 
(OR 27·3 (95% CI 6·6 - 113·8), p<0·001) in AMI cases compared to controls91.  
Two other studies reported non-significant associations (OR 0·9 (95% CI 0·2 - 
3·1), p=0·81)87 and OR 0·5 (95% CI 0·1 - 2·6), p=0·44)88; in the fourth study it was 
not possible to calculate an odds ratio as no influenza antibodies were detected in 
either group89.  A further case control study examined the prevalence of influenza 
virus antigen in the lungs of deceased patients on autopsy90.  Comparing patients 
who died of AMI to those dying of cancer revealed no significant difference - OR 
1·0 (95% CI 0·1 - 8·6), p=0·99.  Results of individual observational studies are 
shown in table 2.3.
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Authors (year) 
 
Study design Sample size Exposure (definition) Odds ratio (95% CI) P value 
Zheng (1998)85 
 
 
Pesonen (2008)86 
 
 
Nicholls (1977)87  
 
 
 
 
Ponka (1981)88 
 
 
 
 
Mattila (1998)89 
 
 
 
 
Porter (1999)90 
 
 
Guan (2008)91 
 
 
 
 
Spodick (1984)78 
 
 
 
Case crossover 
 
 
Case control  
 
 
Case control  
 
 
 
 
Case control  
 
 
 
 
Case control  
 
 
 
 
Case control  
 
 
Case control  
 
 
 
 
Case control 
 
 
 
2, 264 cases 
 
 
110 cases 
323 controls 
 
38 cases 
21 controls 
 
 
 
49 cases 
37 controls 
 
 
 
40 cases 
71 controls 
 
 
 
20 cases 
118 controls 
 
99 cases 
110 controls 
 
 
 
150 cases 
150 controls 
 
 
Influenza-like illness 
(symptoms) 
 
Influenza-like illness (symptoms)  
 
 
1) Influenza-like illness 
(symptoms) 
2) Influenza (antibodies in paired 
sera) 
 
1) Influenza-like illness 
(symptoms) 
2) Influenza (antibodies in paired 
sera) 
 
1) Influenza-like illness 
(symptoms) 
2) Influenza (antibodies in paired 
sera) 
 
Influenza (viral antigen in lung 
tissue)  
 
1) Influenza A (IgG in single serum 
sample) 
2) Influenza B (IgG in single serum 
sample) 
 
Respiratory infection (symptoms) 
 
 
 
2·4 (1·7-3·4) 
 
 
3·8 (1·4-10·8) for 2-3 symptoms 
v 0-1 symptoms 
 
1·7 (0·5-5·6)*  
 
0·9 (0·2-3·1)* 
 
 
1·2 (0·3-4·4)* 
 
0·5 (0·1-2·6)*  
 
 
3·0 (1·1-8·2)* 
 
No influenza antibodies detected 
in either group 
 
1·0 (0·1-8·6)* 
 
 
7·5 (1·3-43·0)  
 
27·3 (6·6-113·8) 
 
 
2·19 (no CI given) 
 
 
 
- 
 
 
0·011 
 
 
0·41* 
 
0·81* 
 
 
0·84* 
 
0·44* 
 
 
0·03* 
 
- 
 
 
0·99* 
 
 
0·023 
 
<0·001 
 
 
<0·02 
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Table 2.3 Observational studies of association between either presumed influenza infection or non-specified respiratory infection and AMI 
* Calculated from crude figures given.  #Incidence ratios rather than odds ratios reported 
 
 
 
 
 
Penttinen(1996)79 
 
 
Meier (1998)80 
 
 
 
 
Meyers (2004)81 
 
 
Clayton (2005)82 
 
 
Clayton (2008)83 
 
 
 
Smeeth (2004)84 
Case control 
 
 
Case control 
 
 
 
 
Case control  
 
 
Case control  
 
 
Case control 
 
 
 
Self-controlled 
case series 
83 cases 
249 controls 
 
1,922 cases 
7,649 controls 
 
 
 
335 cases 
199 controls 
 
119 cases 
214 controls 
 
11,155 cases  
11,155 controls 
 
 
20,486 cases 
Respiratory infection (No. of GP 
visits) 
 
Respiratory infection 
(GP visit) 
 
 
 
Respiratory infection (symptoms)  
 
 
Respiratory infection (symptoms) 
 
 
Respiratory infection  
(GP visit)  
 
 
Respiratory infection  
(GP visit) 
3·2 (1·2-8·5) for 4 v 3 visits 
1·4 (0·8-2·3) for 1 v 0 visits 
 
3·6 (2·2-5·7) on days 1-5 
2.3 (1·3-4·2) on days 6-10 
1·8 (1·0-3·3) on days 11-15 
1·0 (0·7-1·6) on days 16-30 
 
2·4 (1·1-5·4)* 
 
 
1·0 (0·5-1·9)  
 
 
2·1 (1·4-3·2) on days 1-7 
1·9 (1·4-2·6) on days 8-28 
1·2 (0·9-1·5) on days 29-91 
 
#4·95 (4·4-5·5) on days 1-3 
3·2 (2·8-3·6) on days 4-7 
2·8 (2·5-3·1) on days 8-14 
1·4 (1·3-1·5) on days 15-28 
0·01 
0·19 
 
<0·01 
(test for 
trend) 
 
 
0·03*  
 
 
0·98 
 
 
<0·001 
(test for 
trend) 
 
- 
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2.5.4.iv Limitations of case control studies 
Eight of the 15 included case control studies were judged to be prone to selection 
bias because of the use of hospital-based control groups that may not have been 
representative of the population from which cases arose.  Control groups were 
recruited from people admitted or attending for other reasons eg fractures (one 
study)81, other cardiac conditions (three studies)87,89,92, occupational health 
checks (one study)91, cancer (one study)90, and acute non-specified admissions 
(two studies)78,88.  It is possible that the reason for hospitalisation among some of 
these controls was triggered or affected by ILI, which is likely to have biased 
effect estimates towards the null.  The remaining seven case control studies were 
either nested within cohort studies (two studies)79,94 or selected controls from 
the community (five studies)80,82,83,86,93, so were judged to have been less prone to 
selection bias. 
 
Recall bias was also potentially a problem in the six case control studies that 
relied on self-reported vaccination status or self-reported symptoms to diagnose 
recent acute respiratory infection clinically78,81,82,86,92,93.  This was less of an issue 
for four studies that verified this information using general practice 
records79,80,83,94 and for the five studies that also used laboratory confirmation of 
influenza infection87–91.  Though serological definitions of influenza exposure 
improve specificity, it can be difficult to estimate the timing of infection basing on 
detection of antibodies, which also rise in response to vaccination.  In three of the 
four antibody studies, paired acute and convalescent sera were tested to try to 
establish the timing of antibody rises, though authors did not control for influenza 
vaccination status87–89.  The study using a single assay to detect influenza IgG, 
though unable to assess timing of any antibody rise, was conducted in a Chinese 
population with an extremely low prevalence of influenza vaccination (two cases 
and one control reported vaccinations)91.  Overall six of the 15 case control 
studies failed to control adequately for potential confounders such as smoking 
status and influenza vaccination78,86–90.  Although in general, case control studies 
are more efficient and therefore require fewer participants than cohort studies, 
nearly two thirds of included studies were clearly underpowered to detect an 
effect of influenza on AMI risk. 
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2.5.4.v Limitations of case only studies 
Two case only studies were included in which each individual acted as their own 
control.  As well as improving statistical efficiency, a major advantage of this type 
of study is the elimination of the effect of fixed confounders such as socio-
economic status and health-seeking behaviour.  Both studies relied upon medical 
records or database data, however, so there is likely to have been missing 
information on other time-varying confounders such as smoking status.  Though 
recall bias may have affected the case crossover study which relied on recall of 
respiratory symptoms85, this is unlikely to have varied systematically within the 
group of AMI patients.  The other study used GP episodes to diagnose acute 
respiratory infections84.  Although this method substantially underestimates total 
numbers of patients with acute respiratory infection or influenza-like illness (as 
most do not present to the GP), it would tend to underestimate any triggering 
effect of infections on AMI rather than to provide false evidence of effect.   
 
2.5.5 Observational and intervention studies of influenza vaccine 
 
2.5.5.i Observational studies 
Eight observational studies - four case control81,92–94, three cohort95–97 and one 
self-controlled case series84 - compared the incidence of AMI or cardiovascular 
events in those vaccinated against influenza with those who had not received 
vaccination.  Results were mixed.  Three studies showed a protective effect, one 
showed a slight protective effect that was not statistically significant, and four 
showed no evidence of effect (table 2.4).  These null studies included a small 
cohort study that was underpowered to detect a protective effect of vaccine95 and 
a self-controlled case series study84, designed to examine whether AMI was 
triggered by influenza vaccination.  This study focussed only on short-term 
effects, comparing the relative incidence of AMI in the period immediately 
following influenza vaccination with other time periods for the same individual.  
As the effect of influenza vaccination may last for several years, it was therefore 
unlikely to have demonstrated a protective effect (because there would be no true 
baseline time periods for an individual).
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Authors (year) Study design  Sample size Outcome Odds or hazard ratio (95% 
CI) 
P value  
Siscovick (2000)93 
 
 
Naghavi (2000)92 
 
 
Meyers (2004)81 
 
 
Heffelfinger (2006)94 
 
 
Jackson (2002)95 
 
 
Armstrong (2004)96 
 
 
Wang (2007)97 
 
 
 
Smeeth (2004)84 
 
 
 
Case control 
 
 
Case control 
 
 
Case control 
 
 
Case control 
 
 
Cohort 
 
 
Cohort 
 
 
Cohort  
 
 
 
Self-controlled 
case series 
342 cases 
549 controls 
 
109 cases 
109 controls 
 
335 cases 
199 controls 
 
750 cases 
1,735 controls 
 
1,378 subjects 
(127 events) 
 
24,535 subjects 
(2,193 events) 
 
102,698 subjects 
(484 events) 
 
 
20,486 cases 
Primary cardiac 
arrest 
 
Recurrent AMI 
 
 
AMI 
 
 
AMI 
 
 
1) AMI or CVD death 
2) AMI  
 
CVD death 
 
 
‘Heart disease’ 
death  
 
 
AMI 
OR 0·51 (0·33- 0·79) 
 
 
OR 0·33 (0·13-0·82) 
 
 
OR 0·90 (0·60-1·35) 
 
 
OR 0·97 (0·75-1·27) 
 
 
HR 1·18 (0·79-1·75) 
HR 1·23 (0·81-1·87) 
 
HR 0·87 (0·73-1·02) 
 
 
HR 0·78 (0·64-0·96) 
 
 
 
IR 0·8 (0·6-0·9) on days 1-3* 
IR 0·7 (0·8-1·0) on days 8-14 
IR 1·0 (1·0-1·1) on days 15-28 
-  
 
 
0·017 
 
 
0·59 
 
 
0·95 
 
 
- 
- 
 
0·09 
 
 
<0·05 
 
 
 
-  
 
 
 
Table 2.4 Case control, case only and cohort studies showing the association between influenza vaccination and CVD death or AMI  
* Measured incidence ratio (IR) for AMI occurring in time periods immediately following vaccination compared to other time periods in vaccinated individuals. 
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2.5.5.ii Intervention studies 
Two intervention studies102,103 that were recently included in a Cochrane 
systematic review104, used a randomised controlled trial design to examine 
whether influenza vaccination protected against AMI and CVD death as well as a 
range of composite cardiovascular outcomes.  The FLUVACS study105 randomised 
301 patients (200 post AMI and 101 presenting for planned angioplasty/stent 
with no history of unstable angina, AMI, coronary artery bypass graft (CABG) or 
angioplasty) to either influenza vaccine or control groups.  Sequential follow up at 
6 months, one and two years showed a significantly reduced risk of 
cardiovascular death in the intervention group, which diminished over time (HR 
0·25 (95% CI 0·07 - 0·86), p=0·01 at 6 months106; HR 0·34 (95% CI 0·17 - 0·71), 
p=0·002 at 1 year105; HR 0·33 (95% CI 0·07 - 1·59), p=0·14 at 2 years)107.  Data on 
subsequent AMI, collected as part of a composite endpoint, showed that there was 
no effect of vaccine on AMI risk at one year, with equal numbers of events in 
vaccine and control groups (HR 0·99 (0·43 - 2·32), p=0·99).  Results of other 
composite endpoints are shown in table 2.5.  
 
The Polish FLUCAD study randomised 658 patients with angiographic evidence of 
coronary artery disease to receive either influenza vaccination or placebo102.  A 
significant protective effect of influenza vaccination was seen against coronary 
ischaemic events (HR 0·54 (95% CI 0·29 - 0·99), p=0·047) after median follow up 
of 298 days.  There was no significant effect on the other outcomes - CVD death 
(HR 1·06 (95% CI 0·15 - 7·56), p=0·95) or major adverse cardiac events (HR 0·54 
(95% CI 0·24 - 1·21), p=0·13) - see table 2.5. 
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Table 2.5 Randomised controlled trials of the effect of influenza vaccination for prevention of coronary heart disease 
 
# Hazard ratios for results of follow up at one year (combined for AMI and elective PCI patients) 
*MACE = major adverse cardiac event (cardiovascular death, AMI, coronary revascularisation) 
† Coronary ischaemic event = MACE or hospitalisation for myocardial ischaemia 
Study 
(year) 
Study population No. allocated to 
intervention or 
control groups 
Outcome(s) Hazard ratio  
(95% CI) 
P value  
FLUVACS 
(2004)105 
 
                    
 
  
 
 
 
FLUCAD 
(2008)102 
 
 
 
 
 
1) 200 AMI patients 
 
2) 101 elective PCI 
patients (no history 
of AMI/ unstable 
angina/CABG/ PCI) 
 
 
 
658 patients with 
angiographically-
confirmed coronary 
artery disease 
151 intervention/ 
150 control 
 
 
 
 
 
 
 
325 intervention/  
333 placebo  
 
1) CVD death 
 
2) CVD death or AMI 
 
3) CVD death or AMI or 
recurrent ischaemia 
leading to 
hospitalisation  
 
1) CVD death 
 
2) ‘MACE’* 
 
3) Coronary ischaemic 
event† 
HR 0·34 (0·17-0·71)# 
 
HR 0·59 (0·32-1·10)# 
 
HR 0·59 (0·40-0·86)#  
 
 
 
 
HR 1·06 (0·15-7·56) 
 
HR 0·54 (0·24-1·21) 
 
HR 0·54 (0·29-0·99) 
  
0·002  
 
0·09 
 
0·004 
 
 
 
 
0·95 
 
0·13 
 
0·047 
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2.5.5.iii Meta-analysis of intervention studies 
Pooled results from the two randomised controlled trials for 476 vaccinated 
participants and 483 unvaccinated controls suggested a reduction in 
cardiovascular death in the vaccinated group (figure 2.2).  There was some 
evidence of heterogeneity between trials (I2=61%, p=0·08).  The fixed effects 
model showed a significant protective benefit - RR 0·39 (95% CI 0·20 - 0·77), but 
given the heterogeneity, the random effects model may provide a better estimate.  
For this model, the confidence interval was wider and the estimated protective 
effect less marked - RR 0·51 (95% CI 0·15 - 1·76).  For the outcome AMI, no 
significant effect of influenza vaccination was seen in either model - RR 0·85 
(95% CI 0·44 - 1·64) (figure 2.3). 
 
 
Figure 2.2 Pooled analysis of the effect of influenza vaccination on risk of CVD death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
M-H Overall  (I-squared = 61.1%, p = 0.077)
FLUVACS PCI
Name
FLUCAD
FLUVACS MI
D+L Overall
0.39 (0.20, 0.77)
0.98 (0.30, 3.18)
RR (95% CI)
1.02 (0.15, 7.23)
0.19 (0.07, 0.53)
0.51 (0.15, 1.76)
11/476
5/51
Events,
Treatment
2/325
4/100
28/483
5/50
Events,
Control
2/333
21/100
100.00
%
18.02
Weight
(M-H)
7.05
74.93
  
1.1 10
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Figure 2.3 Pooled analysis of the effect of influenza vaccination on risk of AMI 
 
 
 
2.5.5.iv Limitations of vaccine studies 
Observational studies  
As well as general methodological issues detailed previously for case control and 
case only studies, studies of influenza vaccine using any observational design are 
likely to be biased as to who receives vaccine.  Typically vaccinated patients are 
healthier than their unvaccinated counterparts, which tends to lead to 
overestimation of vaccine effectiveness108.  Two of the three included cohort 
studies attempted to control for this ‘frailty selection bias’ by examining the 
seasonality of effects of influenza vaccination on CVD death (whereby any 
protective effect would be expected to be greatest during the influenza 
season)95,96.  One of these studies also used a novel approach to confounding by 
avoiding direct comparisons of mortality between vaccinated and unvaccinated 
people, instead comparing responses to circulating influenza in both groups96.  It 
is likely, however, that residual confounding may have affected the other two 
cohort studies that obtained information on clinical and behavioural variables 
from medical records95,97.  
 
 
 
M-H Overall  (I-squared = 0.0%, p = 0.859)
D+L Overall
Name
FLUVACS PCI
FLUCAD
FLUVACS MI
0.85 (0.44, 1.62)
0.85 (0.44, 1.64)
RR (95% CI)
0.98 (0.26, 3.71)
0.68 (0.25, 1.90)
1.00 (0.33, 3.00)
16/476
Events,
Treatment
4/51
6/325
6/100
19/483
Events,
Control
4/50
9/333
6/100
100.00
Weight
(M-H)
21.34
%
46.97
31.70
  
1.1 10
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Interventional studies 
Randomised controlled trials provide the best evidence for a protective effect of 
influenza vaccine against adverse cardiovascular outcomes, and indirectly for the 
triggering effect of influenza on cardiovascular disease.  Nonetheless the two 
trials described were not large and few cardiovascular events (39 cardiovascular 
deaths and 35 AMIs) actually occurred.  Methods for randomisation and 
allocation concealment in the FLUVACS study were unclear (though this would be 
less likely to affect hard outcomes such as cardiovascular death); neither study 
investigated the occurrence of influenza in participants.  In a recent Cochrane 
systematic review104, the risk of bias was described as ‘moderate’ for FLUVACS 
but low for ‘FLUCAD’ using the scoring system in the Cochrane Handbook for 
Systematic Reviews of Interventions.  In addition both trials involved patients 
with established cardiovascular disease, which may limit the generalisability of 
findings to other groups.  The Cochrane review concluded that, despite the 
significant protective effect of influenza vaccination seen against CVD death and 
some composite outcomes, pooled data from these two RCTs were insufficient to 
evaluate the effectiveness of influenza vaccine on cardiovascular events104.  
 
2.6 Discussion 
 
2.6.1 Summary of findings 
 
A range of observational studies undertaken in different settings have generally 
tended to support the hypothesis that acute respiratory infections - and influenza 
in particular - can trigger AMI.  There is also more limited evidence for an adverse 
effect on cardiovascular death.  Two relatively small randomised trials suggest 
that influenza vaccination reduces the risk of cardiovascular death and some 
coronary ischaemic events.  
 
2.6.2 Study strengths 
 
This review used a systematic, transparent search strategy, considering studies in 
all languages and from all time periods for inclusion.  I used focussed outcome 
measures ‘myocardial infarction’ and ‘death from cardiovascular disease’, which 
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would tend to increase specificity of findings.  I considered several graded 
definitions of influenza (laboratory-confirmed influenza, influenza-like illness and 
acute respiratory infection) as well as examining influenza vaccine studies to 
include evidence from a range of study types.  Examining effects across different 
populations using a range of methodologies would tend to increase the strength 
and generalisability of findings as well as limiting the effect of biases intrinsic to 
individual study designs.  This heterogeneity meant that it was, however, not 
possible to produce a combined estimate of effect across all studies. 
 
2.6.3 Study limitations – publication bias 
 
Some degree of publication bias (whereby studies with negative findings are less 
likely to be reported) may have affected this review.  Searches of clinical trial 
registries (including the WHO International Clinical Trials Registry, the Cochrane 
Central Registry of Controlled Trials and http://clinicaltrials.gov) for unpublished 
trials revealed only two extra completed trials of the effect of influenza vaccine on 
cardiac outcomes in populations with CVD, both of which were completed in 2008 
but were yet to be published (at the time of this review in 2009).  Formal tests of 
publication bias in observational studies were not possible because we did not 
use meta-analysis; however it is notable that the larger and better quality studies 
tended to produce positive results.  
 
2.6.4 Study limitations – issues with study quality 
 
Some quality issues with included studies have been highlighted already in 
relevant sections.  These included the lack of power of several smaller studies, 
especially earlier case control studies, to detect any effect of influenza on the 
development of AMI.  Several case control studies were also limited by poor 
selection of controls: using controls groups such as those admitted to hospital for 
other cardiac conditions, might potentially introduce selection bias if their reason 
for admission was also influenced by influenza.  Defining influenza for research 
purposes is difficult: clinical definitions, especially involving participant recall, 
were likely to have been affected by recall bias; triangulating information from 
several sources eg general practice records, laboratory data and symptoms 
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tended to produce more reliable results.  Both ecological and early individual 
observational studies tended not to control for potential confounding factors, 
though later studies produced more robust effect estimates using multivariable 
analysis.  While I did not use a quality scoring system, scoring systems for the 
quality of observational studies have not been widely validated or agreed.  
Included studies were critically evaluated by design according to STROBE 
guidance, and particular limitations highlighted throughout.   
 
2.6.5 Interpretation of findings 
 
Despite limitations of individual studies, results tended to be consistent across 
different populations in different time periods (encompassing the effects of 
several different circulating influenza strains).  The most statistically powerful 
studies, eg those performed in large primary care databases, were able to show 
that the increased risk of AMI following respiratory infection was transient.  This 
is in keeping with the hypothesis that influenza may act as an acute inflammatory 
and pro-coagulant stimulus through mechanisms such as transient alteration of 
endothelial function109,110.  Only a few ecological studies attempted to quantify the 
population impact of influenza on cardiovascular disease by reporting a 
percentage of excess influenza deaths attributable to CVD.  Almost all studies 
covered time periods of seasonal influenza circulation and some also included 
CVD deaths occurring in years of pandemic influenza.  Though figures varied 
substantially between studies, partly because of varying case definitions and 
differential influenza circulation across years, even the lowest reported figures 
for excess CVD deaths were large; it was estimated that 18% of excess deaths in 
the USA in the 1918 influenza pandemic were due to cardiovascular disease29. 
 
2.6.6 Implications for policy and practice 
 
Though this review has focussed on influenza, a large body of literature suggests 
that a range of acute and chronic bacterial and viral infections may be associated 
with increased AMI risk111.  Influenza remains an important focus, however, 
because of the potentially important clinical and public health impact.  Not only is 
influenza one of the most commonly occurring respiratory infections, but it is the 
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only viral respiratory infection for which there is effective available prophylaxis.  
Currently annual influenza vaccination is recommended in many countries for 
those with chronic medical conditions including established cardiovascular 
disease and diabetes but not for individuals with other cardiac risk factors such as 
hypertension112,113.  Uptake of influenza vaccination is suboptimal, especially in 
those with chronic diseases.  Findings from this review highlight the need to 
encourage vaccine uptake wherever indicated, especially in those with diabetes 
(which increases AMI risk) and existing cardiovascular disease, as recommended 
by the American Heart Association/ American College of Cardiology 
Foundation114.  There is some evidence that antiviral drugs (amantadine, 
oseltamivir and zanamivir) prevent influenza and lessen its severity115.  Limited 
observational evidence suggests that antiviral drugs may be protective against 
adverse cardiovascular outcomes in people with influenza infection116–118 but no 
study of antiviral drugs in influenza met inclusion criteria for this review.  Clear 
evidence of benefit from prospective trials is lacking; therefore the potential role 
of these drugs in preventing vascular events among high risk groups is uncertain. 
 
2.6.7 Future directions 
 
From these studies it is unclear whether influenza is more likely to trigger AMI 
than acute respiratory infections caused by other organisms.  The size of any 
effect seen varies across existing studies (with some studies failing to 
demonstrate an effect).  The public health impact of influenza on numbers of AMIs 
remains unknown.  Current studies also fail to provide a definitive answer about 
whether influenza vaccine is effective at reducing the risk of cardiac events.  Of 
particular importance for policymakers will be a clear definition of the population 
most at risk from influenza-associated AMIs: at present it is not certain whether 
the effect is confined to those with existing cardiovascular disease.  In chapter 3 I 
aim to address some of these questions by investigating the effect size and impact 
in two different settings and populations (England & Wales and Hong Kong) using 
a range of data sources and methods to control for confounding.   
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SUMMARY BOX 
 
 
 
SUMMARY  
 A systematic literature review and meta-analysis of trial evidence was 
done focussing on the relationship between influenza (including 
influenza-like illness, acute respiratory infection or influenza 
vaccination) and AMI or cardiovascular death 
 39 studies  were identified: 17 ecological, 20 individual observational 
studies and 2 RCTs of influenza vaccine as protection against adverse 
cardiac outcomes from a range of locations and time periods 
 In general studies tended to support the hypothesis that acute 
respiratory infections - and influenza in particular - can trigger AMI, 
with more limited evidence for an association with cardiovascular 
death.  The effect size and population impact remain unclear. 
 Two small RCTs suggested that influenza vaccination reduces the risk of 
cardiovascular death and some coronary ischaemic events in people 
with existing cardiovascular disease, though results from pooled 
analysis failed to reach statistical significance. 
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2a. Appendix to chapter 2 
 
2.7 Update: studies published since this review 
  
In addition to my own work, seven studies published since this review was 
undertaken and fulfilling the original inclusion criteria were identified in a 
literature search performed on 12th October 2012.  These were 2 ecological 
studies examining the association between influenza virus circulation and 
cardiovascular mortality and 5 studies (1 randomised controlled trial and 4 
observational studies) of the effect of influenza vaccination on cardiac outcomes. 
 
2.7.1 Ecological studies 
 
One ecological study in Colombia119 presented incidence rate ratios to compare 
rates of cardiovascular mortality in people aged ≥60 years during times of peak 
influenza circulation with the rest of the year in the time period 1997-2005.  
Excess influenza-related CVD mortality was quantified as an IRR 1.08 (95% CI 
1.06 - 1.11) from Poisson regression models that controlled for autocorrelation 
but not for other environmental or temporal confounders.   
 
In an ecological study from Hong Kong120, linear regression models were used to 
estimate influenza-related excess cause-specific mortality using the difference 
between estimated mortality rates in the presence or absence of recorded 
influenza activity between 1998 and 2009.  Influenza was associated with an 
average of 2.0 deaths from cardiovascular disease per 100,000 person years after 
controlling for calendar time, temperature, absolute humidity, RSV activity, a one 
week lag between influenza and cardiovascular death and a covariate to account 
for the transition in coding system from ICD-9 to ICD_10.  In this study, 18% of 
influenza-associated excess deaths were due to cardiovascular causes.  
 
Although methods used were disparate, with variable control for environmental 
confounders, both studies provide further evidence of the contribution of 
influenza to cardiovascular mortality across different populations and time 
periods.   
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One further modelling study, carried out to assess influenza-related excess global 
mortality during the first 12 months of circulation of the 2009 influenza A H1N1 
pandemic virus121, estimated that 83,300 cardiovascular deaths (46,000-179,000) 
were attributable to pandemic influenza.  These accounted for 29% of influenza-
attributed excess mortality.  As this estimate was modelled, however, from crude 
respiratory mortality rates associated with pandemic influenza multiplied by the 
ratio of excess deaths from respiratory and cardiovascular diseases rather than 
using primary data it did not meet formal inclusion criteria.  
 
2.7.2 Individual-level observational vaccine studies  
 
Four individual-level observational studies used different study designs to 
examine the effect of influenza vaccination on AMI (3 studies)122–124 or major 
adverse vascular events including cardiac death and nonfatal AMI (1 study)125.  
 
In a self-controlled case series study examining risk of AMI after influenza 
vaccination in a UK primary care population122 a reduction in AMI was seen in the 
first 60 days after vaccination, greatest in the first 14 days - season-adjusted IR 
0.68 (95% CI 0.60 - 0.78).  There was a somewhat lower incidence ratio for early 
vaccinations (1st Sept – 15th Nov) compared to late vaccinations. A protective 
effect did not continue past 60 days but this may have coincided with the end of 
the influenza season. 
 
In a prospective cohort study conducted in elderly people in Hong Kong dual 
vaccination with influenza and pneumococcal vaccination was associated with a 
reduced incidence of AMI compared to no vaccination (HR 0.52 (95% CI 0.38 - 
0.71))123.  Influenza vaccination alone did not produce a significant effect – HR 
0.85 (95% CI 0.59 - 1.33) although numbers of cardiac events were small.   
 
A large prospective cohort study nested within two global RCTs (the Ongoing 
Telmisartan Alone and in Combination With Ramipril Global EndPoint Trial 
(ONTARGET) and the Telmisartan Randomized Assessment Study in ACE 
Intolerant Subjects with Cardiovascular Disease (TRANSCEND) trials) found a 
reduction in major adverse cardiovascular events in people who received 
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influenza vaccination – overall adjusted OR 0.65 (95% CI 0.58 - 0.74)125.  This 
estimate varied by influenza season and was significant for three seasons in 
which there was a good match between vaccine antigen and circulating strains 
but not the fourth (2003/04) when the match was incomplete.  There was, 
however, evidence of protection outside the influenza season. 
 
Finally, a matched case control study conducted in a UK primary care database 
found a reduction in odds of AMI in people who had received influenza 
vaccination within the last year – adjusted OR 0.81(95% CI 0.77 - 0.85)124.  Early 
vaccination was associated with greater benefit than later vaccination (21% v 
12% reduction in AMI).  A protective effect did not persist after one year. 
 
Overall these studies suggest that influenza vaccination affords some degree of 
protection against cardiovascular events, although effect sizes varied between 
studies. When health outcomes are compared between vaccinated and 
unvaccinated individuals in observational studies it may be difficult to 
disentangle the effect of healthy user bias.  In situations where protective effects 
of influenza vaccination are not biologically plausible, for example outside the 
influenza season and in the first 14 days after vaccination (before a full immune 
response has been mounted), the possibility of residual biases is raised.  This 
highlights the need for robust trial evidence. 
 
2.7.3 Individual-level intervention vaccine studies 
  
There has been one further intervention trial126.  In a prospective randomised 
open with blinded endpoint (PROBE) study, 439 patients aged ≥50 years 
attending hospital in Thailand with acute coronary syndrome were randomised to 
receive influenza vaccination or not.  At 12 months, the vaccinated group had 
significantly fewer major adverse cardiovascular events (including deaths and 
hospitalisations for acute coronary syndrome, stroke or heart failure) – 9.5% 
versus 19.3%, adjusted HR 0.67 (95% CI 0.51 - 0.86), p=0.005.  There were also 
fewer hospitalisations for ACS in vaccinated patients compared to controls – 4.5% 
versus 10.6%, adjusted HR 0.68 (95% CI 0.47 - 0.98), p=0.039.  There was no 
significant difference in the incidence of cardiovascular death between the two 
68 
 
groups – 2.3% versus 5.5%, adjusted HR 0.39 (95% CI 0.14 - 1.12), p=0.088 – 
although the number of events was small. 
 
2.7.4 Updated meta-analysis 
 
When the meta-analysis was updated with results from this trial, the new pooled 
estimate showed a 54% reduction in risk of cardiovascular death in patients with 
existing cardiovascular disease who received influenza vaccination compared to 
controls (compared to a 49% reduction previously).  The fixed effect model 
showed a highly significantly protective effect and in the random effects model 
the protective effect only just failed to reach statistical significance – RR 0.46 
(95% CI 0.21 - 1.02).  Using the outcome AMI the new pooled point estimate also 
tended towards greater protection than before (a 33% reduction in events 
compared to 15% previously) but the effect was still not significant in either 
model – RR 0.66 (95% CI 0.39 - 1.13).  Results are presented in figures 2.4 & 2.5. 
 
Figure 2.4 Updated pooled analysis of the effect of influenza vaccination on risk of CVD death 
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Figure 2.5 Updated pooled analysis of the effect of influenza vaccination on risk of AMI 
 
  
M-H Overall  (I-squared = 0.0%, p = 0.555)
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3. Weekly time series study of influenza circulation and acute 
myocardial infarction in England & Wales and Hong Kong 
 
3.1 Description of chapter contents 
 
In this ecological time series study I investigate the relationship between 
influenza circulation and AMI-associated hospital admissions and deaths in 
England & Wales and in Hong Kong, where the summer influenza peak provides a 
natural experiment to examine any relationship with AMI independent of cold 
weather effects.  Data sources include routinely collected data on hospital 
admissions from Hospital Episode Statistics (England) and the Hospital Authority 
of Hong Kong coded by International Classification of Disease codes.  Similarly 
coded data on deaths are obtained from the Office for National Statistics (England 
& Wales) and Hong Kong Special Administrative Region Census and Statistics 
Department.  Influenza data are based on ILI consultations and proportions of 
laboratory specimens testing positive for influenza.  Poisson regression models 
adapted for time series are used to analyse any relationship between influenza 
and AMI, controlling for seasonality, long-term trends, environmental variables 
(weekly mean temperature and relative humidity) and lag times.  Estimates are 
made of the proportion of AMI admissions and deaths attributed to influenza 
under the models in each setting. 
 
3.2 Study rationale and introduction to data sources 
 
3.2.1 Effects of weather conditions on AMI and influenza 
 
A central problem in population-level studies of associations between influenza 
circulation and cardiovascular events is the potential for confounding by 
contemporaneous environmental stimuli.  A J-shaped curve has been described in 
which extremes of temperature are associated with increased mortality from all 
causes including cardiovascular disease127.  Cold weather induces various 
physiological changes such as increased blood pressure128, altered levels of 
clotting factors, vasopressors and C-reactive protein129 and an increase in whole 
blood viscosity130.  It thus may produce a pro-thrombotic state in which 
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myocardial infarction is more likely to occur131.  Hot ambient temperatures also 
place increased demands on the cardiovascular system and are associated with 
rises in mortality, especially among the elderly in whom ageing, the presence of 
chronic conditions and medication use may impair thermoregulation and 
homeostasis132.  Climatic factors including temperature and humidity affect 
influenza circulation133, with greater virus spread occurring in winter months.  I 
therefore decided to compare data from a sub-tropical climate (Hong Kong), 
where winters are warmer and there is a summer as well as a winter peak in 
influenza circulation, with data from England & Wales to examine whether a 
relationship between influenza and AMI was present in either or both settings 
after controlling for environmental factors. 
 
3.2.2 Clinical influenza surveillance  
 
Both England & Wales and Hong Kong have robust surveillance systems for 
influenza and publish routinely collected data based on clinical and 
microbiological definitions.  These datasets are described below to inform choices 
of surveillance data used in the study.  Influenza surveillance in the United 
Kingdom is co-ordinated through the Health Protection Agency Influenza 
Surveillance Section of the Respiratory Disease Department.  Traditionally, 
clinical surveillance has occurred through sentinel GP practices reporting weekly 
rates of consultations for influenza-like illness per 100,000 GP-registered 
persons.  The Royal College of General Practitioners (RCGP) Weekly Returns 
Service has a network of approximately 100 GPs reporting throughout England & 
Wales; there are also separate schemes for other countries in the UK.  These data 
are now supplemented by various telephone and internet-based surveillance 
schemes including the NHS Direct Syndromic Surveillance Scheme, the National 
Pandemic Flu Service (in 2009/2010 only), FluSurvey (an online survey of 
influenza in the general population co-ordinated through the London School of 
Hygiene & Tropical Medicine since 2009) and a community influenza telephone 
survey for the season 2011/2012 (run by the Health Protection Agency).  There is 
also a Medical Officers of Schools Association scheme, in which 42 boarding 
schools covering a population of 12,000 children predominantly in Southern 
England, send weekly reports of illnesses including ILI to the Respiratory 
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Diseases Department at the Health Protection Agency Centre for Infections (HPA 
CfI).  Influenza surveillance weeks run Monday to Sunday and are standardised 
across surveillance schemes.  In Hong Kong, weekly consultation rates for ILI per 
1,000 people are reported by sentinel general out-patient clinics and general 
practitioners and available online since 1998.  Currently (in 2012) the scheme 
comprises data from 64 general out-patient clinics and around 50 general 
practitioners in private practice.  Other clinical data are available on (all cause) 
school absenteeism rates as well as hospital admission rates for children aged 0-4 
with a primary diagnosis of influenza, via the University of Hong Kong’s School of 
Public Health Dashboard.  In Hong Kong ILI is defined as fever plus either cough 
or sore throat, while in England & Wales there is no formal definition. 
 
3.2.3 Laboratory influenza surveillance 
 
Microbiological data on influenza in England arise either through one of two 
sentinel virological surveillance schemes or from routine laboratory reports.  The 
HPA Virus Reference Department (VRD) / RCGP sentinel swabbing scheme 
involves around 85 English general practices participating in the RCGP clinical 
scheme.  General practitioners obtain nose and throat swabs from patients 
presenting with symptoms of influenza-like illness.  Specimens are tested at the 
VRD by real-time polymerase chain reaction for influenza and respiratory 
syncytial virus.  An advantage to these data is the presence of denominators, 
which allows the proportion of positive specimens to be determined.  A second 
virological surveillance scheme (the HPA CfI/ Regional Microbiology Network) is 
co-ordinated through a sentinel network of HPA and NHS laboratories.  Routine 
laboratory reports on clinical specimens yielding positive results for respiratory 
pathogens are also reported weekly to the HPA CfI through a voluntary scheme, 
although data on numbers tested are not routinely available.  Around 80% of 
influenza isolates reported in England, Wales and Scotland are sent to the HPA 
VRD for subtyping and antigenic characterisation.  In Hong Kong, monthly 
summary isolate tables are published on numbers and proportions of specimens 
testing positive for influenza obtained from patients who presented to the GP or 
general out-patient clinics with ILI as well as from patients hospitalised with 
acute respiratory diseases. 
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For this study I decided to use ILI data from sentinel surveillance in primary care 
as well as proportions of specimens testing positive for influenza: these are well 
established systems with clear denominators (to enable illness rates to be 
calculated) and data are available dating back to the late 1990’s.   
 
3.3 Aims and objectives 
 
Aim: to investigate the relationship between population levels of influenza 
circulation and hospitalisations and deaths due to AMI in England & Wales and 
Hong Kong.  
 
Objectives: 
1) To describe time trends in influenza circulation, and AMI-related hospital 
admissions and deaths for the period 1999-2008 in England & Wales and 
Hong Kong. 
2) To generate Poisson regression models of the relationship between 
influenza circulation and AMI in each setting adjusting for seasonality, 
long-term trends, lag times and potential environmental confounders such 
as temperature and relative humidity.  
3) To perform sensitivity analyses investigating the effect of using different 
methods to model environmental and temporal confounders. 
4) To investigate the presence of age or gender differences in effects 
5) To model whether two ‘counterfactual conditions’ – colon cancer and 
fractured neck of femur – were associated with influenza under similar 
conditions. 
6) To estimate the proportion of AMI-related hospital admissions and deaths 
attributable to influenza under the models in each setting. 
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3.4 Methods  
 
3.4.1 Data on AMI outcomes 
 
I obtained data on numbers of hospitalisations and deaths associated with AMI 
occurring during the period January 1999 until December 2008 classified using 
the International Classification of Diseases, Ninth Revision (ICD-9 code 410) and 
Tenth Revision (ICD-10 codes I-21, I-22 and I-23).  In England, I applied for 
hospitalisation data from Hospital Episode Statistics (the NHS Information Centre 
for Health and Social Care), which gave counts of AMI-associated hospitalisations 
based on the coded discharge diagnosis of finished consultant episodes by fiscal 
week of admission, age-group, sex, and region.  Further information on the 
structure of the Hospital Episode Statistics database is given in chapter 5, section 
5.2, p127.  I also obtained daily mortality data on deaths from AMI or its 
complications by age group and sex in England and Wales from the Office for 
National Statistics.  Equivalent AMI data for Hong Kong for the same time period 
were obtained from the Hospital Authority of Hong Kong (hospitalisations) and 
the Hong Kong Special Administrative Region Census and Statistics Department 
(deaths).  I then aggregated daily numbers of hospitalisations and deaths 
associated with AMI in both regions by influenza surveillance week.  I calculated 
age-standardised rates of AMI with reference to the World Health Organisation 
World Standard Population.   Hospitalisation data for two counterfactual 
conditions – colon cancer (ICD-9 codes 153 and 154; ICD-10 codes C18, C19 and 
C20) and fractured neck of femur (ICD-9 820; ICD-10 S72.0 and S72.1) chosen 
due to its increased incidence in winter – were also obtained for both settings. 
 
3.4.2 Data on influenza circulation 
 
Weekly influenza surveillance data were obtained for both settings.  In England 
and Wales, these were weekly rates of GP consultations for ILI from the RCGP 
network for the time period 1999–2008.  Weekly proportions of nose and throat 
swabs testing positive for influenza virus during the influenza season (week 40–
week 20) over the same time period were also obtained from the HPA/RCGP 
swabbing scheme.  In Hong Kong, I obtained weekly rates of ILI consultations per 
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1000 persons reported by sentinel general practitioner and general out-patient 
clinics (GOPC) from the Centre for Health Protection.  Laboratory surveillance 
data obtained from the same source comprised monthly proportions of 
specimens that tested positive for influenza.  I used linear interpolation to 
generate weekly proportions of specimens testing positive from these monthly 
data.  In sensitivity analysis I also interpolated monthly proportions of influenza 
virus–positive specimens to weekly proportions using spline functions. 
 
3.4.3 Data on environmental variables 
 
I requested data on daily minimum, mean, and maximum temperatures for the 
time period of the study from the Meteorological Office Hadley Centre Central 
England Temperature dataset via the British Atmospheric Data Centre.  Central 
England temperatures are representative of a roughly triangular area bounded by 
Bristol, Lancashire, and London.  I used the MIDAS Land Surface Observation 
Stations dataset (also obtained from the British Atmospheric Data Centre) to 
provide daily data on relative humidity for an approximately equivalent area 
(incorporating weather stations in Somerset, Lancashire, and London).  For Hong 
Kong, daily data on minimum, mean, and maximum temperature and mean daily 
relative humidity were obtained from the Hong Kong Observatory.  I then 
calculated the mean of each daily temperature and humidity parameter across 
influenza surveillance weeks for each setting. 
 
3.4.4 Statistical analysis 
 
I modelled the weekly number of acute myocardial infarction-related events 
(either hospitalisations or deaths) in each setting using a Poisson regression 
model with a scale parameter set to the Pearson Χ2 statistic divided by the 
residual degrees of freedom to model over-dispersion134.  I adjusted for long-term 
trends in rates of AMI-associated hospitalisations and deaths using both a linear 
and quadratic term for calendar year.  This enabled only acute effects of the 
exposure (influenza circulation) on the outcome (AMI) to be assessed.  In Hong 
Kong, data from 2003 were excluded from analysis, because the 2003 outbreak of 
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severe acute respiratory syndrome (SARS) substantially affected both health-
seeking behaviour and the reliability of reporting.   
 
In the main model I controlled for seasonal changes in AMI patterns using Fourier 
terms with 6 harmonics per year.  In the Fourier approach, regular seasonal 
cycles are modelled as a linear combination of pairs of sine and cosine terms 
(harmonics) of varying wavelengths.  Different numbers of harmonics were 
assessed initially and the model with the lowest Akaike Information Criterion 
(AIC) chosen as the final model135.  Second, in sensitivity analysis I modelled AMI 
seasonality through simple stratification by month in place of Fourier terms.  
Third I modelled both seasonality and long-term trends using spline functions; a 
spline function has a flexible shape, with smoothness determined by the number 
of knots (or breakpoints) within splines, and is useful for modelling unknown and 
potentially variable seasonal and long term patterns136.  In the spline models a 
judgement was made about the most appropriate number of knots per year to 
include.  This was guided by the AIC and based on a balance between providing 
adequate control for potential confounders whilst avoiding generating large 
numbers of parameters and leaving insufficient information from which to 
estimate effects of influenza.  Adequate seasonal adjustment allows variation in 
AMI-associated events explained by seasonality to be removed, allowing better 
assessment of the effect of the exposure (influenza).   
 
The primary exposure was weekly levels of influenza.  In England and Wales, 
weekly GP consultations for ILI were used to represent circulating influenza: in 
temperate zones, weeks with highest ILI rates correspond to or closely track 
weeks with the highest proportion of samples testing positive for influenza 
virus137.  ILI data were also available throughout the year whereas virus data 
were only available in weeks 40-20.  In contrast in Hong Kong, the primary 
measure of influenza used was weekly proportion of specimens testing positive 
for influenza virus: patterns of influenza seasonality are less clear in subtropical 
climates, so ILI data are thought to be less specific for influenza than in temperate 
zones138.  Influenza surveillance data are potentially affected by delays in both 
consulting and reporting and thus may lag behind the true community incidence 
of infection.  Therefore, I performed separate regressions with the exposure 
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variable lagged up to 4 weeks in either direction. Results are presented as an 
incidence rate ratio (IRR) for AMI-associated hospitalisation or death for a 10th–
90th percentile change in influenza circulation.  Final models were chosen with 
reference to the lowest AIC.   
 
Models also included mean weekly temperature and relative humidity, both 
modelled as 4-knot natural cubic splines to allow for non-linearity.  Sensitivity 
analyses included use of weekly mean temperature modelled as a linear term and 
as a low threshold effect, with the cut-off based on graphs showing where the 
predicted risk ratio of AMI-associated death or hospitalisation rose to >1, and use 
of daily minimum and maximum temperatures averaged separately by week and 
included in models as natural cubic splines.  I examined the partial 
autocorrelation function to investigate the presence of any residual 
autocorrelation.  All models were fitted with a term for residuals lagged by 1 
week, because some degree of autocorrelation at a lag of 1 week remained after 
adjusting for yearly and seasonal patterns.   
 
I repeated analyses using two different outcomes unlikely to be associated with 
influenza circulation: hospital admissions for colon cancer and fractured neck of 
femur in both settings.  I also conducted an exploratory analysis to examine the 
relationship between influenza and AMI by age and sex.  Finally, I calculated the 
proportion of AMI-related events attributed to influenza by predicting the 
number of AMIs under the final model (X) and under a model assuming zero 
circulating influenza (Y) as (X -Y)/X.  This calculation was repeated for weeks of 
high influenza circulation (≥90th percentile of ILI consultations or proportion of 
specimens testing positive).   All analyses were performed using Stata (Stata 
Statistical Software: Release 11. College Station, TX: StataCorp LP). 
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3.5 Results 
 
3.5.1 Descriptions of AMI and influenza patterns 
3.5.1.i England & Wales 
Between January 1999 and December 2008, there were 1,219,150 AMI-associated 
hospitalisations (median 2421 per week; interquartile range (IQR) 2112 - 2578) 
in England, of which 62.5% occurred in male patients.  The median weekly age-
standardised rate was 2.81 cases per 100,000 persons.  Over the same time 
period 410,204 AMI-associated deaths (median 777 deaths per week; IQR 639 -
908 deaths per week) were reported in England and Wales.  Both AMI-associated 
deaths and hospitalisations demonstrated a marked winter peak.   
 
GP consultation rates for ILI varied from 0.8 to 270.8 consultations per 100,000 
persons per week (mean 16.2 consultations per 100,000 persons per week) and 
were highest in 1998–1999 and 1999–2000, corresponding to circulation of the 
A/Sydney/5/97 strain of influenza A H3N2 subtype.  ILI consultations showed a 
similar distribution to the weekly percentage of specimens testing positive for 
influenza virus during the influenza season, which ranged from 0% to 100% 
(mean 18.1%).  Figure 3.1 below shows that seasonal peaks in ILI consultations 
during the study period correlated well with the proportion of specimens testing 
positive for influenza. 
 
Figure 3.1 GP consultation rates for ILI in England & Wales compared to the proportion of 
specimens testing positive for influenza from 1999 to 2008 
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3.5.1.ii Hong Kong 
In Hong Kong, during the period from January 1998 to December 2008, there 
were 65,108 AMI-associated hospitalisations (median 110 per week; IQR 97 - 
126), equating to a median weekly age-standardised rate of 1.11 cases per 
100,000 persons.  59.6% of these occurred in male patients.  There were also 
18,780 AMI-associated deaths (median 32 deaths per week; IQR 27 - 38 deaths 
per week).  There appeared to be a large winter peak, as well as a smaller summer 
increase in the number of AMIs. 
 
The percentage of specimens testing positive for influenza virus (measured 
throughout the year) varied from 0.3% to 51.9% (mean 13%) per week.  Figure 
3.2 demonstrates the weaker correlation between clinical ILI and laboratory 
isolation rates in Hong Kong compared to England & Wales.  Table 3.1 describes 
ILI consultations, proportions of specimens testing positive for influenza and 
additional descriptions of exposure variables such as mean temperature and 
relative humidity in both settings.  
 
Figure 3.2 GP consultation rates for ILI in Hong Kong compared to the proportion of specimens 
testing positive for influenza from 1998 to 2008 
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Table 3.1 Description of influenza and meteorological variables in England & Wales and Hong Kong over the study period  
*‘P10’ refers to 10th percentile, ‘P25’ to 25th percentile etc 
† England & Wales laboratory data on proportion of specimens testing positive for influenza only available during the influenza surveillance season (weeks 40 – 20) 
 
Variable No. of weeks Mean (SD) Min P10* P25 P50 P75 P90 Max 
Influenza – England & Wales 
GP consultation rate for ILI (per 100,000) 
Specimens testing positive for influenza (%) 
 
 
520 
325† 
 
 
16.2 (24.1) 
18.1 (20.9) 
 
 
0.8 
0 
 
 
3.0 
0 
 
 
5.1 
0 
 
 
9.5 
9.6 
 
 
18.2 
33.3 
 
 
34.2 
50 
 
 
270.8 
100 
 
Meteorological variables – England & Wales 
Mean temperature (ºC) 
Relative humidity (%) 
 
 
520 
520 
 
 
10.4 (4.8) 
80.6 (5.3) 
 
 
-0.1 
61.8 
 
 
4.2 
73.4 
 
 
6.4 
76.8 
 
 
10.2 
81.1 
 
 
14.5 
84.6 
 
 
16.7 
87.2 
 
 
22.0 
93.6 
 
Influenza – Hong Kong 
GP consultation rate for ILI (per 1,000) 
GOPC consultation rate for ILI (per 1,000) 
Specimens testing positive for influenza (%) 
 
 
571 
571 
570 
 
 
47.1 (12.4) 
5.4 (2.6) 
13.0 (10.3) 
 
 
22.9 
1.0 
0.3 
 
 
35.0 
2.8 
1.8 
 
 
38.9 
3.7 
4.1 
 
 
45.3 
4.8 
10.7 
 
 
52.0 
6.5 
19.4 
 
 
60.3 
8.3 
27.0 
 
 
123.0 
19.7 
51.9 
 
Meteorological variables – Hong Kong 
Mean temperature (ºC) 
Relative humidity (%) 
 
571 
571 
 
 
23.6 (4.8) 
78.0 (7.9) 
 
11.4 
40.6 
 
16.9 
66.9 
 
19.7 
74.3 
 
24.7 
79.4 
 
27.7 
83.4 
 
29.0 
86.6 
 
30.5 
93.6 
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3.5.2 Modelling AMI seasonality and long-term trends 
 
Table 3.2 shows the number of parameters and AICs associated with various 
different ways of modelling seasonality and long-term trends in AMI deaths in 
both settings.  The main three types of model for seasonality shown are a) models 
with an indicator variable for month, 2) models with Fourier terms and 3) models 
using spline functions.  Three models, highlighted in bold, represent the models 
judged to be the ‘best fit’ for each category based on the lowest AIC achieved 
without excessively increasing the number of parameters (and ‘over-fitting’ 
models to the data).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
82 
 
 
Contents of model 
Hong Kong England & Wales 
No. of 
parameters 
AIC AIC 
(icomp) 
No. of 
parameters 
AIC AIC 
(icomp) 
Monthly term 
(i.month) 
11 6.71 3830 11 43.66 22700 
Month/year term 
(i.monthyr) 
131 6.64 3788 119 11.17 5805 
Monthly term & 
linear year term & 
linear year term2  
13 6.70 3824 13 12.18 6332 
Fourier terms n=1 & 
linear year  
3 6.76 3859 3 12.58 6539 
Fourier terms n=2 & 
linear year 
5 6.67 3809 5 12.09 6285 
Fourier terms n=3 & 
linear year 
7 6.68 3812 7 12.01 6242 
Fourier terms n=4 & 
linear year 
9 6.68 3813 9 11.83 6148 
Fourier terms n=5 & 
linear year 
11 6.67 3808 11 11.67 6068 
Fourier terms n=6 & 
linear year 
13 6.68 3810 13 11.61 6036 
Fourier terms n=6 
& linear year term 
& linear year term2 
14 6.66 3802 14 11.58 6018 
Spline (knots=0.7 
per year) 
10 7.17 4094 9 18.56 9654 
Spline (knots=0.8 
per year) 
11 7.16 4091 10 18.46 9597 
Spline (knots=0.9 
per year) 
12 7.15 4085 11 18.23 9481 
Spline (knots= 1 per 
year) 
13 7.14 4076 12 18.02 9370 
Spline (knots= 2 per 
year) 
24 6.91 3945 22 15.61 8116 
Spline (knots= 3 
per year) 
35 6.58 3757 32 11.92 6201 
Spline (knots= 4 per 
year) 
46 6.52 3721 42 11.67 6071 
Spline (knots= 5 per 
year) 
57 6.49 3707 52 11.29 5873 
Spline (knots= 6 per 
year) 
68 6.51 3719 62 11.15 5798 
Spline (knots= 7 per 
year) 
79 6.53 3726 72 10.99 5715 
Table 3.2 Models of seasonality and long-term trends, number of parameters and AICs for weekly 
AMI-associated mortality in Hong Kong and England & Wales 
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3.5.3 Associations between influenza and AMI 
3.5.3.i AMI-associated deaths 
Graphs of seasonal patterns of influenza circulation and numbers of AMI-
associated deaths over the study time course are shown in figure 3.3.  A clear 
correlation between the two crude variables is demonstrated, most obviously in 
England & Wales, where numbers of events are higher and there is only one 
influenza peak per season. 
 
Figure 3.3 Weekly influenza circulation and number of AMI-associated deaths in England & Wales 
and Hong Kong   
 
3.3a England & Wales 
 
3.3b Hong Kong 
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Table 3.3 (below) shows results from crude and adjusted Poisson regression 
analysis for both settings.  These initial models assumed no lag time between 
reporting of influenza and AMI death.  A strong association was seen between GP 
consultations for ILI and AMI-associated deaths in England & Wales, both before 
and after adjusting for environmental temperature, humidity and autocorrelation 
(adjusted IRR 1.036 (95% CI 1.028 - 1.043), p<0.001).  In Hong Kong  there was a 
similarly robust association between the proportion of specimens testing positive 
for influenza virus and AMI-associated deaths occurring in the same week 
(adjusted IRR 1.077 (95% CI 1.013 - 1.145), p=0.018) for a 10th–90th percentile 
change in proportion of positive specimens after adjusting for potential 
confounding factors. 
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Table 3.3 Adjusted IRRs for the change in AMI-associated deaths associated with a 10th-90th percentile change in influenza circulation 
Model England & Wales Hong Kong 
IRR (95% CI) p value AIC IRR (95% CI) p value AIC 
Adjusted for seasonality and 
long-term trends 
1.0359 (1.0290-1.0429) <0.001 11.07 1.0705 (1.0043-1.1410) 0.036 6.63 
As above adjusted for 
temperature 
1.0355 (1.0287-1.0424) <0.001 10.97 1.0723 (1.0067-1.1422) 0.030 6.60 
As above adjusted for 
temperature & humidity 
1.0355 (1.0286-1.0424) <0.001 10.98 1.0780 (1.0121-1.1482) 0.020 6.59 
As above adjusted for 
temperature, humidity and 
residual autocorrelation 
1.0356 (1.0278-1.0434) <0.001 10.71 1.0770 (1.0129–1.1453) 0.018 6.54 
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In England and Wales the best fitting models included lags of either –1 week 
(adjusted IRR 1.051 (95% CI 1.043 - 1.058), p<0.001) for a 10th–90th percentile 
change in ILI consultations occurring 1 week later, or –2 weeks (adjusted IRR 
1.056 (95% CI 1.049 - 1.064), p<0.001).  In Hong Kong, the best model fits were 
seen around lag 0, with similar results given by models including lags of –1 week 
(adjusted IRR 1.076 (95% CI 1.012 - 1.144), p=0.02) and +1 week (adjusted IRR 
1.074 (95% CI 1.010 - 1.142), p=0.023).  An additional description of the lag time 
between ILI consultations and AMI-associated deaths is shown in figure 3.4. 
 
Figure 3.4 Schematic illustration of the interpretation of lag times in the analysis of associations 
between AMI–associated death and ILI consultations. For example in the analysis with a lag time 
of -1 week, AMI-associated deaths in week 1 are correlated with ILI consultations in week 2, etc. 
 
 
 
 
3.5.3.ii AMI-associated hospitalisations 
In England and Wales, ILI consultations lagged by –1 to –3 weeks (representing 
the best model fits) were associated with AMI-associated hospitalisation after 
adjusting for seasonality and environmental variables. There was strong evidence 
of a small effect: IRR for a lag of –1 week, 1.009 (95% CI 1.003 - 1.015), p=0.004; 
IRR for a lag of –2 weeks, 1.013 (95% CI 1.008 - 1.019), p<0.001; IRR for a lag of –
3 weeks, 1.012 (95% CI 1.006 - 1.019), p<0.001.  There was no association 
between ILI consultation rates and AMI-associated hospitalisations reported in 
the same week - IRR 1.002 (95% CI 0.996 - 1.003), p=0.59. 
 
In Hong Kong, an association was seen between the proportion of influenza 
positive specimens and AMI-associated hospitalisations in the same week (IRR 
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1.066 (95% CI 1.024 - 1.109), p=0.002), after adjustment for seasonality and 
environmental variables.  Similar model fits and results were given by models 
including lag times of –1 week (IRR 1.067 (95% CI 1.025 - 1.110), p=0.001) and 
+1 week (IRR 1.066 (95% CI 1.024 - 1.109), p=0.002).  Table 3.4 shows the effect 
of including different lag times for influenza reporting on AMI-associated 
hospitalisations and deaths. 
 
 
Lag time 
(weeks)δ 
England & Wales Hong Kong 
Adjusted IRR (95% CI)* 
for AMI hospitalisations 
p value Adjusted IRR (95% CI)† for 
AMI hospitalisations 
p value 
– 4  
– 3 
– 2 
– 1 
   0 
+ 1  
+ 2 
+ 3 
 
1.006 (1.000-1.012) 
1.012 (1.006-1.019) 
1.013 (1.008-1.019) 
1.009 (1.003-1.015) 
1.002 (0.996-1.008) 
0.996 (0.990-1.002) 
0.994 (0.988-1.000) 
0.997 (0.991-1.003) 
0.05 
<0.001 
<0.001 
0.004 
0.59 
0.21 
0.04 
0.35 
1.032 (0.991-1.074) 
1.043 (1.002-1.086) 
1.057 (1.015-1.100) 
1.067 (1.025-1.110) 
1.066 (1.024-1.109) 
1.066 (1.024-1.109) 
1.059 (1.017-1.102) 
1.035 (0.994-1.078) 
0.13 
0.04 
0.007 
0.001 
0.002 
0.002 
0.005 
0.09 
Lag time 
(weeks)  
Adjusted IRR (95% CI)* 
for AMI deaths 
p value 
 
Adjusted IRR (95% CI)† for 
AMI deaths 
p value 
 
– 4  
– 3 
– 2 
– 1 
   0 
+ 1  
+ 2 
+ 3 
 
1.020 (1.012-1.028) 
1.042 (1.033-1.050) 
1.056 (1.049-1.064) 
1.051 (1.043-1.058) 
1.036 (1.028-1.043) 
1.021 (1.013-1.029) 
1.013 (1.005-1.021) 
1.010 (1.002-1.018) 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
0.002 
0.015 
1.010 (0.950-1.074) 
1.027 (0.966-1.092) 
1.043 (0.981-1.110) 
1.076 (1.012-1.144) 
1.077 (1.013-1.145) 
1.074 (1.010-1.141) 
1.068 (1.004-1.136) 
1.056 (0.992-1.124) 
0.75 
0.40 
0.18 
0.020 
0.018 
0.023 
0.037 
0.089 
Table 3.4 Adjusted IRRs for the change in AMI associated with a 10th-90th percentile change in 
influenza circulation, lagged by differing numbers of weeks in England & Wales and Hong Kong 
 
δNote a lag time of ‘minus 2 weeks’ refers to influenza activity occurring two weeks after AMI 
events in week 0, whereas a lag of ‘plus two weeks’ refers to ILI consultations taking place two 
weeks before AMI events in week 0. 
*IRR for a 10th – 90th percentile change in GP ILI consultations adjusted for seasonality and long-
term trends, weekly mean temperature, weekly mean relative humidity and residual 
autocorrelation 
†IRR for a 10th – 90th percentile change in proportion of specimens testing positive for influenza 
adjusted for the same factors as above 
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3.5.4 Sensitivity analyses 
 
Adjustments were made to the final model to test the robustness of effect 
estimates.  Modelling AMI seasonality using alternative methods such as spline 
functions or indicator variables for month with a linear and quadratic term for 
calendar year had little effect on the magnitude and direction of influenza effect 
estimates.  Including weekly mean temperature modelled as a linear term and as 
a low threshold effect gave similar results to the final model in which temperature 
was included as a natural cubic spline.  The best model fits were seen at 
temperature lags of either 0 or 1 week, which gave similar results.  Use of the 
mean of weekly maximum and then of weekly minimum temperatures modelled 
as natural cubic splines made little difference to effect estimates.  In Hong Kong, 
use of the weekly percentage of positive specimens interpolated using a spline 
function rather than simple linear interpolation gave slightly lower point 
estimates but similar effects for both AMI-associated deaths and AMI-associated 
hospitalisations.  Results of the main sensitivity analyses are shown in table 3.5. 
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Table 3.5 Sensitivity analyses showing effect of varying seasonality, temperature and measures of exposure in England & Wales and Hong Kong 
 φ Ncs = natural cubic spline 
*IRR for the effect of a 10th – 90th percentile change in weekly GP ILI consultations lagged by minus two weeks on AMI, adjusted for seasonality and long-term 
trends, weekly mean temperature, weekly mean relative humidity and residual autocorrelation 
† IRR for the effect of a 10th – 90th percentile change in weekly proportion of specimens testing positive for influenza virus on AMI (with no lag), adjusted for 
seasonality and long-term trends, weekly mean temperature, weekly mean relative humidity and residual autocorrelation 
Sensitivity analyses AMI hospitalisations (England 
& Wales) 
AMI deaths (England & Wales) AMI hospitalisations (Hong 
Kong) 
AMI deaths (Hong Kong) 
IRR (95% CI) p value IRR (95% CI) p value IRR (95% CI) pvalue IRR (95% CI) pvalue 
Final model 
a) Seasonality 
Indicator month variable  
Splines (3 or 5 knots per yr) 
b) Temperature 
Linear term for mean temp 
Low threshold effect 
Ncsφ of maximum temp 
Ncsφ of minimum temp 
Ncsφ of mean temp averaged 
across weeks 0 and 1 
c) % of positive specimens 
From spline interpolation of 
monthly data 
1.013 (1.008 -1.019)* 
 
1.016 (1.010 – 1.022) 
1.025 (1.016 – 1.034) 
 
1.014 (1.008 – 1.020) 
1.014 (1.008 – 1.020) 
1.014 (1.008 – 1.020) 
1.013 (1.007 – 1.019) 
1.012 (1.006 – 1.017) 
 
 
- 
 
<0.001 
 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
- 
 
1.056 (1.049 – 1.064)* 
 
1.063 (1.055 – 1.071) 
1.063 (1.052 – 1.073) 
 
1.057 (1.050 – 1.065) 
1.057 (1.050 – 1.065) 
1.056 (1.049 – 1.064) 
1.056 (1.048 – 1.063) 
1.056 (1.049 – 1.063) 
 
 
- 
 
<0.001 
 
<0.001 
<0.001 
 
<0.001 
<0.001 
<0.001 
<0.001 
<0.001 
 
 
- 
 
1.066 (1.024 – 1.109)† 
 
1.059 (1.019 – 1.101) 
1.066 (1.016 – 1.118) 
 
1.066 (1.024 – 1.109) 
1.061 (1.019 – 1.104) 
1.065 (1.023 – 1.109) 
1.065 (1.024 – 1.109) 
1.067 (1.027 – 1.108) 
 
 
1.058 (1.021 – 1.097) 
 
0.002 
 
0.004 
0.009 
 
0.002 
0.004 
0.002 
0.002 
0.001 
 
 
0.002 
 
1.077 (1.013 – 1.145)† 
 
1.088 (1.025 – 1.155) 
1.113 (1.030 – 1.201) 
 
1.076 (1.012 – 1.145) 
1.073 (1.009 – 1.141) 
1.076 (1.012 – 1.144) 
1.076 (1.012 – 1.144) 
1.074 (1.010 – 1.141) 
 
 
1.048 (0.993 – 1.107) 
 
0.018 
 
0.006 
0.006 
 
0.019 
0.026 
0.020 
0.020 
0.021 
 
 
0.090 
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3.5.5 Association between influenza and hospitalisations for ‘counterfactual 
conditions’, colon cancer and fractured neck of femur 
 
In England & Wales, hospitalisations for colon cancer were not associated with 
influenza circulation in the same week after adjustment for these same 
confounders (adjusted IRR 1.005 (95% CI 0.990 - 1.021), p=0.48).  Figure 3.5 
shows patterns of influenza circulation and hospitalisations for colon cancer over 
the same time period.  Investigation of lag times revealed that there was also no 
association between colon cancer admissions and influenza circulation lagged by 
up to three weeks in either direction.  For the outcome fractured neck of femur, 
despite a peak in hospitalisations in winter months, there was no association with 
influenza circulation in the same week (adjusted IRR 1.009 (95% CI 0.997 - 
1.021), p=0.16) or lagged by up to three weeks. 
 
Neither hospitalisations for colon cancer (adjusted IRR 0.975 (95% CI 0.938 - 
1.014), p=0.21) nor fractured neck of femur (adjusted IRR 0.994 (95% CI 0.964 - 
1.024), p=0.68) were associated with influenza circulation in the same week in 
Hong Kong after adjustment for seasonality, long-term trends, environmental 
confounders and residual autocorrelation.  
 
Figure 3.5 Weekly hospitalisations for colon cancer and ILI consultation rates in England & Wales 
from 1999-2008 
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3.5.6 Analysis stratified by age-group and gender  
 
In both settings, the strongest associations between influenza and AMI were seen 
in the oldest age groups (those aged 80 years and above, and, to a lesser extent, 
those aged 60–79 years).  In England & Wales, the adjusted IRR for AMI 
hospitalisations associated with influenza in the over 80s was 1.028 (95% CI 
1.010-1.046), p=0.002 compared to adjusted IRR 0.965 (95% CI 0.931 - 1.000), 
p=0.05) in the under 40s.  In Hong Kong the over 80s had an adjusted IRR of 
1.161 (95% CI 1.086 - 1.240), p<0.001 compared to adjusted IRR 0.892 (95% CI 
0.675 - 1.178), p=0.42 for people aged under 40 years.  Incidence rate ratios for 
women appeared to be slightly higher than those seen for men – table 3.6. 
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Table 3.6 Models of the association between influenza and AMI in England & Wales and Hong Kong overall and stratified by gender and age group.  Note no age-
specific data were available for Hong Kong AMI deaths. 
 
*IRR for the effect of a 10th – 90th percentile change in weekly GP ILI consultations lagged by minus two weeks on AMI, adjusted for seasonality and long-term 
trends, weekly mean temperature, weekly mean relative humidity and residual autocorrelation 
† IRR for the effect of a 10th – 90th percentile change in weekly proportion of specimens testing positive for influenza virus on AMI (with no lag), adjusted for 
seasonality and long-term trends, weekly mean temperature, weekly mean relative humidity and residual autocorrelation 
Stratification E&W AMI hospitalisations† 
 
E&W AMI deaths† HK AMI hospitalisations* HK AMI deaths* 
IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value IRR (95% CI) P value 
Overall result 
 
Gender 
Males 
Females 
 
Age group 
Under 40 
40 to 59 
60 to 79 
80 and over 
 
1.013 (1.008-1.019) 
 
 
1.007 (0.993-1.022) 
1.015 (1.000-1.031) 
 
 
0.965 (0.931-1.000) 
1.000 (0.985-1.015) 
1.009 (0.995-1.023) 
1.028 (1.010-1.046) 
<0.001 
 
 
0.303 
0.045 
 
 
0.050 
0.994 
0.208 
0.002 
1.056 (1.049-1.064) 
 
 
1.049 (1.040-1.057) 
1.064 (1.055-1.073) 
 
 
0.974 (0.890-1.065) 
1.034 (1.016-1.053) 
1.053 (1.043-1.062) 
1.064 (1.054-1.073) 
<0.001 
 
 
<0.001 
<0.001 
 
 
0.563 
<0.001 
<0.001 
<0.001 
1.066 (1.024-1.109) 
 
 
1.041 (0.993-1.091) 
1.103 (1.043-1.165) 
 
 
0.892 (0.675-1.178) 
0.982 (0.895-1.078) 
1.057 (1.006-1.111) 
1.161 (1.086-1.240) 
0.002 
 
 
0.099 
0.001 
 
 
0.419 
0.706 
0.030 
<0.001 
1.077 (1.013 - 1.145) 
 
 
1.032 (0.952-1.119) 
1.141 (1.044-1.247) 
 
 
N/A 
0.018 
 
 
0.440 
0.004 
 
 
N/A 
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3.5.7 Predicted percentage of AMIs attributable to influenza 
 
Proportions of AMI-associated deaths attributed to influenza under the final 
models ranged from 3.9% - 5.6% for Hong Kong and 3.1% - 3.4% for England and 
Wales, depending on the model of seasonality used.  Proportions of AMI-
associated hospitalisations attributed to influenza were smaller in both settings: 
3.0% - 3.3% and 0.7% - 1.2%, respectively.  In weeks in which influenza 
circulation was in the ≥90th percentile, 9.7% - 13.6% of AMI-associated deaths in 
Hong Kong and 10.7% - 11.8% of AMI-associated deaths in England and Wales 
were attributed to influenza.  For AMI-associated hospitalisations, the 
corresponding figures were 7.5% - 8.2% and 2.5% - 4.6%.  Figure 3.6 shows an 
example of excess AMI deaths expected in Hong Kong at times of peak influenza 
circulation. 
 
Figure 3.6 Predicted AMI deaths in Hong Kong under the model (blue) compared to predicted 
deaths under a model where influenza circulation was set to zero (orange) 
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3.6 Discussion 
 
3.6.1 Summary of findings 
 
These results demonstrate strong associations between population levels of 
influenza and AMI-associated deaths and hospitalisations in both a temperate 
(England and Wales) and subtropical climate (Hong Kong) after adjustment for 
temporal trends and relevant environmental confounders.  I estimate that a small 
but important proportion of AMIs in both settings may be attributed to influenza, 
with figures increasing in weeks of highest influenza circulation.   
 
3.6.2 Study strengths 
 
A strength of this study was the comparison of data from a temperate and a 
subtropical climate.  Although most early ecological studies were done in 
temperate zones, it has more recently been suggested that influenza-associated 
mortality in warm regions such as Hong Kong is comparable to that of temperate 
regions139.  I saw a slightly greater effect of influenza on both AMI-associated 
deaths and hospitalisations in Hong Kong versus England and Wales, but this 
should be interpreted with caution because population size, and therefore the 
number of events in Hong Kong, was much lower.  Extremes of temperature are 
known to be associated with deaths due to cardiovascular disease140.  The use of 
several methods to control for temperature and the differing relationship of 
influenza with temperature in Hong Kong, including the presence of a summer 
influenza peak, reduced the chance that residual confounding by environmental 
variables was responsible for effects observed.  Another strength was the use of 
the same models with two other ‘counterfactual conditions’ (colon cancer and 
fractured neck of femur) as outcomes, which found no association with influenza, 
despite the increased incidence of fractured neck of femur in winter.  This 
suggests that associations seen with AMI were not spurious and related to the 
modelling method.  This is also the first study to estimate the influenza- 
attributable risk of AMI-hospitalisations and deaths: previous ecological studies 
have tended instead to estimate the proportion of influenza-associated excess 
mortality due to cardiovascular or AMI deaths. 
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3.6.3 Study limitations – reporting delays in routine surveillance data 
 
Weaknesses inherent to using routine surveillance data for research include 
potential lack of coverage and lack of timeliness141.  Although underreporting of 
influenza is common, this would tend to dilute rather than bias the direction of 
our results.  Reporting delays are potentially more problematic.  One United 
Kingdom–based study showed that telephone calls to NHS Direct for colds and 
influenza preceded GP reports of the same symptoms by 1 - 3 weeks142.  This may 
explain why we saw the best model fits, and greatest estimates of effect, when UK 
influenza data was lagged by –1 to –3 weeks (representing our assumption that 
reported ILI consultations represent illness occurring in the community some 
time earlier).  A US study found a 1 to 2 week lag between internet searches for 
influenza-associated information and primary care consultations for ILI101.  A 
survey of 918 people with an ILI attending GPs in England showed that 
approximately one half of persons aged >45 years waited at least 6 days before 
consulting a GP, with 13% waiting for two or more weeks143.  Although 
consultation delays in surveillance data are the most likely explanation, peaks in 
AMIs might precede GP reports of ILI if triggered by other synchronous 
environmental events; however, we used multiple sensitivity analyses to control 
for temperature.  
 
3.6.4 Study limitations – controlling for circulating respiratory viruses 
   
Other respiratory viruses such as respiratory syncytial virus (RSV) or human 
metapneumovirus may cause influenza-like illness symptoms.  While their 
association with AMI is not known, it is possible that some of the apparent 
association between influenza and AMI was explained by co-circulating 
respiratory viruses.  Although I considered controlling for other viruses, 95% of 
RSV samples in the United Kingdom are recovered from children144, and RSV 
seasonality tends to differ from that of influenza.  Human metapneumovirus is not 
common in adults145 and data were not available for the time period of the study.  
In the United Kingdom, although ILI consultations lack specificity for influenza, 
the highest positive predictive values of ILI occur at times of peak influenza 
circulation34.  I did not use influenza virus data, which were limited by relatively 
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small numbers of specimens (mean 37 per week) and confined to the influenza 
season.  The peak week of influenza virus activity in the UK tends to precede the 
peak for ILI consultations by around 2 weeks146.  In Hong Kong, where influenza 
virus data were used as the main exposure, I did not see the same pattern of lag 
times.  Differences in consulting behaviour may explain the reduced reporting 
delay in Hong Kong influenza data.  After the SARS outbreak of 2003, official 
advice was to consult a doctor as soon as influenza-like symptoms are 
experienced.  In contrast, campaigns in the UK throughout the late 1990s aimed to 
discourage attendance at the GP for colds and ILI, to try to reduce unnecessary 
prescriptions of antibiotics144. 
 
3.6.5 Interpretation of results in context of previous findings 
 
Similar studies have shown rises in related but less specific outcomes, such as 
deaths due to cardiovascular disease30,64,71, or less sensitive outcomes, such as 
autopsy-confirmed AMI-associated deaths76, during influenza epidemics.  Based 
on the systematic literature review in chapter 2, I believe that this is the first 
study to examine the relationship between influenza circulation and national 
rates of fatal and non-fatal AMI in two different settings and populations.  
Compared to previous studies a more robust approach is taken to controlling for 
environmental temperature to minimise the risk of residual confounding.  Present 
results are similar to the small number of previous studies that did control 
appropriately for temperature71,120.  As with other ecological studies that 
presented results stratified by age30,65,71,73,77, I saw associations between influenza 
and adverse cardiovascular events that were most marked in the oldest-aged 
persons, who are more likely to have extensive underlying coronary disease.  In 
population-level analyses, however, it is not possible to ascertain whether AMI-
associated events occurred in individuals with underlying cardiovascular disease.  
Although results showed a stronger association between influenza and AMI-
associated deaths versus AMI-associated hospitalisations, it remains unclear 
whether influenza is likely to trigger cardiac events of greater severity.  Finally, it 
is difficult to compare the population impact estimated in this study with 
previous studies as I calculated percentage of AMI deaths attributed to influenza 
rather than % of excess influenza mortality due to CVD, although findings are in 
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keeping with one previous figure of 8% from a Colombian study of seasonal 
influenza119.  I considered % of AMI deaths due to influenza to be a more 
meaningful measure of population impact and also did not have data on other 
influenza-attributable causes of mortality to estimate the other figure.   
 
3.6.6 Implications for policy and practice 
 
Overall, up to 5.6% of AMI-associated deaths in Hong Kong and 3.4% in England 
and Wales were attributed to influenza (equating to 1052 and 13,947 deaths, 
respectively).  Although this is a relatively small proportion, in England and 
Wales, over the study period, influenza vaccination rates among persons aged 65 
years were around 65% - 75%41.   In Hong Kong, influenza vaccine was not 
introduced for community-dwelling older people until 2004, with uptake 
estimated at 31.2% in 2004 and 48.1% in 2005147.  The effect of influenza on AMI 
occurred mainly in elderly persons who – especially in England and Wales – are 
relatively highly vaccinated.  Without access to seasonal influenza vaccine, the 
potential for impact on AMI events could be much greater.  This study highlights 
the need for more effective influenza vaccines in the elderly.  In this group in 
particular acute cardiac events should be considered when anticipating influenza 
outbreaks, both for health service planning and timing of health awareness 
campaigns.  For examples health awareness messages about cardiac symptoms 
for the elderly, their carers and nursing home staff could be aligned with the start 
of laboratory influenza surveillance.  
 
3.6.7 Future directions 
 
I found a consistent association between seasonal influenza circulation and acute 
AMI-associated hospitalisations and deaths in two different settings characterized 
by differing populations, climates, and patterns of health-seeking behaviour.   
While there is fairly consistent ecologic evidence that influenza virus circulation 
and ILI is related to cardiovascular mortality and some individual-level evidence 
that acute respiratory infections may be related to AMI, further work is needed at 
individual level, ideally incorporating laboratory confirmation of influenza and 
information on underlying illnesses.  Chapter 4 describes an individual-level 
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study based on primary care records, using data from influenza surveillance to 
explore this association further. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SUMMARY 
 A weekly time series regression analysis was used to examine 
associations between population levels of influenza and AMI –
associated hospitalisations and deaths in a temperate (England & 
Wales) and subtropical climate (Hong Kong) 
 Strong associations were seen between influenza circulation and AMI 
outcomes in both settings after adjusting for a range of temporal and 
environmental confounders 
 Effects were greatest in elderly individuals, especially those aged ≥80 
years  
 No association was found between influenza circulation and the 
counterfactual conditions fractured neck of femur or hospitalisation 
for colon cancer in either setting 
 Up to 5.6% of AMI-associated deaths in Hong Kong and 3.4% in 
England and Wales were attributed to influenza, with figures rising in 
weeks of highest influenza circulation 
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4. Self-controlled case series analysis of acute respiratory 
infection and incident myocardial infarction using the General 
Practice Research Database  
 
4.1 Description of chapter contents  
 
The study described in this chapter uses individual-level primary care records 
from the General Practice Research Database (GPRD) to examine the association 
between GP consultations for acute respiratory infection and incident myocardial 
infarction.  The GPRD is a rich resource containing virtually complete anonymised 
medical records on a large representative sample of around 8% of the UK 
population.  This analysis uses self-controlled case series which is related to the 
cohort method but has the additional advantage of removing the need to control 
for fixed confounders.  It allows detailed investigation of the timing of respiratory 
primary care consultations in relation to AMI.  Effects are examined by age and 
gender.  A preliminary investigation is done into whether acute respiratory 
infections judged more likely to be caused by influenza (by medical codes used to 
classify illness and timing of the episode in relation to circulating influenza virus) 
have a different effect to acute respiratory infections without these indicators of 
influenza.     
 
4.2 Study rationale and introduction to data sources and methods 
 
4.2.1 General Practice Research Database 
 
Individual-level data are essential to avoid the risk of ecological biases associated 
with studying a phenomenon at population level alone.  To generate adequate 
power for individual-level analyses I used data from anonymised electronic 
medical records of individuals registered at general practices contributing to the 
GPRD148.  Worldwide this is the largest computerised database of longitudinal 
primary care records, with data currently collected on around 5.2 million active 
patients from approximately 630 primary care practices throughout the UK. 
GPRD started collecting data in 1987 but historical records can date back decades 
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before this.  Unlike traditional data collected for research, GPRD records arise 
from an unselected population with effectively 100% participation.  Types of 
information available include demographic details, clinical consultation records, 
referral information, results of clinical investigations and prescribing data as well 
as behavioural and lifestyle factors such as smoking and alcohol consumption.  
Further detail on the structure of the GPRD dataset in relation to this analysis is 
given in section 4.4.1.  To access GPRD data for this study, I designed a data 
specification based on time period, outcome diagnosis (incident AMI) and patient 
characteristics - appendix 10.1.1.  All records for patients fulfilling specification 
criteria were then extracted centrally at GPRD.  
 
4.2.2 Quality control in GPRD 
 
Quality control and regular auditing of data are central to GPRD.  Individual 
patient records are labelled as ‘acceptable’ for use in research if various 
conditions relating to quality of data recording and continuity of follow up are 
met eg a year of birth record must be present, age should be less than 115 at the 
end of follow up, gender must be recorded as male, female or indeterminate (see 
footnote for conditions that render a patient’s data unacceptable1).  At practice 
level, the practice is given an ‘up-to-standard’ date, at which the practice is 
considered to have sufficient high quality continuous data for use by researchers.  
This is determined by analysis of the continuity of data entries and avoidance of 
the use of data from ‘ghost’ patients ie those who have died or transferred out of 
the practice.  Diagnoses in GPRD have been well-validated in peer reviewed 
publications including a recent systematic review that demonstrated across 55 
publications that a median of 85.3% of circulatory diagnoses (including AMI) 
were confirmed using both internal and external methods of validation such as 
questionnaires to GPs and use of manual diagnostic algorithms149. 
                                                 
1 The following conditions render the quality of patient data unacceptable for use in research: an 
empty or invalid first registration date; absence of a record for a year of birth; a first registration 
date prior to their birth year; a transferred out reason with no transferred out date; a transferred 
out date with no transferred out reason; a transferred out date prior to their first registration 
date; a transferred out date prior to their current registration date; a current registration date 
prior to their first registration date; a current registration date prior to their birth year; a gender 
other than male/ female/ indeterminate; an age >115 years at end of follow up; recorded 
healthcare episodes in years prior to the birth year; temporary patient registration status  
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4.2.3 Description of self-controlled case series 
 
In self-controlled case series, only ‘cases’ are sampled ie only patients 
experiencing the event or outcome of interest, here AMI, are included in analysis.  
The effect estimate generated in self-controlled case series through conditional 
Poisson regression is an incidence ratio.  This compares the rate or hazard of an 
event occurring in a period following exposure to a potential risk factor to the 
rate or hazard of events occurring in all other observed time periods for each 
individual.  Figure 4.1 shows an example timeline for an individual who 
experiences two periods of exposure to influenza during follow up. 
 
Figure 4.1 Graphical representation of exposure and baseline periods in a self-controlled case 
series timeline 
 
 
 
 
 
 
 
 
 
 
 
 
 
4.2.4 Application and advantages of self-controlled case series 
 
Derived from cohort logic, self-controlled case series was originally developed to 
investigate associations between acute outcomes and transient exposures such as 
risks of adverse events in time periods following vaccinations150.  Subsequently 
the method has been applied more widely to diverse problems from investigating 
the risk of acute cardiovascular events after invasive dental treatment151 to 
examining the risk of fractures associated with thiazolidinedione use 152.  The 
main advantage over other methods for examining the relationship between 
Start of observation 
period 
First presentation 
with ‘influenza’ 
End of observation 
period 
Baseline period 
Risk period after exposure to ‘influenza’ 
28 
days 
28 
days 
Second presentation with 
‘influenza’ 
Time 
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influenza infection and AMI is that self-controlled case series controls implicitly 
for fixed confounders such as genetic factors, socio-economic status, gender, 
frailty and health-seeking behaviour150, as comparisons are within an individual 
at different time points.  Self-controlled case series is also the most valid method 
of analysis when using routinely collected data to avoid the risk that incomplete 
recording of information on residual confounders might compromise reliability or 
generalisability of results.  While fixed confounders are controlled for implicitly it 
is still possible to include time varying confounder such as age and season in 
multivariable models150.   Using people as their own controls avoids the problem 
of selecting an appropriate control group with the inherent risks of indication and 
selection bias.  Self-controlled case series is statistically efficient compared to the 
retrospective cohort method150.   
 
4.2.5 Comparison of self-controlled case series, case control and cohort 
methods 
 
Previous studies have compared results when data were analysed using both self-
controlled case series and either case control or cohort methods.  Taking 
antidepressant use and risk of hip fracture as an example, a case control study 
using GPRD suggested an increased risk of hip fracture in patients who used 
tricyclic antidepressants – OR 4.76 (95% CI 3.06 - 7.41) for 0-14 days after 
prescription153.  An even greater risk of hip fracture was found when examining 
prescriptions for selective serotonin reuptake inhibitors (SSRIs), a newer class of 
antidepressant, for which the OR was 6.30 (95% CI 2.65 - 14.97) for days 0-14.  
When the same data were reanalysed using self-controlled case series, incidence 
ratios for the risk of hip fracture occurring over the same time period were 2.30 
(95% CI 1.82 - 2.90) and 1.96 (95% CI 1.35 - 2.83) respectively153.  This suggested 
that while both classes of antidepressant drug were associated with a small 
independent increase in hip fracture risk in the first weeks of treatment, effect 
sizes were artificially inflated by using the case control approach, more so in the 
SSRI group.  This is likely to be due to residual biases eg indication bias (where 
the indication for the drug, here depression, is itself associated with an increased 
risk of falling and therefore of hip fractures) and selection bias (whereby frailer 
people are preferentially prescribed SSRIs as these are thought to have fewer side 
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effects, but frailty is associated with increased risk of hip fracture).  Residual 
biases also appeared to inflate effect sizes when using cohort methods compared 
to self-controlled case series in the same dataset to examine any association 
between influenza vaccination and exacerbations of asthma in children154.   
 
4.2.6 Assumptions affecting self-controlled case series 
 
There are several assumptions made when using self-controlled case series that 
are relevant to this analysis.  In brief: the probability of exposure (here acute 
respiratory infection) should not be affected by occurrence of an outcome event 
(here AMI); event risk should be small over the observation period; there must be 
variability in the time or age of event; the length of follow up should not be 
influenced by occurrence of an outcome event150.  These will be discussed further 
in the appropriate sections.  
 
4.3 Aims and objectives  
 
Aim: To investigate the association between GP consultation for acute respiratory 
and AMI using the GPRD. 
 
Objectives:  
1) To examine whether there was a greater incidence of AMI in time periods 
following GP consultation for acute respiratory infection using self-
controlled case series adjusted for age and season. 
2) To identify whether there was a biological gradient of risk in days following 
GP consultation for acute respiratory infection. 
3) To investigate whether any effect varied by age and gender. 
4) To explore whether acute respiratory infections that a) occurred during 
time periods when influenza was circulating and b) were coded with 
influenza-like illness codes were more likely to be associated with AMI than 
other illness episodes. 
5) To examine the effect of inclusion of fatal episodes of AMI (as this goes 
against one of the assumptions on which the self-controlled case series is 
based). 
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4.4 Methods 
 
4.4.1 Data sources 
 
For this analysis, GPRD records were used as the source of both outcome and 
exposure information.  A typical record contained an encrypted patient identifier 
variable that was consistent throughout all files and allowed GPRD information 
from different files to be merged.  Demographic details such as sex, age and year 
of birth were available for each patient as well as a practice code and details of 
registration with the practice including dates of new registration and transfer out 
(if relevant).  In general, details of clinical encounters in primary care eg a new 
occurrence of a respiratory illness or symptom are entered into the ‘Clinical’ files 
by the GP who chooses the most appropriate descriptive term for the illness from 
a drop down list.  A corresponding Oxford Medical Information Systems (OXMIS) 
or Read code is also given and the date of encounter entered.  AMI records 
typically reach a general practice through hospital correspondence eg discharge 
letters.  The diagnosis is likely to be entered into the ‘Clinical’ files.  Additionally, 
details of investigation results (such as electrocardiographic findings reflecting a 
myocardial infarction) could be entered into a patient’s ‘Test’ file and information 
about referrals eg for further cardiac investigations following myocardial 
infarction may be entered into the ‘Referral’ file.  While the dataset also comprises 
‘Therapy’ files containing drug information coded using Prescription Pricing 
Authority codes as well as date, dosage and method of administration, therapy 
files were not used to identify either outcome or exposure events as they were 
felt to be too indirect and non-specific.  Lastly the dataset includes various files of 
‘Additional Clinical Data’, including records of ‘Death administration’ used to 
identify dates of death and thereby end of follow up.    
 
4.4.2 Study population and follow up 
 
Patients were drawn from those registered with a practice contributing data to 
the GPRD during the study period 01/01/1999 until 31/12/2008.  Potentially 
eligible patients had experienced a first AMI during this period and were aged 
≥40 years at the time of event.  Patients entered the study either at the study start 
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date or at their date of registration with a GPRD practice or at the date a practice 
reached ‘up-to-standard’ status, whichever was latest.  Follow up continued until 
the earlier of either the study end date or the date a patient left the practice (eg 
due to death or transferring to another general practice).  According to GPRD 
documentation the most reliable way to identify deaths in GPRD is to have a 
record of leaving the practice with a ‘transfer out’ reason of ‘Death’.  It is 
recognised, however, that there may be a delay between a patient’s actual date of 
death and the date that they are ‘de-registered’ from the practice (the median 
delay for all deaths in GPRD is 19 days).  Therefore a list of ‘Statement of Death’ 
codes provided with the dataset by GPRD was used to extract records of deaths 
from ‘Clinical’ and ‘Referral’ files.  In addition records were also extracted from 
the ‘Death administration’ area of the ‘Additional Clinical Data’ files along with 
dates of death.  These records were appended and duplicates and those with 
missing or impossible dates (eg date of death before the start of the study or 
before AMI) were removed.  The earliest recorded date of death from any of these 
files was taken as the end of follow up where it occurred no earlier than 95 days 
before the recorded date that a patient left the practice (as advised by 
documentation from GPRD).  Otherwise if no other record of death was found but 
the ‘transfer out reason’ was ‘Death’, registration records were used and the end 
of follow up for that individual was taken as the leaving date from the practice. 
 
4.4.3 Sample size calculations  
 
The user-written Stata command ‘sampsi_sccs’ was used to calculate sample size 
requirements.  Assuming an incidence ratio of 3 (‘rho’), a duration of the post-
exposure risk period of 28 days (based on findings from a previous similar study 
in GPRD84) and a duration of entire observation period of 3,304 days (based on 
median length of follow up), the sample size needed would be 593 to estimate 
results with 90% power at the 5% significance level.  Reducing the IR and 
reducing the length of the post exposure risk period both increase sample size 
requirements.  Table 4.1 below shows the different sample sizes required for this 
study under varying conditions. 
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Post exposure risk period (days) Rho = 3 Rho = 2 
 
91 
 
28 
 
14 
 
7 
 
193 
 
593 
 
1171 
 
2328 
587 
 
1837 
 
3644 
 
7257 
Table 4.1 Sample sizes needed for self-controlled case series in GPRD under different conditions 
  
4.4.4 Generating codelists 
 
Before extracting records for use in the analysis it was necessary to generate lists 
of all Read and OXMIS codes that could be used by GPs to code relevant conditions 
or events.  The general method is described here and then additional specific 
details discussed in sections 4.4.5 (outcome), 4.4.6 (exposure), 4.4.8 (‘influenza-
like illness’ codes).  Taking incident myocardial infarction codes as an example, 
initial discussions were had and brainstorming done with a senior clinician 
experienced in use of general practice data (Professor Smeeth) to identify likely 
terms.  The complete dictionary of Read codes was searched electronically for 
appropriate words eg ‘myocardial infarction’, ‘heart attack’, ‘myocardial 
thrombosis’ according to a Stata loop defined by Dave and Petersen155.  Word-
searches (along with the attached code) were saved in a temporary file.   Similar 
searches were then carried out for likely codes based on code stems identified 
during the word searches and files were again saved temporarily.  Results from 
word- and code-searches were merged, duplicates were removed and lists of 
potential terms reviewed.  Irrelevant codes and those where the myocardial 
infarction described was not necessarily incident were removed manually.  The 
final codelists were reviewed and agreed by the research team before being used 
for data extraction. 
 
4.4.5 Outcome 
 
Records for the first occurrence of AMI were identified with a codelist for incident 
myocardial infarction generated using methods as described above.  Records 
containing these codes were extracted from the ‘Clinical’, ‘Referral’ and ‘Test’ files 
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along with the date of event and duplicates removed.  In primary care data the 
level of detail entered on AMI varies from very specific codes (such as 
‘Postoperative transmural myocardial infarction inferior wall’) to the very general 
(‘Heart attack’).  Therefore no attempt was made to extract further information 
on type of AMI in this analysis.  In chapter 5 linked MINAP records were used to 
classify and then stratify analysis by AMI type.  All AMI records had to occur at 
least 6 months after the start of a patient’s follow up in GPRD to reduce the risk of 
historical recording of events.  For this reason I also removed records of AMI 
recorded on the same day as a routine encounter eg a well person screen or new 
patient registration visit.  The analysis was restricted to first AMI events only to 
maintain relative homogeneity of the sample and also because a person’s risk 
profile changes considerably after an AMI.  This may invalidate the assumption of 
the self-controlled case series that a person can be compared with themselves in 
all other time periods (as after a first event a person would be at considerably 
higher risk of subsequent AMI events).  The first recorded date of AMI was taken 
to be the AMI date and any subsequent AMI records dropped.  This dataset of first 
AMI events was then merged with demographic and registration information for 
each individual and date checks done to ensure that no AMI records occurred 
before the start or after the end of a person’s follow up.  In sensitivity analysis 
fatal events were defined as those with a date of death (based on the earliest 
plausible death record) within 28 days of an AMI.  These records were dropped 
and analysis repeated.  This was done to ensure that no bias was introduced 
through including records in which the length of follow up was dependent on 
occurrence of an outcome event. 
 
4.4.6 Exposure 
 
To be included in self-controlled case series analysis patients had to have both a 
record of first AMI and a record of GP consultation for acute respiratory infection 
occurring at any time during their follow up.  A codelist was devised using 
methods previously described for acute respiratory infection with a systemic 
component eg ‘acute bronchitis’, ‘tracheitis’, ‘pneumonia’ designed to capture the 
more severe end of a spectrum of acute respiratory infections that present to 
general practice.  These would include illnesses caused by influenza virus.  Three 
108 
 
subsets of codes from this list were defined according to table 4.2 for use in 
different analyses.  Episodes classified by isolated respiratory symptoms, eg sore 
throat, were not extracted as these were thought unlikely to represent either 
influenza or its complications.  Records of episodes with general acute respiratory 
infection codes (codelist 1) were extracted from Clinical GPRD files along with the 
date of consultation.  Where there were multiple different codes entered for the 
same day of illness, the first record was saved (the exact code did not matter as 
initially we were interested in the date only).  Any records occurring within 28 
days of a previous acute respiratory infection code were dropped as these were 
likely to refer to the same episode of illness.  This dataset of respiratory records 
and dates was merged on patient identifier with AMI, demographic and 
registration records to generate the initial dataset for analysis (dataset a).   
 
Codelist Contents Rationale 
 
1  
 
 
 
 
2 
 
 
 
 
3 
 
 
4 
Acute respiratory infection 
codes with a systemic 
component eg ‘chest 
infection’, ‘acute bronchitis’ 
 
As list 1 but minus non 
influenza organism-specific 
codes eg ‘staphylococcal 
pneumonia’ 
 
Influenza-like illness codes eg 
‘influenza with pharyngitis’ 
 
As list 1 but minus influenza-
like illness codes 
Used to extract episodes of 
acute respiratory infection 
 
 
 
Used to extract episodes 
where diagnosis could 
plausibly be influenza  
 
 
Used to extract influenza-like 
illness episodes 
 
Used to allow comparison 
between episodes of general 
acute respiratory infection 
and influenza-like illness  
 
Table 4.2 Description of codelists used to extract ARI episodes 
 
4.4.7 Influenza surveillance data 
 
To identify infections more likely to be caused by influenza I used information on 
timing of influenza virus circulation from national surveillance systems.  First, 
episodes of acute respiratory infection where the diagnosis could plausibly be 
influenza were extracted from Clinical records as before using codes from codelist 
2.  Again, duplicate records for the same day of illness were removed, as were 
episodes occurring within 28 days of the initial illness date.  To identify weeks in 
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which influenza virus was circulating (and therefore in which acute respiratory 
infections presenting to the GP were more likely to be caused by influenza virus) 
weekly proportions of nose and throat specimens testing positive for influenza 
virus by reverse-transcriptase polymerase chain reaction covering the study 
period were used.  These were taken from patients with ILI attending sentinel 
general practices in England under the HPA/ RCGP swabbing scheme (described 
in section 3.2.3, p72).  The peak week of influenza circulation for each influenza 
season was defined as the week with the highest proportion of specimens testing 
positive if the total number of specimens was ≥20.  In separate analyses, two, 
three and four weeks either side of this peak week were labelled as influenza 
circulation weeks.  Separate datasets of acute respiratory infections occurring in 
influenza circulation weeks (dataset b) and non-circulation weeks (dataset c) 
were generated and records sorted and merged on patient identifier with AMI, 
demographic and registration records as above.  
 
4.4.8 ‘Influenza-like illness’ codes 
 
I also considered that the probability of an episode of respiratory illness being 
caused by influenza virus may vary according to codes used by GPs to classify 
illness.  Therefore I conducted an analysis of the effect of episodes of acute 
respiratory infection coded with ILI codes on AMI incidence compared to that of 
episodes coded with other acute respiratory infection codes.  To generate 
datasets for this analysis episodes of ILI were extracted from Clinical files using 
codelist 3 (influenza-like illness codes).  The first date of recording of ILI was 
taken as the date of the episode and any duplicate records of ILI occurring within 
28 days were dropped.  This dataset of ILI records and dates was merged on 
patient identifier with AMI, demographic and registration records to generate the 
ILI dataset (dataset d). 
 
To generate a comparison dataset containing episodes coded with other acute 
respiratory infection codes (codelist 4), records of infections were extracted from 
Clinical files and full duplicates removed.  A ‘general respiratory infection’ label 
was applied to each record to distinguish from ILI records in subsequent steps.  
After sorting by patient identifier and date, records were merged with dataset d 
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(which contained only ILI records).  When both an ILI code and a general code 
were entered for a patient on the same day this episode was classified as an ILI 
and deleted from the dataset of ‘other acute respiratory infections’.  When an ILI 
record occurred within the same episode of illness as a general code (ie within 28 
days) this was also classified as an ILI and any records related to that episode of 
illness removed from the dataset.  Examples of how episodes of acute respiratory 
infection might be coded in GPRD are shown in table 4.3, along with whether the 
episode would be classified as ILI or general acute respiratory infection.  Any ILI 
records were purged from the dataset, then remaining records were sorted and 
merged on patient identifier with AMI, demographic and registration records to 
generate a general acute respiratory infection dataset (dataset e). 
 
Example 
episode 
Example codes used 
 
Date Classification of episode 
 
Episode 1 
 
Influenza-like illness  
 
06-12-2001 
 
ILI 
 
 
Episode 2 
 
Acute bronchitis 
 
27-02-2004 
 
General ARI 
 
 
Episode 3 
 
Acute bronchitis 
Influenza-like illness 
 
 
17-12-2003 
19-12-2003 
 
ILI 
 
Episode 4 
 
Influenza-like illness 
Acute bronchitis 
 
 
21-05-2000 
29-05-2000 
 
ILI 
 
Episode 5 
 
Chest infection 
Streptococcal pneumonia 
 
 
03-03-2007 
05-03-2007 
 
General ARI 
 
Episode 6 
 
Chest infection 
Influenza-like illness 
Streptococcal pneumonia 
 
 
12-01-2002 
13-01-2002 
28-01-2002 
 
ILI 
Table 4.3 Example episodes with how they might be coded in GPRD and classification as an ILI or 
general ARI 
 
4.4.9 Data management 
 
For each of the five datasets (a= all acute respiratory infections including 
influenza, b= acute respiratory infections in weeks of influenza circulation, c= 
acute respiratory infections outside the influenza season, d= influenza-like 
illnesses only, e=general acute respiratory infections excluding ILI), infections 
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occurring outside the study period were dropped.  Any AMI records in persons 
aged <40 years were removed as these persons were judged not to be clinically 
representative of the sample: triggers for AMI in those under 40 are likely to 
differ from those of older age groups eg hereditary disorders such as familial 
hypercholesterolaemia or recreational cocaine use may be more important.  Dates 
of AMI and acute respiratory infection as well as the start and end date of follow 
up were converted to age in days at each of these events based on year of birth 
and an assumed birth date of 30th June for each individual (halfway through the 
calendar year).  Data were then reshaped into a wide format in preparation for 
self-controlled case series analysis (see below). 
 
Example of ‘long’ coding: 
Id 1701 ARI date 07/05/2005 AMI date 03/06/2005 
Id 1701 ARI date 02/12/2006 AMI date 03/06/2005 
 
Example of ‘wide’ coding: 
Id 1701 ARI date_1 07/05/2005 ARI date_2 02/12/2006 AMI date 03/06/2005 
 
4.4.10 Statistical analysis 
 
Weekly numbers of AMIs recorded in GPRD across the study period were 
presented graphically.  Weekly numbers of GP consultations for acute respiratory 
illnesses and the subset of these coded as influenza-like illness were examined 
and compared with rates of ILI consultations per 100,000 population from RCGP 
surveillance data.  Characteristics of participants including those with and 
without a record of acute respiratory infection were described. 
 
Self-controlled case series analysis was performed to examine the incidence of 
AMI in time periods following a consultation for acute respiratory infection 
compared to baseline time periods for each person.  The exposure period (during 
which it was hypothesised that an acute inflammatory stimulus such as influenza 
could plausibly provoke a systemic effect) was divided into 1-3, 4-7, 8-14, 15-28 
and 29-91 days following an acute respiratory consultation.  I excluded from 
baseline the time period from the day of consultation up to 14 days before as an 
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AMI occurring in this time window may affect subsequent likelihood of attending 
the GP (and self-controlled case requires that the probability of exposure is not 
affected by the occurrence of an outcome event).  Incidence ratios were calculated 
for AMIs occurring in each exposure period compared to baseline time periods for 
each person in univariable analysis.   I did not include fixed confounders such as 
gender and socio-economic status in models as self-controlled case series 
controls implicitly for such factors.  I created multivariable models by adjusting 
for age in 1-year and then 5-year age-bands and for season in 3 month blocks 
(January – March, April – June, July – September, October – December) as these 
are time varying confounders associated with both AMI and risk of respiratory 
infection. 
The initial analysis examined the risk of AMI occurring after acute respiratory 
infection classified using all general acute respiratory infection codes including 
influenza compared to other time periods (dataset a), adjusted for age and 
season.  I also stratified by age-group and gender, testing for heterogeneity in 
incidence ratios for AMI occurring 1-3 days after respiratory consultation using 
the Cochran Q statistic.  This is the classical measure of heterogeneity between 
studies in meta-analyses (calculated as the weighted sum of squared differences 
between individual study effects and the pooled effect across studies)156 but it can 
also be used to measure heterogeneity in effect estimates across strata.  It is 
known to have low power to test heterogeneity especially when the number of 
studies or strata is small157.   
Subsequent analyses examined AMI risks occurring after episodes of respiratory 
illness occurring in times of influenza circulation (dataset b) compared to those 
outside times of influenza circulation (dataset c) and compared the effect of 
episodes classified with influenza-like illness codes (dataset d) with those coded 
with general acute respiratory infection codes (dataset e) to explore whether any 
triggering effect was greater for illnesses judged more likely to be due to 
influenza.  Again heterogeneity in incidence ratios for respiratory infection 
episodes judged more and less likely to be influenza was investigated using the 
Cochran Q statistic.  Finally a sensitivity analysis was done to remove fatal 
episodes (where a patient had a record of death within 28 days of the AMI record) 
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and compare results to those obtained in the initial analysis.  All data 
management and analyses were done using Stata (Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP). 
 
4.5 Results  
 
4.5.1 Description of outcome 
 
From an original dataset of 38,274 records of first incident myocardial infarction 
occurring at least 6 months after patients had registered with the GP, 653 records 
were dropped for the following reasons: 40 occurred on the day of a routine 
health-check, 6 had a date of death preceding date of AMI, 607 occurred in people 
aged less than 40 years.  The remaining 37,621 first AMIs that occurred in people 
aged ≥40 during the study period are shown in figure 4.2 below (mean = 3,726 
per year).  Incidence showed a seasonal pattern, with the graph peaking in winter 
months.  Numbers of AMIs remained relatively stable across the study period, 
except for a dip at the end of 2008 (the final data collection period). 
 
Figure 4.2 Number of AMIs recorded in GPRD per week 1999-2008 
   
From this cohort of 37,621 patients with a first AMI, 15,917 also had a record of 
consultation for an acute respiratory infection so were eligible for inclusion in 
self-controlled case series analysis. 
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4.5.2 Description of exposure 
 
15,917 patients had 38,519 records of GP consultations for acute respiratory 
infection during the study period (mean 2.4 among those with at least one 
record), of which 2,200 illnesses were classified as ILI.  Acute respiratory 
infection consultations showed a very marked seasonal distribution, peaking in 
winter.  Patterns of consultations for acute respiratory infection extracted from 
GPRD to form dataset a) are shown in figure 4.3 along with ILI rates from the 
RCGP surveillance scheme for the same time period.  There was a very close 
match in temporal distribution of illnesses. 
 
Figure 4.3 No. of ARI consultations recorded in GPRD per week from 1999-2008 compared to 
RCGP ILI rates per 100,000 from national surveillance schemes 
 
 
4.5.3 Description of participants 
 
Although only patients with a record of both incident AMI and acute respiratory 
infection were eligible for inclusion in the analysis, a comparison of 
characteristics of AMI patients with and without records of acute respiratory 
infection is shown in table 4.4.  In general those without a record of acute 
respiratory infection during the study period were more likely to be male (64.7% 
versus 58.7%), had a slightly shorter period of follow up and were more likely to 
have died within 28 days of AMI.  For the 15,917 AMI patients included in self-
controlled case series analysis, 58.7% were male with a median age of 72.3 years 
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(IQR 61.9 - 80.7 years).  Median follow up time was 9.0 years (IQR 6.2 - 10.0 
years).   
 
Characteristic Patients with ARI 
record, n=15,917 
No. (%) 
Patients without ARI 
record, n=21,704   
No. (%) 
Gender 
Male 
Female 
 
Agegroup 
40-49 
50-59 
60-69 
70-79 
80-89 
90+ 
 
Death within 28 
days of AMI 
Y 
N 
 
Median follow up 
(years) (IQR) 
 
 
9,335 (58.7) 
6,582 (41.3) 
 
 
957 (6.0) 
2,381 (15.0) 
3,644 (22.9) 
4,654 (29.2) 
3,511 (22.1) 
770 (4.8) 
 
 
 
1,963 (12.3) 
13,954 (87.7) 
 
 
9.0 (6.2-10.0) 
 
14,044 (64.7) 
7,660 (35.3) 
 
 
1,885 (8.7) 
3,920 (18.0) 
5,020 (23.1) 
5,787 (26.7) 
4,260 (19.6) 
832 (3.8) 
 
 
 
3,853 (17.8) 
17,851 (82.2) 
 
 
8.4 (4.6-10.0) 
Table 4.4 Characteristics of AMI patients with and without ARI records 
 
4.5.4 Effect of general acute respiratory infection on AMI 
 
Self-controlled case series analysis using dataset a) showed a marked increased 
risk of AMI occurring after GP consultation with acute respiratory infection – 
unadjusted incidence ratio 3.71(95% CI 3.15 - 4.38) for days 1-3, 2.99 (95% CI 
2.54 - 3.51) for days 4-7, 2.53 (95% CI 2.21 - 2.89) for days 8-14, 1.89 (95% CI 
1.69 - 2.11) for days 15-28  and 1.36 (95% CI 1.27 - 1.46) for days 29-91.  
Adjusting for age in 5 year age-bands gave similar results – IR 3.72 (95% CI 3.16 - 
4.38) for days 1-3, 2.99 (95% CI 2.55 - 3.50) for days 4-7, 2.52 (95% CI 2.21 - 
2.88) for days 8-14, 1.88 (95% CI 1.68 - 2.10) for days 15-28 and 1.30 (95% CI 
1.22 - 1.39) for days 29-91. 
 
In final multivariable models I adjusted for age in 5 year age-bands as well as 
season in 3-month blocks.  This gave an adjusted incidence ratio of 3.65 (95% CI 
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3.10 - 4.30) for days 1-3, which tapered over time – see table 4.5.  There were no 
significant differences in risks between men and women (p=0.62).  In contrast 
risks increased markedly with age, from a small increased risk in those aged 
under 60 years –adjusted IR 1.81 (95% CI 1.05 - 3.13) – to a > five-fold increase in 
risk in the over 80’s – adjusted IR 5.30 (95% CI 4.09 - 6.86) (p=0.001). 
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Table 4.5 Adjusted IRs for AMI after ARI overall and stratified by gender and age group  
 
±Number of AMI events occurring in each risk period 
∞p values presented from Cochran Q test for heterogeneity in incidence ratios for AMI in days 1-3 after acute respiratory infection between different strata.   
*For each age group, incidence ratios for AMI in days 1-3 after acute respiratory infection are compared with the result for <60 years
Model Risk 
period 
after 
infection 
(days) 
Age- and season-adjusted incidence ratio (95% CI) 
Overall 1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
3.65 (3.10-4.30)       
2.93 (2.50-3.44)       
2.47 (2.17-2.82)       
1.84 (1.65-2.06)       
1.28 (1.20-1.37)       
1.00                              
n=147±  
n=156  
n=228  
n=332  
n=1,067  
n=13,987 
 Men Women p∞ 
By gender 1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
 
3.53 (2.83-4.40) 
2.93 (2.37-3.61) 
2.62 (2.21-3.10) 
1.83 (1.58-2.12) 
1.15 (1.04-1.26) 
1.00 
3.83 (3.00-4.90) 
2.95 (2.32-3.76) 
2.30 (1.86-2.84) 
1.87 (1.58-2.22) 
1.47 (1.33-1.63) 
1.00 
 
0.62 
 <60 years 60-70 years p 70-80 years p >80 years p 
By age group* 
 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
 
1.81 (1.05-3.13) 
2.83 (1.93-4.14) 
1.74 (1.20-2.51) 
1.27 (0.94-1.73) 
1.05 (0.88-1.24) 
1.00 
 
3.27 (2.29-4.68) 
2.08 (1.41-3.06) 
1.75 (1.26-2.42) 
1.50 (1.17-1.93) 
1.05 (0.90-1.23) 
1.00 
 
0.076 3.38 (2.50-4.58) 
2.44 (1.79-3.33) 
2.75 (2.19-3.44) 
2.09 (1.73-2.52) 
1.28 (1.13-1.45) 
1.00 
 
0.051 5.30 (4.09-6.86) 
4.20 (3.25-5.41) 
3.20 (2.56-4.00) 
2.19 (1.80-2.66) 
1.60 (1.41-1.80) 
1.00 
0.001 
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4.5.5 Comparison of effects of ARI episodes judged more and less likely to be 
due to influenza on AMI 
 
Results from self-controlled case series using dataset b) (episodes of acute 
respiratory infection occurring in influenza circulation weeks) compared to 
dataset c) (episodes occurring outside of times of influenza circulation) are 
shown in table 4.6 below.  Episodes occurring during peak weeks of influenza 
circulation did not have a significantly greater effect on AMI than episodes 
occurring at other times, using definitions 1, 2 or 3 for the influenza season.  
Episodes coded with an ILI code had a slightly higher adjusted incidence ratio 
than those with a general respiratory infection code but this difference was not 
statistically significant.  For this analysis IRs remained high (>3) up to day 14 
following consultation with an acute respiratory infection.  
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Table 4.6 Adjusted IRs for AMI after ARI episodes judged more and less likely to be due to 
influenza   
 
Definition 1 = 2 weeks either side of peak week, definition 2 = 3 weeks either side of peak week, 
definition 3 = 4 weeks either side of peak week 
 
 
 
 
 
 
 
 
Risk period 
after infection 
(days) 
Age- and season-adjusted incidence ratio (95% CI)  
 
 Peak weeks 
(definition 1) 
Non peak weeks 
(definition 1) 
P value 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
2.91 (1.85-4.59) 
3.49 (2.43-5.03) 
2.44 (1.74-3.40) 
1.64 (1.23-2.20) 
1.25 (1.05-1.48) 
1.00 
3.66 (3.07-4.36) 
2.75 (2.30-3.27) 
2.38 (2.06-2.75) 
1.78 (1.58-2.01) 
1.26 (1.17-1.36) 
1.00 
0.36 
 Peak weeks 
(definition 2) 
Non peak weeks 
(definition 2) 
P value 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
2.84 (1.93-4.19) 
2.98 (2.14-4.15) 
2.16 (1.60-2.90) 
1.67 (1.31-2.13) 
1.12 (0.96-1.30) 
1.00 
3.72 (3.10-4.45) 
2.81 (2.35-3.37) 
2.44 (2.11-2.83) 
1.77 (1.56-2.01) 
1.28 (1.19-1.38) 
1.00 
0.22 
 Peak weeks 
(definition 3) 
Non peak weeks 
(definition 3) 
P value  
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
3.25 (2.34-4.50) 
2.66 (1.94-3.64) 
2.19 (1.68-2.85) 
1.58 (1.26-1.98) 
1.18 (1.04-1.35) 
1.00 
3.62 (2.99-4.37) 
2.91 (2.42-3.49) 
2.44 (2.09-2.84) 
1.80 (1.59-2.05) 
1.27 (1.18-1.38) 
1.00 
0.57 
 ILI code 
 
General ARI code P value 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
3.87 (2.00-7.46) 
3.26 (1.75-6.08) 
3.61 (2.29-5.69) 
1.45 (0.87-2.41) 
1.31 (1.01-1.70) 
1.00 
3.56 (3.00-4.22) 
2.89 (2.45-3.41) 
2.35 (2.05-2.71) 
1.86 (1.66-2.08) 
1.28 (1.20-1.38) 
1.00 
0.81 
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4.5.6 Sensitivity analysis excluding fatal events 
 
Of 15,917 AMI events included in the above analyses, 1,963 (12.3%) had an 
earliest record of death that was within 28 days of AMI date, of which 1,675 
(10.5%) deaths occurred on the day of AMI.  When these records were excluded 
from self-controlled case series the adjusted IR for AMI fell to 2.49 (95% CI 2.01 - 
3.09) for days 1-3, IR 2.23 (95% CI 1.83 - 2.72) for days 4-7, IR 2.06 (95% CI 1.76 
- 2.41) for days 8-14, IR 1.50 (95% CI 1.32 - 1.72) for days 15-28 and IR 1.13 
(95% CI 1.05 - 1.22) for days 29-91.   
 
4.6 Discussion  
 
4.6.1 Summary of findings 
 
In summary there was a 3.65 fold increase in the age- and season-adjusted risk of 
AMI in the first three days following GP consultation with acute respiratory 
infection, which tapered over time.  Risks were highest in those aged over 80 
years.  There were no significant differences in risks of AMI associated with 
episodes of acute respiratory infection occurring in time periods when influenza 
was circulating compared to other time periods, or for episodes classified using 
influenza-like illness codes rather than general acute respiratory infection codes.  
Risks were diminished to around 2.5 fold when fatal events were excluded.  
 
4.6.2 Strengths of study 
 
This study was conducted in a large representative sample of the UK population 
so results are likely to be generalisable to adults in the UK.  Quality of GPRD data 
is high and the database has been well validated with a median of 89% of GPRD-
recorded diagnoses confirmed for all cases through both internal and external 
sources of validation149.  Self-controlled case series analysis has the major 
advantages of reducing risks of bias through inappropriate choice of controls (as 
people act as their own controls) and implicitly controlling for fixed 
confounders150.  This is particularly important when using routinely collected 
primary care data, where there may be variable recording of potential 
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confounding factors.  Another advantage of self-controlled case series is the 
ability to use multiple risk periods, which allowed us to identify a gradient of risk 
for AMI after acute respiratory infection.  We did not know the onset date of 
infections but instead used the date of diagnosis.  In one study of ILI in general 
practice 80% of patients consulted more than 36 hours after symptom onset158 
while another study of sore throat showed that one third of patients had 
symptoms of >3 days duration159.  As the date of attending the GP is likely to be 
some time after the onset of respiratory symptoms, the true effect on AMI may be 
even higher than that observed.   
 
4.6.3 Study limitations - timing of AMI 
 
Using the GPRD to obtain information on AMI – a condition where care would 
have been received in hospital rather than at the GP – introduces the potential for 
inaccurate recording.  While the diagnosis itself is likely to be accurate149, 
potential issues arise with regard to sensitivity and timing.  Missed recording of 
AMI in GPRD (ie false negatives) would not introduce bias into the analysis; the 
study power would simply be reduced by a smaller sample size.  Inaccurate data 
entry on timing of the event is potentially more problematic: for self-controlled 
case series analysis using short risk periods, even a small proportion of AMI 
records with inaccurate dates could introduce considerable bias.  While I 
removed records of AMI events recorded on the same day as routine health 
checks or within 6 months of a patient registering with a practice, this only 
removed a relatively small number of records.  With no way to validate timing of 
AMI events, the use of influenza surveillance data to define the influenza season is 
rendered less accurate as it relies heavily on fairly tightly defined time windows 
of virus circulation.  Some factors in the dataset and results suggest that there is a 
residual risk of retrospective recording of AMI.  First it is known that death 
records have a median 19 days delay from true date of death, and AMI records are 
entered in a similar way.  Second there was a peak in AMI records for the 1st 
January each year that suggests recording error.  Third, high incidence ratios for 
AMI after respiratory infection were apparent for several weeks (whereas the 
likely biological effect would occur days after infection, suggesting delayed 
recording of AMI.  This was particularly apparent for ILI episodes where the 
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incidence ratio remained >3 for up to 14 days.  If AMI recording were delayed, 
this would suggest that the true effect of acute respiratory infections including ILI 
on AMI was higher than that observed. 
 
4.6.4 Study limitations - diagnosing influenza using primary care data 
 
Identifying influenza infections in primary care data is challenging as cases rarely 
have microbiological confirmation.  While some studies have based influenza 
diagnosis on codes used by GPs to classify respiratory illnesses160,161, this method 
alone would fail to identify influenza infections classified using non-specific 
respiratory illness codes.  In this study relatively few illnesses were classified 
with specific ILI codes.  This decreased statistical power to detect an effect in the 
‘ILI’ group and diluted the ‘non-ILI’ group; while point estimates varied 
substantially, the difference between groups was not significant.  I also identified 
illnesses likely to be caused by influenza through linked influenza surveillance 
data because the positive predictive value for influenza of having an acute 
respiratory infection during time periods when influenza is circulating is known 
to be high34.  No greater effect was observed in peak weeks of influenza 
circulation compared to non-peak weeks, however, despite varying the number of 
weeks included in the ‘peak’ and ‘non-peak’ periods.  This would suggest that 
either influenza has a similar effect compared to other respiratory infections or 
alternatively that this method was insufficiently sensitive to divide illnesses into 
influenza and non- influenza episodes.  As described above, accurate timing of 
AMI events is crucial for this stratified analysis.  Other possible approaches to 
addressing this question are discussed in section 4.6.6 (future directions). 
 
4.6.5 Interpretation of results in context of previous findings 
 
Previous large primary care database studies using either case control or case 
only designs have shown an association between GP attendance with acute 
respiratory infection and subsequent AMI.  My incidence ratio for AMI in days 1-3 
after acute respiratory infection – IR 3.65 (95% CI 3.10 - 4.30) – was in the same 
direction as but somewhat lower than that of an earlier comparable self-
controlled case series study in GPRD – IR 4.95 (95% CI 4.43 - 5.53)84.  Though I 
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adjusted for season as a proxy for environmental factors which would tend to 
lead to a more conservative effect size, this would not account for all of the 
difference in incidence ratios.  The time period of the study and codelists used to 
extract incident myocardial infarction and acute respiratory infection records 
were also different, which may account for the different effect size seen.  I 
identified a biological gradient of effect on AMI which was also apparent after 
acute respiratory infection in this other self-controlled case series analysis84 and 
in two other primary care database studies using a case control design80,83.  As 
with our study, previous individual level studies attempting to focus on a specific 
triggering effect of influenza have shown mixed results.  One Chinese study in a 
largely unvaccinated population found a significant association between the 
presence of serum influenza antibodies and AMI91 but three other small case 
control studies were underpowered and failed to detect any association87–89.  
Whether influenza is more likely than other acute respiratory infections to trigger 
AMI remains an area for further study. 
 
4.6.6 Future directions 
 
Better data are needed on the timing of AMI events, as well as on diagnosis to 
ensure that AMIs recorded meet standard international criteria58.  This would 
also allow stratification by AMI type which is important because different 
pathophysiological pathways underlying ST- and non ST-segment elevation 
myocardial infarctions (STEMI and NSTEMI) might be more or less susceptible to 
interaction with or triggering effects of respiratory viruses.  Better data on AMI 
timing would also help to ensure the validity of analyses based on timing of the 
influenza season.  In chapter 5 similar analyses are performed in linked datasets 
to address some of the study limitations. 
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SUMMARY 
 A self-controlled case series analysis was carried out using General 
Practice Research Database records to examine the incidence of AMI in 
time periods following GP consultation with acute respiratory 
infection compared to other time periods. 
 37,621 people aged ≥40 years had a first AMI during the study period 
(1999-2008), of whom 15,917 had also consulted for acute respiratory 
infection. 
 There was a 3.65-fold (95% CI 3.10 - 4.30) increase in the age- and 
season-adjusted risk of AMI in the first three days after acute 
respiratory infection, which fell to baseline by 28 days 
 Risks were greatest in people aged over 80 years but no gender 
differences were seen. 
 There was no effect of stratifying ARI episodes by levels of circulating 
influenza or codes used to classify illness, although whether influenza 
is more likely to trigger AMI than other acute respiratory infections 
remains inconclusive.   
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5. Extension to self-controlled case series analysis using linked 
databases: GPRD, MINAP and HES 
 
5.1 Description of chapter contents 
 
This study extends work carried out in the previous chapter by using primary 
care data on acute respiratory infections from the General Practice Research 
Database (GPRD) linked to detailed information on diagnosis and timing of AMI 
through the Myocardial Ischaemia National Audit Project (MINAP) database and 
Hospital Episode Statistics (HES).  MINAP is a cardiac disease registry designed to 
capture in-depth information on all episodes of acute coronary syndrome 
presenting to hospitals in England & Wales.  Approximately half of GPRD practices 
are linked to MINAP.  HES is a national data warehouse for England containing 
details of all admissions to NHS hospitals, with reason for admission classified by 
International Classification of Diseases (ICD) code.  Individually-linked 
anonymised patient records from GPRD, MINAP and HES were brought together 
by the CArdiovascular disease research using Linked Bespoke studies and 
Electronic Records (CALIBER) programme. 
 
In this chapter, self-controlled case series analysis is used to examine the 
association between GP consultation for acute respiratory infection and incident 
myocardial infarction.  A comparison of results when using AMI recorded in 
MINAP, HES and GPRD is done, with models adjusted for age and season.  Effects 
are examined by age, gender, type of AMI and presence of previous vascular 
disease.  A number of sensitivity analyses are performed.  Subsequent models 
examine whether episodes of acute respiratory infection judged more likely to be 
caused by influenza (through medical codes used to classify illness, timing of the 
episode in relation to the influenza season and vaccination status of the patient at 
the time of infection) are associated with higher risks of AMI than other episodes.   
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5.2 Study rationale and introduction to data sources 
 
Use of linked datasets allows collation of information from sources including 
primary and secondary care and disease registries to enhance the breadth of data 
available for research.  For this study, linked data were used to ensure that the 
most accurate and complete data were available on timing of AMI, which is 
essential for self-controlled case series analysis.  The data linkage also allowed 
the AMI diagnosis to be refined, for example by investigating whether influenza 
was more likely to trigger STEMIs than NSTEMIs, which would not be possible 
using GPRD data alone.  In general linked datasets also offer the opportunity to 
validate outcomes, although this was not done formally here.   
 
The CArdiovascular disease research using Linked Bespoke studies and Electronic 
Records (CALIBER) programme162 links information from GPRD and MINAP using 
patient pseudo-identifiers and an encrypted key file.  Pseudo-identifiers are 
replaced with a CALIBER identifier to produce a fully anonymised dataset for use 
in research.  Currently linked data are available for the time period 01/01/2003 
until 31/07/2009. 
 
5.2.1 Myocardial Ischaemia National Audit Project (MINAP) 
 
MINAP contains anonymised electronic records of hospital admissions for acute 
coronary syndromes from all hospitals in England & Wales where such patients 
are admitted163.  MINAP began in 1998 with the aim of developing a dataset of 
acute STEMIs to allow clinicians to evaluate their management of patients against 
national standards specified by the National Service Framework for Coronary 
Heart Disease164.  Subsequently the dataset expanded to include all acute 
coronary syndromes.  In 2011 the dataset contained records on 873,000 
patients165.  These records contain information on demographic details, medical 
history, date and timing of episode, diagnosis, investigations and treatment.  
Further detail on the MINAP dataset structure relevant to this analysis is given in 
section 5.4.1.   
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Quality is monitored continuously through assessment of the completeness of 20 
key data entry fields for patient with NSTEMI.  Nationally these fields are 99% 
complete165.  In addition there is an annual data validation study in which 
hospitals are required to re-enter data from 20 randomly selected case records in 
20 fields into an online data validation tool.  Data are compared between the 
original entry and the re-entered data for each variable.  In 2011 97.5% of eligible 
hospitals in England and Wales participated in the data validation study and the 
median hospital score was 94.8% (IQR 90.0 - 97.8)165.   
 
5.2.2 Hospital Episodes Statistics (HES) 
 
HES is a large secure national data warehouse for England containing details of all 
admissions to NHS hospitals.  Data on episodes of admitted patient care are 
available from 1989 onwards, with more than 12 million records added each 
year166.  Each ‘episode’ of care under a different consultant has a new record, so 
one patient may be responsible for several episodes within the dataset, even 
within the same hospital admission.  The ICD coding system167 is used to record 
reasons for admission, with the ICD-10 classification in use since 1995.  Types of 
information contained in HES records includes clinical data on diagnosis and 
procedures undergone, demographic details such as age, gender and ethnicity, 
administrative information such as date of admission and geographical details 
such as area of residence.  Further details on variables used from the HES dataset 
in this analysis are given in section 5.4.1.   
 
The HES Data Quality team checks and reports quality of data during processing 
based on factors such as the level of population of all fields, use of obsolete or 
invalid provider codes, numbers of potential duplicate episodes and comparisons 
of monthly activity compared to previous months.  A monthly quality report is 
available at HES online as well as a high level summary of key figures. 
 
5.2.3 General Practice Research Database (GPRD) 
 
The GPRD has been described in detail in chapter 4 (sections 4.2.1 and 4.4.1).  
GPRD records used for this analysis were slightly different as they were provided 
128 
 
by CALIBER and contained a CALIBER identifier rather than a GPRD identifier.  
Individual CALIBER datasets given to researchers do not contain exhaustive 
information on all variables found in GPRD but instead are tailored to the 
individual project.  This dataset contained records on registration, demographics, 
cardiovascular risk factors, AMI, episodes of acute respiratory infection, influenza 
vaccinations and deaths.  Episodes of acute respiratory infections and influenza 
vaccinations were extracted using updated codelists to reflect the new GPRD Gold 
classification system.    
 
5.3 Aims and objectives 
 
Aim:  To investigate the association between episodes of acute respiratory 
infection, in particular those likely to be caused by influenza, and AMI using 
linked data from GPRD, MINAP and HES. 
 
Objectives: 
1) To examine whether there was a greater incidence of AMI recorded in 
MINAP (primary outcome) in time periods following GP consultation for 
acute respiratory infection using self-controlled case series adjusted for 
age and season. 
2) To compare the above with results obtained using the secondary outcomes 
AMI recorded in HES and AMI recorded in GPRD. 
3) To investigate whether any effect varied by age, gender, type of AMI and 
history of vascular disease. 
4) To explore whether acute respiratory infections that a) occurred during 
time periods when influenza was circulating, b) were coded with ILI codes, 
c) occurred in unvaccinated individuals or d) had a combination of the 
above indicators of influenza were more likely to be associated with AMI 
than other illness episodes. 
5) To test the robustness of effect estimates through various sensitivity 
analyses including a) exclusion of fatal AMI episodes, b) exclusion of 
episodes where symptom date was inferred from hospital discharge date, 
c) inclusion of records with missing discharge diagnosis, d) adjusting for 
age in 1 year bands. 
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5.4 Methods  
 
5.4.1 Data sources 
 
For these analyses, MINAP records and then separately HES records and GPRD 
records were used as the source of information on outcome while, as before, 
GPRD records were used to obtain information on exposure and follow up.  
MINAP data are collected directly from hospital medical records by nurses and 
clinical audit staff and entered securely via a dedicated data application165.  
Information collected includes demographic details, the presence or absence of 
cardiovascular risk factors, previous cardiac drug use, timing of the AMI episode 
(including separate data entry fields for date and time of: symptom onset, call for 
help, arrival of help, arrival of services, admission to hospital etc), diagnosis on 
admission and discharge eg STEMI or NSTEMI, procedures performed such as 
angiography and treatments received.  HES records contained an anonymous 
patient identifier for linkage to GPRD and MINAP, admission and discharge dates 
of the hospitalised episode as well as ICD codes used to classify AMI.  Further 
detail on outcome definitions is given in section 5.4.5. 
 
5.4.2 Study population and follow up 
 
Potentially eligible patients were those registered with a GPRD practice linked to 
MINAP during the study period 01/01/2003 until 31/07/2009 and who had a 
first AMI recorded in MINAP aged ≥40 years.  As for the previous study, follow up 
began either at the date of registration with a GPRD practice or at the practice’s 
‘up-to-standard’ date or at the study start date (01/01/2003), whichever was 
latest.  Follow up ended either at the study end date (31/07/2009) or at the date 
of censoring (due to death or leaving the practice), whichever was earlier.  Dates 
of death were obtained from a file provided by CALIBER containing the CALIBER 
patient identifier and death dates (originally from GPRD).  As before if there were 
discrepancies the earliest date of death was used.  This was used as the end date 
of follow up unless it was more than 95 days before the leaving date of the 
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practice and the leave reason was ‘death’, in which case the date of end of 
registration was used (according to advice in GPRD documentation).   
  5.4.3 Sample size calculations 
 
As in chapter 4, the user written Stata command ‘sampsi_sccs’ was used to 
calculate sample size requirements.  For an incidence ratio (‘rho’) of 3, a duration 
of the post exposure risk period of 28 days and a duration of the entire 
observation period of 2,403 days (based on median length of follow up) the 
sample size needed would be 453 to estimate results with 90% power at the 5% 
significance level.  Table 5.1 below shows the different sample sizes required for 
this study under varying conditions.  
 
Post exposure risk period (days) Rho = 3 Rho = 2 
91 
 
28 
 
14 
 
7 
 
144 
 
453 
 
856 
 
1697 
436 
 
1345 
 
2658 
 
5286 
Table 5.1 Sample sizes needed for self-controlled case series in MINAP under different conditions 
 
5.4.4 Explanation of codelists used 
 
For this analysis, codelists for outcome and exposure events were obtained in 
several different ways depending on the origin of required variables.  For the 
outcome AMI, the codes used to extract records were either MINAP discharge 
diagnosis codes, HES ICD-10 codes or GPRD Gold codes (with a codelist generated 
by the CALIBER team) depending on the dataset used to generate AMI records.  
For the exposure acute respiratory infection (later subdivided into ILI and other 
codes according to table 4.2) GPRD Gold codelists of Read codes were used to 
extract records.  These were generated by Dr Sara Thomas at LSHTM, a 
collaborator on this work, using similar methods to those described previously.  
Dr Thomas also provided GPRD Gold codelists for influenza vaccination, which 
were used to divide records of acute respiratory infection into those more and 
less likely to be due to influenza infection depending on an individual’s 
vaccination status.  Further details of outcome codes are given in section 5.4.5 
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and exposure codes in section 5.4.6.  For all GPRD-derived variables, records were 
extracted by the CALIBER team.  AMI records and acute respiratory infection 
records came from GPRD Clinical files; influenza vaccination records were 
extracted from GPRD Immunisation and Therapy records.  Datasets containing a 
unique CALIBER patient identifier, medical code and date of event were provided 
by CALIBER for use in this analysis.  
 
5.4.5 Outcomes 
 
5.4.5.i Acute myocardial infarction recorded in MINAP (primary outcome) 
Identification of AMI events was based on codes entered in the discharge 
diagnosis field (see appendix 10.1.2).  Records were deleted if they contained the 
following codes that were unlikely to relate to AMI, such as ‘Chest pain ?cause’, 
‘Acute coronary syndrome – troponin negative’, ‘Other’, ‘Threatened myocardial 
infarction’, ‘Myocardial infarction unconfirmed’ and ‘Missing’.  Records were also 
deleted where the discharge diagnosis was ‘Acute coronary syndrome –troponin 
unconfirmed’ if there was no separate confirmation of a positive cardiac marker 
result.  All remaining records met internationally agreed criteria for AMI58 and 
could be further subdivided into STEMI and NSTEMI based on troponin and ECG 
findings following the universal definition.  In this study there was no need to 
restrict to AMI events that happened at least 6 months after a patient registered 
with a practice because using the MINAP-recorded outcome removed the risk of 
retrospective recording.  As in the previous study only first events were included.  
Therefore after removing records of subsequent AMI events in MINAP, the MINAP 
dataset was merged with the linked GPRD dataset of myocardial infarction 
records.  MINAP records of AMI were deleted if there was both a positive history 
of AMI noted in the MINAP record and a confirmatory AMI code in the GPRD 
record occurring more than 28 days before the MINAP recorded event.   
When no symptom onset date was recorded in MINAP (31.5% of records), I 
substituted the date of call for help (11.6%), arrival of help (0.2%), arrival of 
services (0.8%), admission (16.1%), reperfusion (0.06%), cardiac arrest (0.05%), 
referral for investigation (0.6%), local angiogram (0.2%) or first local 
intervention (0.03%).  The median number of days from symptom onset to 
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hospital discharge was calculated and used to estimate symptom onset date for a 
small number of records where only the date of discharge was available (1.5%).  
Records with no dates attached were excluded (0.4%).  This dataset of first AMI 
events recorded in MINAP was then merged with demographic and registration 
information for each individual from GPRD and date checks done to ensure that 
no AMI records occurred before the start or after the end of a person’s follow up.   
 
5.4.5.ii Acute myocardial infarction recorded in HES (secondary outcome) 
A series of linked HES records of AMI coded by ICD-10 diagnosis were used as a 
secondary outcome in sensitivity analysis.  Records containing ICD-10 codes I21 
(acute myocardial infarction) and I23 (complications following acute myocardial 
infarction) were retained and merged with patient demographic and registration 
information from GPRD.  Records containing ICD-10 codes I22 (subsequent 
myocardial infarction) were excluded as these were, by definition, not first AMI 
events.  The admission date was used as a proxy for event date.  Again I did not 
specify a minimum length of follow up needed in GPRD prior to AMI as recording 
AMI events separately (in HES) should minimise the risk of retrospective 
recording.  AMI records occurring before the start or after the end of a person’s 
follow up in GPRD were removed.  I excluded records relating to hospitalisations 
for second or subsequent infarctions in HES.  Records were also excluded where 
there was a previous AMI recorded in the linked GPRD record occurring at least 
28 days before the admission date in HES.  It was not possible to subdivide 
records further into type of AMI as ICD-10 codes do not allow easy distinction 
between STEMI and NSTEMI. This dataset of first AMI events recorded in HES was 
then merged with demographic and registration information for each individual 
from GPRD.  Any AMI records occurring before the start or after the end of a 
person’s follow up were excluded.   
 
5.4.5.iii Acute myocardial infarction recorded in GPRD (secondary outcome) 
AMI recorded in GPRD was used as another secondary outcome in this analysis.  
CALIBER provided three datasets of AMI records extracted from GPRD for STEMI, 
NSTEMI and myocardial infarction with phenotype not otherwise specified.  
<10% of GPRD AMI records had a specified phenotype so all codes were 
combined to give a general ‘AMI’ outcome.  The AMI date entered was the event 
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date specified by the hospital in the discharge letter sent to the general practice.  
Records of AMI from the three datasets were appended and the earliest record for 
each person was taken as the date of first event.  Records of events occurring less 
than 6 months after the start of a patient’s registration with a practice were 
removed.  As only specific GPRD records related to outcome, exposures and 
follow up were extracted by CALIBER, events recorded on the same day as a 
routine health check or new patient screen were unable to be removed.  As 
before, AMI records were merged with demographic and registration information 
for each individual.  When using the GPRD AMI outcome, unlike the MINAP or HES 
outcomes, both events and follow up time were generated from the same dataset 
so it was unlikely that AMI events would be recorded outside a patient’s period of 
registration with the GP.  Follow up time for each individual was also constrained 
by the dates that linked data were available (01/01/2003 – 31/07/2009) and 
some patients had historical records dating back decades.  Therefore any AMI 
records occurring outside of a person’s follow up were removed.   
 
5.4.6 Exposure 
 
As for analyses in the previous chapter, data on primary care consultations for 
acute respiratory infection were extracted from GPRD Clinical files using four 
codelists.    The main codelist (codelist 1) contained codes to describe acute 
respiratory infection with a systemic component eg ‘acute bronchitis’, ‘tracheitis’, 
‘pneumonia’ designed to capture more severe episodes of acute respiratory 
infection presenting to general practice.  Any organism-specific codes that did not 
relate to influenza (eg staphylococcal pneumonia) were then excluded to define a 
subset of codes where the diagnosis could plausibly be influenza (codelist 2).  
Finally I divided codes from the main list into two further subsets: one contained 
specific ILI codes only (codelist 3) and the other contained all other codes for 
comparison (codelist 4).  Any consultations for acute respiratory infection 
occurring within 28 days of a previous consultation were excluded as they were 
likely to relate to the same illness.  ARI codelists are given in appendix 10.1.3. 
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5.4.7 Identifying ‘influenza’ infections 
 
Identifying acute respiratory infections judged to be more and less likely to be 
caused by influenza was done in three ways.  First (as before – see section 4.4.8) 
the effect on AMI of episodes coded with an ILI code was compared to the effect of 
episodes coded with a general acute respiratory infection code (list 3 versus list 
4).  Second, levels of circulating influenza according to surveillance data were 
used to define peak time periods of influenza circulation (see section 4.4.7).  
Episodes of acute respiratory infection that could plausibly be due to influenza 
were extracted using list 2 and classified as occurring at either peak or non-peak 
times of influenza circulation.  Third I categorised the influenza vaccination status 
of patients at the time of acute respiratory infection as either ‘vaccinated’ (making 
an infection less likely to be caused by influenza virus), having ‘residual 
protection’ or as ‘unvaccinated’ (when acute respiratory infections were most 
likely to be caused by influenza).  ‘Vaccinated’ episodes occurred when influenza 
vaccination had been received at least 14 days before the illness in the same year 
(classed as 1st September until 31st August to encompass the start of the influenza 
vaccination season).  Episodes with ‘residual protection’ were those in which a 
patient had received influenza vaccination in the last 5 years but not in the same 
year in which the infection occurred.  ‘Unvaccinated’ episodes occurred when 
there had been no influenza vaccination in the last 5 years.  For this analysis 
episodes of acute respiratory infection were also extracted with codes from list 2 
to maximise sensitivity.  Finally I examined the effect of illness episodes with 
increasing numbers of indicators of influenza infection: illness during influenza 
circulation weeks, ILI code and unvaccinated status.  
 
5.4.8 Data management and statistical analysis  
 
Any records of acute respiratory infection occurring outside a person’s follow up 
period were dropped.  Records of AMI occurring in persons aged <40 years were 
also removed from the dataset.  Dates of AMI and acute respiratory infection as 
well as the start and end date of follow up were converted to age in days at each 
of these events.  For analyses using the MINAP AMI outcome I was able to obtain a 
more exact date of birth than in the previous chapter using information from the 
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MINAP dataset in which age in years at admission was recorded to two decimal 
places.  This was converted to age in days at event then subtracted from the 
admission date to give a birth date.  For the HES and GPRD AMI outcomes, records 
of birth year were obtained from GPRD and date of birth calculated by assuming a 
birth day of 30th June (halfway through the calendar year).  Data were reshaped 
into a wide format in preparation for self-controlled case series analysis. 
 
A flowchart of records was generated to illustrate when and why potential AMI 
records were dropped.  Characteristics of participants with a record of acute 
respiratory infection were described.  Self-controlled case series analysis was 
used to examine the incidence of MINAP-recorded AMI (the primary outcome) in 
time periods following a consultation for acute respiratory infection compared to 
baseline time periods for each person.  As before the exposure period was divided 
into 1-3, 4-7, 8-14, 15-28 and 29-91 days following an acute respiratory 
consultation.  The time period from the day of consultation up to 14 days before 
was excluded from baseline as an AMI occurring in this time window may affect 
subsequent likelihood of attending the GP.  Incidence ratios were calculated for 
AMIs occurring in each exposure period compared to baseline time periods for 
each person adjusted for age in 5-year agebands and season in 3-month blocks.   
 
The initial analysis examined the risk of AMI occurring after any acute respiratory 
infection classified using list 1 compared to other time periods.  I stratified by 
age-group, gender, type of AMI (STEMI v. NSTEMI) and history of previous 
vascular disease (defined by a history of angina, percutaneous coronary 
intervention, coronary artery bypass graft, peripheral vascular disease or 
cerebrovascular disease recorded in MINAP) and tested for heterogeneity using 
the Cochran Q statistic.  Results obtained from this analysis were compared with 
results when using HES AMI and then GPRD AMI as an outcome.  I carried out 
several sensitivity analyses including 1) adjusting for age in 1 year agebands, 2) 
excluding records where the patient died in hospital, 3) excluding records for 
which symptom onset date was inferred using discharge date and average length 
of stay and 4) including records with missing discharge diagnoses.   
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Subsequent analyses examined AMI risks occurring after episodes of respiratory 
illness most likely to be caused by influenza to explore whether any triggering 
effect was specific to influenza.  These analyses used the primary outcome 
MINAP-recorded AMI.  I compared the effect on AMI of 1) influenza-like illnesses 
with general acute respiratory infections, 2) acute respiratory infections at times 
of peak influenza circulation with illnesses at non-peak times, 3) acute 
respiratory infections after influenza vaccination with illnesses occurring in 
unvaccinated time periods or time periods with residual protection, and 4) acute 
respiratory infections with increasing numbers of markers of influenza with 
illnesses with no markers of influenza.  Again heterogeneity in incidence ratios for 
respiratory infection episodes judged more and less likely to be influenza was 
investigated using the Cochran Q statistic.  All analyses were done using Stata 
(Stata Statistical Software: Release 11. College Station, TX: StataCorp LP). 
 
5.5 Results  
 
5.5.1 Description of primary outcome 
 
25,129 potential myocardial infarction records were identified in the MINAP 
database for 22,024 persons.  Of these 13,921 records were dropped for reasons 
outlined in figure 5.1.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
137 
 
Figure 5.1 Flowchart of AMI records identified in MINAP dataset.  Note that some records could 
have been excluded for multiple reasons but records were excluded according to the hierarchy 
shown  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The weekly pattern of first AMIs recorded in MINAP during the study period is 
shown in figure 5.2.  Numbers remain relatively stable over time and there is 
some evidence of a seasonal pattern with numbers peaking in winter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
25,129 dated MINAP ACS records identified 
 
5,102 had a discharge diagnosis that 
did not meet AMI criteria 
Reasons for exclusion: 
1,748 occurred before the start 
of follow up 
4,043 occurred after the end of 
follow up 
2,845 were not first AMI events 
183 occurred in persons aged <40 
years 
11,208 AMI records left 
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Figure 5.2 Number of AMIs recorded in MINAP per week from 2003-2009 
 
 
5.5.2 Description of participants 
 
Of the remaining 11,208 persons with a first AMI record, 3,927 (35.0%) had also 
consulted for an acute respiratory infection and were included in analyses.  These 
individuals had 8,204 episodes of acute respiratory infection (mean 2.1 per 
person) during the study period.  Their median age was 73.1 years (IQR 62.5 -
81.4) and 60% were male (table 5.2).   
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Characteristic No. (%) 
Gender  
   Men 
   Women 
 
 
2,360 (60.1) 
1,567 (39.9) 
Age group  
   40–49 
   50–59 
   60–69 
   70–79 
   80–89 
   ≥90 
 
 
212 (5.4) 
565 (14.4) 
873 (22.2) 
1,122 (28.6) 
945 (24.1) 
210 (5.3) 
History of vascular disease† 
   Angina  
   PCI∞ 
   CABGα 
   Peripheral vascular disease 
   Cerebrovascular disease 
 
 
839 (25.9) 
130 (4.1) 
124 (3.9) 
144 (4.7) 
282 (9.1) 
 
Type of myocardial infarction 
   STEMI 
   NSTEMI 
 
 
1,604 (40.8) 
2,323 (59.2) 
Death in hospital† 
   Y 
   N 
 
250 (6.6) 
3,548 (93.4) 
                     Table 5.2 Characteristics of study participants (n=3,927)  
 
†% given out of those with non-missing data 
∞PCI = percutaneous coronary intervention; αCABG = coronary artery bypass graft 
 
5.5.3 Effect of general acute respiratory infection on primary outcome 
(MINAP-recorded AMI) 
 
Risk of AMI was substantially higher in days following acute respiratory infection 
– adjusted IR 4.19 (95% CI 3.18 - 5.53) for days 1–3 – with the effect tapering 
over time.  The effect was most marked in the oldest age groups, with the 
adjusted IR rising to 5.94 (95% CI 3.90 - 9.04) for days 1–3 after acute respiratory 
infection in the over 80s (p=0.023).  There was no evidence of interaction by 
gender (p=0.82), type of AMI (p=0.53) or history of previous vascular disease 
(p=0.73)(table 5.3). 
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Table 5.3 Adjusted IRs for AMI occurring after ARI overall and stratified by gender and age group 
±Number of AMI events occurring in each risk period 
Model Risk period after 
infection (days) 
Age– and season–adjusted incidence ratio (95% CI) 
Overall 1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
4.19 (3.18–5.53)       
2.69 (1.99–3.63)       
1.66 (1.24–2.23)       
1.41 (1.12–1.77)       
1.05 (0.92–1.21)       
1.00                          
n=52± 
n=44  
n=48  
n=80  
n=262  
n=3441 
  Men Women p∞  
By gender 1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
4.32 (3.02–6.19) 
2.01 (1.28–3.16) 
1.28 (0.83–1.97) 
1.39 (1.03–1.89) 
0.99 (0.82–1.19) 
1.00 
4.05 (2.62–6.27) 
3.66 (2.45–5.46) 
2.22 (1.50–3.29) 
1.44 (1.01–2.06) 
1.16 (0.94–1.43) 
1.00 
0.82  
  <60 years 60-70 years p 70-80 years p >80 years p 
By age group* 1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
1.46 (0.47–4.55) 
1.46 (0.54–3.91) 
1.88 (0.97–3.65) 
1.50 (0.88–2.56) 
0.84 (0.59–1.21) 
1.00 
3.93 (2.15–7.18) 
1.89 (0.89–4.00) 
1.09 (0.51–2.30) 
0.96 (0.54–1.71) 
1.03 (0.77–1.38) 
1.00 
0.13 4.14 (2.47–6.95) 
3.55 (2.18–5.78) 
2.31 (1.45–3.66) 
1.81 (1.23–2.65) 
0.96 (0.73–1.26) 
1.00 
0.10 5.94 (3.90–9.04) 
3.18 (1.93–5.25) 
1.40 (0.79–2.48) 
1.35 (0.88–2.07) 
1.31 (1.04–1.66) 
1.00 
0.023 
  STEMI NSTEMI p  
By infarction type 
 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
4.66 (3.04–7.15) 
1.76 (0.97–3.21) 
1.77 (1.12–2.80) 
1.13 (0.74–1.71) 
0.98 (0.78–1.23) 
1.00 
3.89 (2.71–5.60) 
3.25 (2.30–4.60) 
1.60 (1.10–2.33) 
1.58 (1.20–2.09) 
1.10 (0.93–1.31) 
1.00 
0.53  
  No Yes   
By history of previous 
vascular disease 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
4.32 (3.10-6.02) 
3.00 (2.12-4.25) 
1.68 (1.18-2.39) 
1.37 (1.03-1.82) 
0.99 (0.83-1.17) 
1.00 
3.89 (2.35-6.42) 
2.03 (1.11-3.69) 
1.62 (0.97-2.72) 
1.49 (1.00-2.21) 
1.19 (0.95-1.51) 
1.00 
0.73  
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∞p values presented from Cochran Q test for heterogeneity in incidence ratios for AMI in days 1-3 
after acute respiratory infection between different strata.   
*For each age group, incidence ratios for AMI in days 1-3 after acute respiratory infection are 
compared with the result for <60 years 
 
5.5.4 Sensitivity analyses 
 
Results of sensitivity analyses are shown in table 5.4.  Effect sizes did not change 
markedly between different analyses including restricting to AMI events where 
the patient did not die in hospital – adjusted IR 3.56 (95% CI 2.59 - 4.90) for days 
1–3. 
 
Analysis of AMI risk Cases 
included in 
analysis, n 
Age– and season– 
adjusted incidence ratio 
(95% CI) 
Initial analysis 
   All first AMIs after acute respiratory infection 
 
3,927 
 
4.19 (3.18–5.53) 
 
Sensitivity analyses 
  
   Adjusting for age in 1 year age-bands  
 
   Excluding events where patient died in hospital 
 
   Excluding events with symptom date inferred from 
   discharge date and average length of stay 
 
   Including events with missing discharge diagnosis 
3,927 
 
3,548 
 
3,870 
 
 
4,089 
4.14 (3.14–5.46) 
 
3.56 (2.59–4.90) 
 
4.27 (3.24–5.63) 
 
 
3.99 (3.03–5.27) 
 
Table 5.4 Adjusted IRs for AMI occurring in days 1-3 after ARI overall and then under various 
sensitivity analyses 
 
5.5.5 Effect of general acute respiratory infection on secondary outcomes 
(HES- and GPRD-recorded AMI) 
 
5.5.5.i AMI recorded in HES 
15,185 patients aged ≥40 years had a record of first AMI in HES during the study 
period.  Of these patients, 5,420 (35.7%) had also consulted for an acute 
respiratory infection during this time period (mean number of consultations 2.1 
per person among those with at least one consultation record) so were eligible for 
inclusion in self-controlled case series analysis.  56.9% of patients included in 
analysis were male with a median age of 75.0 years (IQR 63.8 - 82.9 years).  
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The age- and season- adjusted incidence ratio for HES-recorded AMI occurring 1-
3 days after consultation for acute respiratory infection was 6.07 (95% CI 4.99 - 
7.38).  As before incidence ratios tapered over time: IR 2.92 (95% CI 2.29 - 3.73) 
for days 4-7; IR 2.41 (95% CI 1.96 - 2.96) for days 8-14; IR 1.55 (95% CI 1.29 - 
1.87) for days 15-28; IR 1.17 (95% CI 1.05 - 1.32) for days 29-91. 
 
5.5.5.ii AMI recorded in linked GPRD records 
14,867 patients aged ≥40 years had a record of first AMI in GPRD during the study 
period.  Of these, 5,502 had a record of acute respiratory infection (mean 2.1 per 
person) so were included in self-controlled case series analysis.  58.0% were male 
with a median age of 73.6 years (IQR 62.8 - 81.8 years). 
 
The age- and season- adjusted incidence ratio for GPRD-recorded AMI occurring 
1-3 days after consultation for acute respiratory infection was 3.16 (95% CI 2.41 - 
4.15).  Incidence ratios fell over time – IR 2.04 (95% CI 1.52 - 2.74) for days 4-7; 
IR 2.15 (95% CI 1.73 - 2.68) for days 8-14; IR 1.68 (95% CI 1.40 - 2.01) for days 
15-28; IR 1.25 (95% CI 1.12 - 1.39) for days 29-91. 
 
Results for the same analysis using MINAP-recorded AMI (the primary outcome) 
compared to AMI recorded in HES and GPRD are shown in table 5.5. 
 
Risk period after 
infection (days) 
Age– and season– adjusted IR (95% CI) 
 
MINAP (n=3,927) HES (n=5,420) GPRD (n=5,502) 
 
1-3 
4-7 
8-14 
15-28 
29-91 
Baseline 
 
4.19 (3.18–5.53)      
2.69 (1.99–3.63)       
1.66 (1.24–2.23)       
1.41 (1.12–1.77)       
1.05 (0.92–1.21) 
1.00 
 
6.07 (4.99-7.38) 
2.92 (2.29-3.73) 
2.41 (1.96-2.96) 
1.55 (1.29-1.87) 
1.17 (1.05-1.32) 
1.00 
 
3.16 (2.41-4.15) 
2.04 (1.52-2.74) 
2.15 (1.73-2.68) 
1.68 (1.40-2.01) 
1.25 (1.12-1.39) 
1.00 
Table 5.5 Comparison between risks of AMI recorded in MINAP, HES and GPRD after ARI  
 
5.5.6 Comparison of effects of ARI episodes judged more and less likely to be 
due to influenza on primary outcome (MINAP-recorded AMI) 
 
There was a higher incidence ratio for AMI after acute respiratory infections 
occurring during peak weeks of influenza circulation compared to non-peak 
weeks (p varied from 0.006 to 0.091 depending on the definition of peak weeks 
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used).  Though the point estimate for episodes coded as influenza-like illness was 
nearly double that of episodes coded as general acute respiratory infection – IR 
7.31 (95% CI 2.72 - 19.64) versus IR 4.03 (95% CI 3.02 - 5.38) for 1–3 days – this 
difference was not statistically significant (p=0.26).  Unvaccinated episodes 
(thought to be most likely to represent influenza infections) were associated with 
similar incidence ratios to episodes for which there was likely to be residual 
vaccine protection (p=0.94) and to vaccinated episodes (p=0.91).  Overall 
comparing acute respiratory infections with at least one indicator of influenza to 
those with no indicators suggested a significantly greater effect on AMI – IR 5.39 
(95% CI 3.89 - 7.45) compared to IR 2.38 (95% CI 1.37 - 4.11) for 1–3 days 
(p=0.012) (table 5.6).  This finding is also shown graphically in figure 5.3. 
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Risk 
period 
after 
infection 
(days) 
“Influenza” indicator   “Non influenza” indicator 
(N=no. of acute respiratory infection records) 
 
Age– and season–adjusted incidence ratio (95% CI)  
 
 Peak weeks1  
(N=1,278) 
Non peak weeks 
(N=6,847)  
p     
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
7.79 (4.71–12.90) 
1.86 (0.77–4.51) 
0.87 (0.33–2.34) 
1.69 (1.01–2.82) 
0.89 (0.62–1.27) 
1.00 
 
3.32 (2.37–4.65) 
2.80 (2.04–3.86) 
1.79 (1.32–2.42) 
1.35 (1.05–1.74) 
1.08 (0.93–1.25) 
1.00 
0.006     
 Peak weeks2  
(N=1,733) 
Non peak weeks  
(N=6,392) 
p     
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
5.95 (3.60–9.81) 
3.68 (2.12–6.40) 
0.99 (0.44–2.23) 
1.54 (0.96–2.47) 
1.02 (0.76–1.36) 
1.00 
 
3.54 (2.53–4.95) 
2.37 (1.66–3.39) 
1.82 (1.33–2.48) 
1.37 (1.06–1.78) 
1.09 (0.94–1.26) 
1.00 
0.091     
 Peak weeks3    
(N=2,226) 
Non peak weeks  
(N=5,899) 
p 
 
    
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
6.34 (4.13–9.72) 
3.07 (1.80–5.22) 
0.89 (0.42–1.88) 
1.32 (0.85–2.07) 
1.06 (0.82–1.36) 
1.00 
 
 
 
3.16 (2.19–4.57) 
2.48 (1.73–3.56) 
1.92 (1.40–2.63) 
1.43 (1.10–1.86) 
1.05 (0.90–1.23) 
1.00 
0.016     
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 ILI code 
(N=410) 
General code 
(N=7,796) 
p     
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
7.31 (2.72–19.64) 
1.37 (0.19–9.74) 
1.56 (0.39–6.28) 
0.79 (0.20–3.16) 
1.17 (0.67–2.05) 
1.00 
4.03 (3.02–5.38) 
2.61 (1.91–3.57) 
1.66 (1.24–2.24) 
1.43 (1.13–1.81) 
1.06 (0.92–1.23) 
1.00 
0.26     
 Unvaccinated 
(N=1,590) 
Residual protect-
ion (N=1,466) 
p Vaccinated 
(N=5,069)  
p   
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
4.15 (2.20–7.83) 
1.90 (0.85–4.29) 
1.87 (0.99–3.51) 
1.91 (1.21–3.03) 
1.08 (0.79–1.46) 
1.00 
4.30 (2.29–8.07) 
2.62 (1.29–5.26) 
2.26 (1.27–4.03) 
0.58 (0.26–1.31) 
1.15 (0.86–1.55) 
1.00 
0.94 3.99 (2.79–5.70) 
2.92 (2.03–4.20) 
1.41 (0.95–2.09) 
1.50 (1.13–1.98) 
1.05 (0.88–1.25) 
1.00 
0.91   
 0 indicators∞ 
(N=3,433) 
1 indicator 
(N= 3,771) 
p 2 or 3*  
(N=921) 
p At least 1  
(N=4,692) 
p 
1-3  
4-7 
8-14 
15-28 
29-91 
Baseline 
 
2.38 (1.37–4.11) 
2.49 (1.56–3.97) 
1.67 (1.08–2.58) 
1.61 (1.17–2.23) 
1.07 (0.88–1.31) 
1.00 
5.53 (3.88–7.88) 
2.76 (1.79–4.26) 
1.61 (1.04–2.48) 
1.12 (0.77–1.63) 
1.03 (0.85–1.26) 
1.00 
0.011 4.31 (1.92–9.68) 
2.73 (1.13–6.60) 
1.58 (0.65–3.82) 
1.64 (0.87–3.07) 
1.08 (0.73–1.59) 
1.00 
0.23 5.39 (3.89–7.45) 
2.80 (1.89–4.13) 
1.63 (1.10–2.40) 
1.21 (0.87–1.68) 
1.05 (0.88–1.26) 
1.00 
0.012 
Table 5.6 Adjusted IRs for AMI after ARI episodes with and without indicators of influenza 
1 Peak weeks of influenza circulation defined using two weeks either side of peak week 
2 Peak weeks = 3 weeks either side of peak week  
3 Peak weeks = 4 weeks either side of peak week  
∞ Indicators of influenza were occurrence of acute respiratory infection during a peak week (using definition 3), presence of an ILI code and unvaccinated status 
* 2 or 3 indicators pooled due to small numbers 
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Figure 5.3 Graph of adjusted IR for MINAP-recorded AMI after ARIs with at least 1 indicator of 
influenza (blue) and with no influenza indicators (red) 
 
 
 
 
5.6 Discussion 
 
5.6.1 Summary of findings 
 
This study, one of the first to use the new GPRD-MINAP data linkage, showed a 
short-term increased risk of AMI in days following acute respiratory infection, 
confirming previous findings using GPRD data alone (chapter 4).  The effect was 
greatest for people aged over 80 years.  Episodes of acute respiratory infection 
occurring when seasonal influenza virus was circulating had significantly higher 
incidence ratios than illnesses occurring in other time periods. 
 
5.6.2 Study strengths 
 
A major strength of this study was the use of a novel data linkage to improve the 
accuracy and timing of data on AMI.  Previous validation studies of AMI in the 
GPRD have found that although AMI diagnoses have a generally high positive 
predictive value149, less is known about the accuracy of recording of timing168.  In 
one validation study, 15% of confirmed cases had a different date of AMI 
recorded in GPRD to that provided by the GP169.  For self-controlled case series 
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analysis using short risk periods, even a small proportion of AMI records with 
inaccurate dates or false positive records could introduce considerable bias.  
Therefore I used MINAP data, which has the advantage of multiple data entry 
fields for information on timing of AMI to allow internal validation of the AMI date 
as well as improved diagnostic precision.  Findings were confirmed in HES, which 
is another independently-recorded source of information on timing of AMI.  Using 
improved data on timing of AMI also increased the precision of stratified analyses 
using influenza surveillance data.  While acute respiratory infections can be 
accurately categorised as occurring either in peak or non-peak periods of 
influenza circulation, delayed recording of AMI (such as may occur when using 
GPRD data alone) would diminish any effect seen.    
 
Using self-controlled case series eliminated any fixed between-person 
confounding that may have affected similar analyses using case control or cohort 
designs170.  Using within-person comparisons also reduced the risk of residual 
bias due to difficulties choosing appropriate controls.  While AMI is an event that 
can potentially affect the length of the observation period (which goes against the 
assumptions on which the case series method is based171), when I excluded AMI 
events where the patient died in hospital this did not significantly alter results.   
 
5.6.3 Study limitations – diagnosing influenza in primary care 
 
As previously noted in chapter 4, influenza infections in primary care are rarely 
microbiologically confirmed.  Therefore in this study several methods were used 
to divide acute respiratory infections into those more and less likely to be due to 
influenza.  As in chapter 4, I used medical codes entered by GPs to classify 
respiratory infections.  While the effect size was substantially higher for ILIs 
compared to other acute respiratory infections, the difference between groups 
was not significant; this analysis was underpowered to detect an effect.  In this 
study two additional methods were used to identify illnesses likely to be caused 
by influenza.  The more powerful was to use linked influenza surveillance data, 
which showed a greater effect in peak weeks of influenza circulation than non-
peak weeks, strongly suggesting that influenza infections are more likely to 
trigger AMI than other respiratory infections.  Varying the number of weeks 
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included in the ‘peak’ and ‘non-peak’ periods resulted in similar magnitudes of 
effect.  When this analysis was done in GPRD alone (chapter 4) no significant 
difference was seen between illnesses occurring in peak and non-peak periods, 
but this was likely to be due to inaccurate data on timing of AMI.   
 
In this study I also used influenza vaccination data to compare ‘vaccinated’ 
against ‘unvaccinated’ illnesses but did not see a difference in effect on AMI.  This 
does not mean that influenza vaccination is ineffective at preventing influenza-
associated AMI; rather, acute respiratory infections occurring after influenza 
vaccination are likely to have a different aetiology.  It is also possible that 
immunisation status was misclassified for some illnesses: I did not have data on 
vaccinations occurring in other settings eg the workplace; influenza vaccine 
effectiveness is around 70% in healthy adults and lower in frail elderly 
populations172.  These results suggest that acute respiratory infections other than 
influenza can also be associated with increased AMI risk.  Combining these 
methods, though, I found significantly higher incidence ratios for illnesses with at 
least one influenza indicator compared to those with no indicators of influenza.  
One final caveat when using primary care data to obtain information on acute 
respiratory infections is that one is reliant on the GP’s diagnosis.  It is possible 
that some symptoms such as chest pain and shortness of breath diagnosed as 
acute respiratory infections actually heralded gradually evolving myocardial loss.  
Incidence ratios would be artificially inflated by any such misclassification. 
  
5.6.4 Interpretation of results in context of previous findings 
 
The main result from this analysis using linked data – an adjusted incidence ratio 
of 4.19 (95% CI 3.18 - 5.53) for AMI occurring 1-3 days after acute respiratory 
infection – was higher than that seen in the previous chapter using GPRD data 
alone – IR 3.65 (95% CI 3.10 - 4.30).  This is perhaps unsurprising as using linked 
data to improve information on AMI timing is likely to have reduced the risk of 
retrospective recording of events that may have occurred in GPRD and would 
dilute effect sizes seen.  Additional confirmation of this result was provided by 
using the secondary outcome HES-recorded AMI, for which the adjusted incidence 
ratio was even higher – IR 6.07 (95% CI 4.99 - 7.38).  This study provided some 
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evidence that the triggering effect of acute respiratory infection on AMI was 
stronger for influenza than for other infections.  This is supported by influenza 
vaccine studies, which provide indirect evidence for a specific triggering effect of 
influenza.  From our previous review, pooled analysis of data from three 
relatively small randomised controlled trials in populations with existing 
cardiovascular disease102,105,126 suggested that influenza vaccine is associated 
with protection against cardiovascular death – relative risk 0.46 (95% CI 0.21 -
1.02) – as well as a 33% reduction in risk of AMI.  Given the potential difficulty of 
capturing confirmed influenza infections accurately in AMI patients, these studies 
might provide the best available evidence of a specific influenza effect.   
 
5.6.5 Implications for policy and practice  
 
This study provides further evidence that seasonal influenza has a stronger 
triggering effect on AMI than some other acute respiratory infections.  Therefore 
findings support increased efforts to maximise uptake of influenza vaccination in 
elderly people and cardiovascular risk groups to protect against cardiovascular as 
well as more obvious respiratory complications of influenza.  This analysis was 
restricted to first AMI events.  People who had these would not necessarily fall 
under the vaccination guidelines as people with established cardiac disease.  
Although we found similar effect sizes in people with and without evidence of 
previous vascular disease using a broad definition, further work on delineating 
high-risk groups is needed.  In particular, further trial evidence is needed on the 
use of influenza vaccine for primary prevention of cardiovascular events in 
previously healthy and at-risk populations.  This is a potential argument for 
lowering the age limit for routine influenza vaccination (currently 65 years in the 
UK) to cover younger age groups at risk of cardiovascular disease. Nonetheless as 
the triggering effect was greatest in older adults, it is recognised that such a 
strategy may not be cost-effective.   
 
5.6.6 Future directions 
 
In studies using primary care data, lack of microbiological confirmation of 
diagnosis remains an issue when investigating infections such as influenza for 
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which laboratory testing is not routinely done.  In future, studies linking primary 
care data on consultations with laboratory data eg from the HPA’s ‘Lab base’ 
database of positive laboratory specimens would help to elucidate the relative 
importance of influenza as an AMI trigger compared to other acute respiratory 
infections.  Chapter 6 describes a primary case control study conducted in 
patients hospitalised with AMI during the 2009 influenza A H1N1 pandemic in 
which influenza testing is built into the protocol.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
SUMMARY 
 Self-controlled case series analysis from the previous chapter was 
repeated using linked data from GPRD, MINAP and HES to enhance 
the accuracy and timing of data on AMI. 
 In the time period 01/01/2003-31/07/2009  there were 11,208 
people with a first AMI recorded in MINAP of whom 3,927 had also 
consulted for acute respiratory infection 
 An even higher AMI risk than before was apparent in the first three 
days after GP consultation for acute respiratory infection – adjusted 
IR 4.19 (95% CI 3.18 - 5.53). 
 The effect was greatest for people aged over 80 years.   
 Episodes of acute respiratory infection occurring when influenza 
virus was circulating had significantly higher incidence ratios than 
illnesses occurring in other time periods, providing some evidence 
that a triggering effect on AMI might be stronger for influenza than 
other acute respiratory infections. 
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6.  Influenza-like illness in acute myocardial infarction patients 
during the winter wave of the influenza A H1N1 pandemic: a 
hospital-based case control study  
 
6.1 Description of chapter contents 
 
This chapter describes a case control study investigating the experience of recent 
respiratory and influenza-like illness in adults hospitalised with AMI during the 
second wave of the 2009 influenza A H1N1 pandemic in London compared  to 
adults hospitalised for acute non-vascular surgical conditions.   The main 
exposure is clinically-defined ILI.  Additional exposures are nasopharyngeal and 
throat swabs testing positive for influenza by real-time polymerase chain reaction 
and presence of IgA antibodies to influenza A in serum samples.  Logistic 
regression models are generated to investigate likelihood of recent infection in 
cases compared to controls.  Findings are placed into context with results from 
other pandemic and seasonal influenza studies.    
 
6.2 Introduction and study rationale 
 
6.2.1 2009 influenza A H1N1 pandemic   
 
As evidenced by work described in chapters 2-5, seasonal influenza can trigger 
cardiovascular complications and deaths, especially in elderly people.  In a 
pandemic situation, however, when there is global spread of a novel influenza 
strain, clinical and demographic profiles of those affected may change 
dramatically.  The most recent influenza pandemic was caused by an influenza A 
H1N1 strain (H1N1pdm09) that emerged in Mexico and the United States in April 
2009173,174.  The UK experienced several waves of infection with this novel strain - 
a first wave occurred in spring and summer 2009 followed by a second wave in 
the winter of 2009/10 and a post-pandemic wave in winter 2010/11175.  Initial 
evidence from the first wave in the UK suggested that typical illnesses were mild 
and affected mainly children and young people176.  The average age of cases 
increased over subsequent waves of the pandemic177 but it is unclear how this 
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affected clinical illness profiles.  Vaccination coverage did not reach high levels 
until the post-pandemic season.   
 
6.2.2 Effect of influenza pandemic on AMI 
 
There have been reports of myocarditis, myocardial injury and left ventricular 
systolic dysfunction in patients with severe H1N1pdm09178,179.  It has been 
suggested that H1N1pdm09 was associated with higher rates of extra-pulmonary 
complications than seasonal influenza180 but this is difficult to compare as 
surveillance of severe influenza-related disease was greatly enhanced during the 
pandemic.  A recent mathematical modelling study estimated that globally there 
were 83,300 cardiovascular deaths associated with the first twelve months of 
H1N1pdm09 circulation in adults aged >17 years121, but the contribution of 
myocardial infarction deaths to this figure is unknown.   
 
6.2.3 Study rationale 
 
In this study I aimed to investigate whether a relationship was evident between 
the pandemic influenza strain H1N1pdm09 and AMI, to extend work in previous 
chapters covering time periods of seasonal influenza circulation.  While using 
primary care records (as for studies described in chapters 4 and 5) has many 
advantages, a potential limitation is lack of information on factors not routinely 
measured in primary care such as laboratory confirmation of influenza.  To 
address the question of whether influenza virus was more strongly associated 
with AMI than other respiratory viruses, accurate diagnosis is essential.  
Therefore I decided to conduct a primary study to measure patients’ influenza 
status directly.  A case control study was the most feasible design to allow data to 
be collected relatively quickly and with limited resources on (theoretically) 
sufficient numbers of patients with AMI.  The following sections describe methods 
to measure influenza for clinical and research purposes.  
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6.2.4 Clinical definitions of influenza 
 
Identifying episodes of true influenza infection is challenging: it is recognised that 
the community burden of influenza is substantially underestimated in health 
service data as most patients with influenza do not seek medical care.  Patients 
who do present with symptoms of influenza rarely have microbiological testing 
and confirmation of diagnosis181.  While various clinical diagnostic criteria exist 
for influenza-like illness182,183, these criteria may correlate poorly with 
laboratory-confirmed influenza184.  In a study of 100 adult patients with PCR-
confirmed influenza A H1N1 (pandemic strain), the WHO definition of influenza-
like illness (acute fever >38°C and cough or sore throat in the absence of another 
diagnosis) had only 50% sensitivity and 87% specificity for differentiating 
influenza from general acute respiratory infections185.  The accuracy of clinical 
case definitions for diagnosing influenza varies depending on patient factors such 
as age, presence of underlying disease and vaccination status as well as external 
factors such as levels of influenza circulation181.  In chapters 4 and 5 these factors 
were explored using stratified analyses.   
 
6.2.5 Laboratory definitions of influenza 
 
Laboratory tests for influenza typically detect either the influenza virus or the 
patient’s immune response to it186.  Tests range from ‘point of care’ tests designed 
to detect influenza virus at the bedside (eg rapid antigen tests based on enzyme 
immunoassays) to nucleic acid testing using reverse-transcriptase polymerase 
chain reaction, to virus culture (the traditional ‘Gold standard’ although it has 
lower sensitivity than PCR-based methods) and finally detection of influenza 
antibodies in sera187.  The choice of test is influenced both by laboratory factors 
such as size, capacity, infrastructure and training of laboratory personnel186 as 
well as clinical or research need, eg the rapidity of diagnosis required.  For this 
case control study requirements were different to those for clinical diagnosis: it 
was suspected that most participants would not have symptoms of influenza 
infection at the point of testing.  Rather it was hypothesised that more patients 
admitted with AMI than control patients may have experienced influenza within 
the last month.  Any test designed to detect influenza virus nucleic acid or 
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proteins used alone would have low sensitivity for identifying recent past 
infections.  I therefore focussed additionally on detection of influenza antibodies 
in sera.   
 
6.2.6 Serological diagnosis of influenza 
 
Traditional serological diagnosis of influenza is based on a fourfold or greater rise 
in specific antibody titre in paired serum samples, the first taken as soon as 
possible after symptom onset and the second around 10-14 days later37.  Tests 
include virus neutralisation, haemagglutinin inhibition, complement fixation, 
enzyme immunoassays and indirect immunofluorescence microscopy186.  
Approximately 80% of subjects demonstrate a protective serum antibody 
response (haemagglutinin inhibition titre>40) after natural influenza infection188.  
The main antibody isotypes comprising the humoral immune response to 
influenza are IgM, IgA and IgG189.  During primary infections, IgM and IgA levels 
peak after 2 weeks and then begin to decline, while serum antibodies of the IgG 
subclass peak at 4-6 weeks188.  IgM antibodies initiate complement-mediated 
neutralisation of the virus and are a hallmark of the primary immune response190.  
IgA levels rise after both primary and secondary infections191.  IgG antibodies are 
present in both primary and secondary immune responses and afford long-lived 
protection in the respiratory tract192.   
 
Several investigators have sought assays that determine IgM, IgG and IgA 
separately from a single serum sample rather than from paired samples.  In a 
cohort of patients with influenza A confirmed by either virus culture or direct 
immunofluorescence assay within 36 hours of symptom onset, IgA antibodies 
were detected in 68% on a single serum assay, compared to 45% for IgM 
antibodies and 62% for IgG191.  Virus-specific IgA and the bulk of IgG was 
synthesised within the first week. Authors conclude that finding specific serum 
IgA is highly indicative of a recent influenza infection and should be the method of 
choice after seven days (when virus itself can no longer be isolated). 
 
The combination of clinical and laboratory methods used to diagnose influenza in 
this study is explained in section 6.4.5.  
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6.3 Aims and objectives 
 
Aim: To conduct a case control study investigating the experience of recent 
influenza infection in patients hospitalised with AMI during the second wave of 
the 2009 influenza A H1N1 pandemic in London compared to adults hospitalised 
for acute non vascular surgical conditions. 
 
Objectives 
1. To investigate whether AMI patients were more likely to have had recent 
ILI (primary exposure) than patients with acute surgical conditions during 
the second wave of the influenza A H1N1 pandemic. 
2. To investigate whether AMI patients were more likely to have had recent 
respiratory illness or concurrent PCR positive influenza or evidence of 
influenza A IgA antibodies in sera (secondary exposures) than patients 
with acute surgical conditions.  
3. To examine whether influenza vaccination was associated with protection 
against AMI. 
 
Supplementary objective 
1. To examine the feasibility and sample size needed to conduct a full scale 
case control study in the event of under-recruitment. 
 
6.4 Methods 
 
6.4.1 Setting and design 
 
This was an observational case control study carried out in hospital in-patients at 
the Royal Free London NHS Foundation Trust between 21st September 2009 and 
28th February 2010.  These dates roughly corresponded to the second (winter) 
wave of H1N1pdm09 circulation.  
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6.4.2 Participants 
 
Cases were patients aged ≥40 years admitted with an acute myocardial infarction 
(defined as a rise in troponin T with ischaemic symptoms and/or typical ECG 
changes, or by angiographic evidence of acute coronary artery thrombosis during 
primary percutaneous coronary intervention).  Controls were patients aged ≥40 
years admitted with an acute surgical condition such as appendicitis, bowel or 
urinary obstruction and no history of AMI within the past month, frequency-
matched for gender, age-group in 5 year age-bands and week of admission.  All 
were English-speaking and able to provide written informed consent.   
 
6.4.3 Procedures for recruitment and obtaining consent 
 
Participants were recruited from the acute cardiology ward and coronary care 
unit (cases) and from ward 9 North A, an acute surgical ward (controls), with the 
aid of their respective clinical teams.  Potentially eligible cases were identified by 
the cardiac clinical audit nurse in three ways: 1) through obtaining a list of names 
of patients on the cardiac catheter list, 2) through reviewing a list of names of 
patients on the cardiac ward from the nurses' handover and 3) through 
examining a list of all patients in the hospital with a positive troponin result and 
checking whether their medical notes recorded a diagnosis of acute coronary 
syndrome.  I was given a list of names of potential cases and discussed whether 
they met eligibility criteria with the cardiology ward registrar.  For recruitment of 
controls, I met the charge nurse on the acute surgical admissions ward every 
morning to be given names of potential participants meeting inclusion criteria.   
 
Patients who were eligible to take part were given a participant information sheet 
by ward nurses.  I returned several hours later to discuss the study’s aims and 
objectives, methods, potential risks and benefits with potential participants who 
had agreed to be approached and answered any questions.  Those who agreed to 
participate signed a study consent form.  Examples of the participant information 
sheet and consent form are given in appendix 10.1.4. 
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6.4.4 Exposures 
 
The main exposure was recent ILI, defined as a history of feeling feverish with 
either cough or sore throat within the last month.  I also used the exposure recent 
acute respiratory infection to capture a history of respiratory illness within the 
last month with any of the following symptoms – fever, chills, dry cough, 
productive cough, myalgia, rhinorrhoea, blocked nose, sore throat, wheeze, 
earache and fatigue – that did not meet ILI criteria.  Additional exposures were 
nasopharyngeal and throat swabs testing positive for influenza by real-time 
polymerase chain reaction, presence of IgA antibodies to influenza A in serum 
samples (concentration>12U/ml defined positivity) and self-reported influenza 
vaccination status. 
 
6.4.5 Data sources and measurement 
 
6.4.5.i Questionnaire and medical records 
Data sources and information collected are summarised in table 6.1.  Briefly, I 
used a questionnaire to investigate recent respiratory and influenza-like illness 
and to collect data on demographics, medical history and influenza vaccination 
status.  I reviewed medical records for details of the current admission and, 
where possible, verified information on confounding factors.   
 
6.4.5.ii Serum samples 
A single serum sample was taken for quantification of IgA antibodies to influenza 
A as a marker of recent exposure.  If a patient was being discharged the same day 
as recruitment a sample was taken immediately, or otherwise requested from the 
ward phlebotomist for the following day.  Serum samples were transported, spun 
down, frozen at -800C and batch tested in the Virology laboratory of the Royal 
Free Hospital using a commercially available enzyme-linked immunosorbent 
assay (ELISA) for influenza A IgA (Biosupply UK, cat no. RE56501).  The ELISA was 
based upon the ‘sandwich principle’ whereby wells were coated with antigen, 
allowing specific antibodies from serum samples to bind to these antigen-coated 
wells.  These were detected by a secondary enzyme-conjugated antibody specific 
for human IgA.  The intensity of colour produced during the substrate reaction 
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was proportional to the amount of IgA-specific antibodies detected.  Results were 
read off a standard curve.  Any samples with equivocal results were repeated.   
 
A test based on a single sample was chosen partly for logistic reasons and partly 
because, in participants with recent (rather than current) influenza, it was also 
likely that an antibody response would already be maximal on the first test so a 
repeat serum sample would not necessarily demonstrate an increasing titre.   
 
6.4.5.iii Respiratory samples 
Combined nasopharyngeal and throat swabs were collected on the day of 
recruitment, placed in viral transport medium and transported to the Virology 
laboratory for storage at -800C.  Samples were tested in batches of 25 for the 
presence of influenza virus RNA using a validated in house real-time polymerase 
chain reaction with a lower limit of detection of 1 RNA copy per reaction193.    
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Type of information 
 
Characteristic Type of variable Data source 
Demographic data Age 
Gender 
Ethnicity 
Marital status 
Employment status 
Years of education 
 
Potential 
confounders 
Patient 
questionnaire 
 
Cardiac risk factor 
data 
Smoking status 
Diabetes 
Hypertension 
Hypercholesterolaemia 
Family history of AMI 
Past history of AMI 
BMI 
 
Potential 
confounders 
Patient 
questionnaire/ 
Medical records 
Respiratory illness 
data 
Any symptoms of 
respiratory illness 
before admission? Y/N 
When? 1-3/ 4-7/ 8-14/ 
15-28 days  
Fever? 
Chills? 
Cough – dry? 
Cough – productive? 
Myalgia? 
Runny nose? 
Blocked nose? 
Sore throat? 
Wheeze? 
Earache? 
Fatigue? 
Influenza vaccination 
status? 
 
Exposure  Patient 
questionnaire 
 
Serological 
evidence of recent 
influenza 
 
PCR evidence of 
recent influenza 
 
 
Evidence of current 
condition 
Influenza A IgA 
 
 
 
Influenza virus RNA 
detected by real-time 
PCR  
 
AMI or acute surgical 
condition 
Exposure  
 
 
 
Exposure  
 
 
 
Outcome  
Serum sample 
 
 
 
Combined 
nasopharyngeal 
and throat swab  
 
Medical records 
(clinical history 
and results of 
imaging and 
biochemical 
investigations) 
Table 6.1 Sources of data collected from cases and controls  
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6.4.6 Approaches to minimise bias and confounding  
 
6.4.6.i Selection bias 
While appropriate selection of controls was critical to reducing selection bias, a 
pragmatic decision was also necessary for logistical and cost purposes.  Hospital-
based controls were chosen partly for feasibility of recruitment but with the 
assumption that they would have been subject to the same selective forces as the 
case group.  Both potential cases and controls transferred from other hospitals 
were excluded.  The source population therefore comprised patients who would 
seek treatment at the Royal Free Hospital if acutely unwell rather than 
corresponding to the population of the local geographic area.  Acute surgical 
admissions were chosen over elective admissions as elective admissions would be 
unrepresentative of exposure distribution in the source population (ie anyone 
with influenza would have their operation postponed).  In addition, acute 
vascular surgical admissions were not included as controls because the 
underlying pathophysiological process leading to acute admission was likely to be 
similar to that resulting in AMI. 
 
6.4.6ii Information bias 
Information bias was reduced through using a standard checklist of questions for 
both cases and controls to obtain information on demographics, cardiac risk 
factors, details of any recent respiratory illness and influenza vaccination status.  I 
developed clear wording to introduce the study to patients and carefully drafted 
participant information sheets to reduce the risk of recall bias.  As I conducted 
interviews myself it was not possible to be blind to the case or control status of 
participants.  Nevertheless I verified information collected at interview using data 
from medical records extracted with a standard data extraction sheet to reduce 
information bias through misclassification of exposure or outcome data.  Samples 
were analysed using batch testing and standardised assay procedures so that 
laboratory scientists were generally unaware of the case or control status of the 
patient.  A Microsoft Access database was designed to store results.  This had 
appropriate ranges entered into all fields where answers could be categorized to 
reduce the risk of data entry errors. 
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6.4.6.iii Confounding 
Frequency matching on gender, age-group and week of admission helped to 
reduce baseline imbalances between groups and to control for factors that may 
confound an association between acute respiratory infection and AMI.  
Information on a range of potential confounders such as smoking status was also 
collected so that these could be controlled for in multivariable statistical models. 
 
6.4.7 Study size considerations 
 
6.4.7.i Sample size calculations 
This study was planned before the advent of the 2009 influenza A H1N1 
pandemic so sample size calculations were based on seasonal influenza data.  
Sample size calculations were performed using the following formula: 
 
n is > [u√(π0(1- π0) + π1(1- π1)) + v√(2π(1- π))]2/ (π1- π0)2 
 
where n gives the number of cases needed and an identical number of controls is 
also required.  Table 6.2 gives an explanation of variables used in this formula. 
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Variable Explanation of 
variable 
Calculation of variable (if 
applicable) 
Value 
π0 Proportion of controls 
exposed 
From the Flu Watch study 
influenza seroconversion rate 
= 22.5% over 4.5 months = 
0.225/4.5 or 0.05 per month 
 
0.05 
OR Odds ratio Based on incidence ratios 
calculated in chapters 4 and 5 
- IR 3.65 (95% CI 3.10-4.30) 
& IR 4.19 (95% CI 3.18–5.53) 
 
3 
π1 Proportion of cases 
exposed 
Calculated from: π1= 
(π0*OR)/1+ π0(OR-1) 
 
0.095238095 
π Proportion of 
participants exposed 
 
(π1 + π0)/ 2 0.072619047 
u Power One-sided percentage point of 
the normal distribution 
corresponding to 100% 
minus the power (ie 90% 
power) 
 
1.28 
v Significance level Percentage point of the 
normal distribution 
corresponding to the two-
sided significance level (ie 5% 
significance) 
 
1.96 
Table 6.2 Explanation of variables included in sample size calculation 
 
Table 6.3 shows the sample size needed for varying levels of power and 
significance, with a case: control ratio of 1:1 to detect an odds ratio of 3 in an 
unmatched case control study.  For 90% power and 5% significance I estimated 
that 236 cases and 236 controls would be required. 
 
Significance Power 
80% 90% 95% 
0.1 
0.05 
0.01 
N=101 (x2) 
N=176 (x2) 
N=262 (x2) 
N= 147(x2) 
N= 236 (x2) 
N= 333(x2) 
N= 235(x2) 
N= 344(x2) 
N= 461(x2) 
Table 6.3 Sample sizes needed to detect an odds ratio of 3 with varying power and significance 
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6.4.7.ii Expected numbers of eligible cases 
The Royal Free hospital typically admits around 200 STEMI patients per year and 
at least 200 patients with NSTEMI.  More patients are admitted with AMI in 
winter than summer.  Of the STEMI patients around 30-33% are transferred from 
other hospitals for angiography (so would not be eligible for inclusion), 20% 
arrive through A&E and 50% direct from the London ambulance service.  All 
NSTEMI patients would theoretically be eligible as they tend not to be transferred 
from other hospitals. In total approximately 240 AMI patients are admitted in six 
months over the winter, of whom around 200 would be eligible for inclusion 
(assuming that all NSTEMI and 70% of STEMI patients would be eligible). 
 
6.4.7.iii Expected numbers of eligible controls 
At the Royal Free Hospital, across all surgical teams and assuming a fairly high 
attrition rate, it is estimated that 10-20 acute surgical patients aged ≥40 years 
could be recruited per week.  This is based on the average number of emergency/ 
semi emergency admissions on an acute surgical take being 8-15 patients of all 
ages, recognising that many will be discharged rapidly or will not be available to 
participate due to undergoing investigations or surgical treatments.  In total there 
would be around 390 eligible acute surgical patients in six months over the 
winter, assuming a mean of 15 eligible admissions per week 
 
6.4.7.iv Expected length of recruitment period  
To recruit 236 cases and 236 controls from a single centre, I anticipated that 
recruitment would need to continue over two influenza seasons.  The timing of 
recruitment was planned to coincide with the timing of the influenza season.  This 
can be unpredictable, especially in the event of an influenza pandemic, so start 
and end dates were flexible. 
 
6.4.7.v Expected effect of missing data 
Efforts were made to minimise missing data on cardiac risk factors and 
demographic factors by correlating answers to questionnaires with data from 
medical records.  It was expected that not all patients who provided 
questionnaire data would have a usable serum sample (due to factors such as 
missing serum samples or possible technical difficulties with the assay).  Use of 
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both clinical and virological endpoints did, however, allow inclusion of these 
participants’ data in analyses even if some laboratory data were lacking.   
 
6.4.8 Data management and coding 
 
6.4.8.i Data entry 
Data from questionnaires and medical records were collected on paper forms and 
entered into a purpose-built Microsoft Access database under a participant’s 
study identification number.  Written records were kept securely in a file in a 
locked filing cabinet in a locked university office.  Laboratory data were emailed 
from the virology laboratory and results entered into the database by study 
identification number.  The Access database was stored securely on the 
University server, which is backed up daily.  ‘Look up tables’ were created on the 
database to correspond to answers from questionnaires with the aim of reducing 
data entry errors.  Reducing the amount of free text entered also helped with 
categorisation of variables for use in generating frequency tables and in analyses.  
 
6.4.8.ii Classification of outcome and exposure 
The outcome, AMI, was categorised as STEMI, NSTEMI or myocardial infarction 
not otherwise specified.  Categories were combined to maximise power for the 
main analysis.  PCR and clinical exposure variables were binary, with codes 
corresponding to the presence or absence of influenza virus on swabs, recent 
respiratory illness, recent influenza-like illness and various symptoms such as 
fever, sore throat and cough.  Antibody concentrations were initially explored as a 
continuous exposure variable, then categorised into ‘positive’ (>12 U/ml), 
‘equivocal’ (8-12 U/ml) and ‘negative’ (>8 U/ml) categories based on standard 
laboratory thresholds.  Equivocal results were dropped for analyses. 
 
6.4.8.iii Classification of confounding variables 
Information on potential demographic and clinical confounding factors was 
generally collected as a categorical variable eg a question on personal history of 
hypertension could be answered using the following: ‘yes on medication’, ‘yes but 
no medication’, ‘no’, but categories combined into a binary ‘yes/no’ response for 
analyses.  Age was grouped into 10-year age-groups from 40 years (the lower 
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limit for inclusion into the study) up to the age of ≥80 years.  Ethnicity was 
grouped as ‘Asian or Asian British’ ‘Black or Black British’, ‘Mixed’, ‘Other’ and 
‘White’ following Census classifications.  Influenza vaccination status was divided 
into several categories: ‘yes this year’, ‘yes last year, ‘yes 2-5 years ago’, ‘yes >5 
years ago’ and ‘no, never’.  This was because participants may have had residual 
protection against seasonal influenza from influenza vaccinations received in 
previous years even if they had not received a vaccination this year.  Vaccination 
status was then re-categorised as a binary variable ‘yes this year’ and ‘no’ (which 
included all other answers) for analyses: it was recognised that vaccinations from 
previous years would not protect against the circulating pandemic influenza 
strain.  The variable BMI was derived from self-reported height and weight using 
the formula BMI = weight (kg) / height2 (m) and grouped into <25 (normal), 25-
29.9 (overweight), 30-39.9 (obese) and 40+ (morbidly obese) categories using 
standard thresholds. 
 
6.4.9 Statistical analysis 
 
Data were analysed using Stata (Stata Statistical Software: Release 11. College 
Station, TX: StataCorp LP).  X2 tests were used to assess baseline comparability 
between cases and controls.  Although numbers were relatively small, conditions 
for use of Fisher’s exact test were not met194.  Characteristics of participants with 
and without missing data were also compared using X2 tests to assess any risk of 
bias associated with missing data.  Information on potential confounding factors 
obtained from questionnaires was validated against information extracted from 
the medical notes on the same factors using Z tests for difference in proportions. 
 
First I used univariable logistic regression analysis to investigate associations 
between recent influenza-like illness, acute respiratory illness or presence of 
influenza IgA antibodies and case/ control status.  Here the log odds ratio for AMI 
in those exposed to recent influenza compared to those unexposed was calculated 
and p values were presented from the Wald test of the null hypothesis that the 
true parameter value of the log odds ratio = 0.  The same approach was taken 
using influenza vaccination as the exposure variable to explore any protective 
effect against AMI. 
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Second I examined potential confounding factors for independent associations 
with both the exposure (influenza) and the outcome (AMI) using X2 tests.  
Multivariable logistic regression models were then generated that included the 
main outcome and exposure as well as age-group, gender and timing of admission 
(factors on which frequency matching was done), influenza vaccination status (an 
a priori confounder) and other potential confounding factors.  These were 
examined in a backwards stepwise procedure using likelihood ratio tests to test 
the effect of removing each one sequentially.  Where p values from likelihood 
ratio tests were <0.1, the factor remained in models.   
 
Third I explored potential interactions using Mantel Haenszel methods to 
generate stratum-specific odds ratios for the effect of influenza on AMI and to test 
for heterogeneity between strata.  Where there was evidence of heterogeneity 
between strata, results were presented by stratum and an interaction term fitted 
into models.  The effect of including an interaction term between factors 
compared to including factors separately in models was tested using the Wald 
test for interaction. 
 
An interim analysis was planned after the first season of data collection to 
monitor recruitment, assess feasibility of data collection methods, investigate 
initial results and plan for a second season of data collection if necessary.  In the 
event of under-recruitment, interim results would be used to infer the sample size 
needed for a full-scale study. 
 
6.5 Results 
 
6.5.1 Characteristics of participants  
 
Between 21/09/2009 and 28/02/2010, 134 participants were recruited.  These 
were 70 cases and 64 controls, for whom acceptance rates were 66% and 67% 
respectively (figure 6.1). 
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Figure 6.1 Cumulative frequency of participant recruitment over time 
 
 
Median age was 63.6 years (IQR 53.3 - 72.6) and 21% of participants were female. 
Cases were significantly more likely to be of Asian or Asian British ethnicity 
(p=0.016), to have a previous history of myocardial infarction (p=0.04) and a 
family history of myocardial infarction (p<0.001) than controls (table 6.4).  Of 70 
patients hospitalised with AMI, 48 met criteria for STEMI, 17 had a NSTEMI and in 
5 cases the subtype of myocardial infarction was unspecified.  Control patients 
were admitted for a range of acute surgical problems that included colorectal, 
urological and orthopaedic conditions.  
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Table 6.4 Characteristics of study participants, n=134 
Characteristic Cases (n=70) Controls (n=64) P value 
Age group 
 40-49 
 50-59 
 60-69 
 70-79 
 80+ 
 
8 (11.4) 
19 (27.1) 
19 (27.1) 
17 (24.3) 
7 (10.0) 
 
13 (20.3) 
18 (28.1) 
15 (23.4) 
11 (17.2) 
7 (10.9) 
 
0.61 
 
 
 
 
Gender 
  Female  
  Male 
 
13 (18.6) 
57 (81.4) 
 
15 (23.4) 
49 (76.6) 
 
0.49 
 
Month of admission 
 September 
 October 
 November  
 December 
 January 
 February 
 
8 (11.4) 
12 (17.1) 
15 (21.4) 
10 (14.3) 
14 (20.0) 
11 (15.7) 
 
7 (10.9) 
15 (23.4) 
14 (21.9) 
10 (15.6) 
11 (17.2) 
7 (10.9) 
 
0.92 
Ethnicity 
 Asian or Asian British 
 Black or Black British 
 Mixed 
 White 
 
18 (25.7) 
2 (2.9) 
0 (0.0) 
50 (71.4) 
 
6 (9.4) 
0 (0.0) 
1 (1.6) 
57 (89.1) 
 
0.03* 
 
 
 
Smoker 
 No never 
 Yes current 
 Yes ex 
 
22 (31.4) 
27 (38.6) 
21 (30.0) 
 
23 (35.9) 
21 (32.8) 
20 (31.3) 
 
0.77 
 
 
Diabetes 
 No 
 Yes  
 
56 (80.0) 
14 (20.0) 
 
52 (81.3) 
12 (18.8) 
 
0.86 
 
Hypertension 
 No 
 Yes  
 
33 (47.1) 
37 (52.9) 
 
38 (59.4) 
26 (40.6) 
 
0.16 
 
Hypercholesterolaemia 
 No 
 Yes  
 
36 (51.4) 
34 (48.6) 
 
36 (56.3) 
28  (43.8) 
 
0.58 
Personal history of AMI 
 No 
 Yes 
 
56 (80.0) 
14 (20.0) 
 
59 (92.2) 
5 (7.8) 
 
0.04 
 
Personal history of stroke 
 No 
 Yes 
 
69 (98.6) 
1 (1.4) 
 
60 (93.8) 
4 (6.3) 
 
0.14 
 
Family history of AMI 
 No 
 Yes 
 
27 (38.6) 
43 (61.4) 
 
45 (70.3) 
19 (29.7) 
 
<0.001 
 
Family history of stroke 
 No 
 Yes 
 
65 (92.9) 
5 (7.1) 
 
58 (90.6) 
6 (9.4) 
 
0.64 
 
BMI category 
18.5-24.9 
25.0-29.9 
≥30.0 
 
20 (30.8) 
36 (55.4) 
9 (13.8) 
 
 
23 (39.0) 
24 (40.7) 
12 (20.3) 
 
0.41 
 
 
 
Influenza vaccination status† 
 Vaccinated 
 Unvaccinated 
 
30 (42.9) 
40 (57.1) 
 
29 (45.3) 
35 (54.7) 
 
0.78 
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*p=0.016 when comparing proportions who are of Asian or Asian British ethnicity to White 
ethnicity †’Vaccinated’ refers to receiving influenza vaccination in the current vaccination year (ie 
since September 2009).  All other years are classed as unvaccinated as the circulating pandemic 
strain was not covered by previous years’ vaccines 
 
6.5.2 Timing of participants’ admissions in relation to national influenza 
circulation 
 
A comparison of study participants’ admission dates with rates of influenza-like 
illness in the community, based on GP consultations per 100,000 of the 
population is shown in figure 6.2.  The peak week for ILI consultations in England 
& Wales was week 43 (ending 25th October 2009) where the rate was 42.8 per 
100,000.  This was also the peak week for influenza virus circulation according to 
data from virological sentinel surveillance schemes, when the proportion of 
positive specimens reached 41.2%.  Our recruitment period spanned this period 
of peak influenza circulation. 
 
Figure 6.2 Number of study participants admitted by influenza surveillance week compared to 
weekly ILI rates from national RCGP surveillance data 
 
 
6.5.3 Description of exposures 
 
6.5.3.i Recent respiratory illness 
29 episodes of recent respiratory illness were reported by 17 cases (24.3%) and 
12 controls (18.8%).  13 illnesses met criteria for influenza-like illness; these 
were reported by 10 cases (14.3%) and 3 controls (4.7%).  The most frequently 
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reported time for the start of respiratory illness was 8-14 days before admission 
(31.0% of illnesses), and 4-7 days was the most frequently reported length of 
illness (37.9%). Symptom profiles of participants reporting recent respiratory 
illness are shown in figure 6.3.  No swabs tested positive for influenza virus 
nucleic acid.   
 
Figure 6.3 Percentage of cases (n=70) and controls (n=64) reporting various symptoms in the 
context of recent respiratory illness  
 
 
6.5.3.ii Laboratory results 
Serum samples were available on 113 of 134 participants (84.3%).  
Characteristics of participants with and without missing serological data were 
similar and are shown in table 6.5.  53/113 (46.9%) of participants tested 
positive for serum influenza A IgA antibodies, representing 25 cases (43.1%) and 
28 controls (50.9%).  62% of participants who were seropositive had received 
influenza vaccination compared to 31% of seronegative participants.  A further 4 
cases (7.3%) and 4 controls (6.9%) had an equivocal result despite repeat testing.  
Antibody titres ranged from 0.8-104.1 U/ml (median 10.8, IQR 4.8-21.0).  The 
distribution of antibody titres is shown in figure 6.4. 
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Characteristic of participant Laboratory data not 
missing, n=113(%) 
Laboratory data 
missing, n=21 (%) 
P value 
Age-group 
 40-49 
 50-59 
 60-69 
 70-79 
 80+ 
 
18 (15.9) 
30 (26.6) 
30 (26.6) 
22 (19.5) 
13 (11.5) 
 
3 (14.3) 
7 (33.3) 
4 (19.0) 
6 (28.6) 
1 (4.8) 
 
0.70 
Gender 
 Male 
 Female 
 
90 (79.7) 
23 (20.3) 
 
16 (76.2) 
5 (23.8) 
 
0.72 
 
Smoker (questionnaire 
data) 
 No never 
 Yes current 
 Yes ex 
 
38 (33.6) 
42 (37.2) 
33 (29.2) 
 
7 (33.3) 
6 (28.6) 
8 (38.1) 
 
0.66 
Diabetes 
 No 
 Yes  
 
92 (81.4) 
21 (18.6) 
 
16 (76.2) 
5 (23.8) 
 
0.58 
Hypertension 
 No 
 Yes  
 
58 (51.3) 
55 (48.7) 
 
13 (61.9) 
8 (38.1) 
 
0.37 
Hypercholesterolaemia 
 No 
 Yes  
 
59 (52.2) 
54 (47.8) 
 
13 (61.9) 
8 (38.1) 
 
0.41 
Personal history of AMI 
 No 
 Yes 
 
96 (85.0) 
17 (15.0) 
 
19 (90.5) 
2 (9.5) 
 
0.51 
 
Family history of AMI 
 No 
 Yes 
 
60 (53.1) 
53 (46.9) 
 
12 (57.1) 
9 (42.9) 
 
0.73 
 
‘Case’ status 
  No 
  Yes 
 
55 (48.7) 
58 (51.3) 
 
9 (42.9) 
12 (57.1) 
 
0.62 
Respiratory illness 
  No 
  Yes 
 
91 (80.5) 
22 (19.5) 
 
14 (66.7) 
7 (33.3) 
 
0.16 
Influenza-like illness 
  No 
  Yes 
Fever 
  No  
  Yes 
Influenza vaccination status 
  Vaccinated 
  Unvaccinated 
 
103 (91.2) 
10 (8.8) 
 
101 (89.4) 
12 (10.6) 
 
 
51 (45.1) 
62 (54.9) 
 
18 (85.7) 
3 (14.3) 
 
18 (85.7) 
3 (14.3) 
 
 
8 (38.1) 
13 (61.9) 
 
 
0.44 
 
 
0.63 
 
 
 
0.55 
Table 6.5 Characteristics of participants with and without missing laboratory data 
NB Due to rounding, percentages may total >100.0% 
 
 
172 
 
 
Figure 6.4 Influenza A IgA antibody concentrations in serum samples, n=113 
   
Note values to the left of the red dotted line denote a negative result, values between the red and 
orange dotted lines represent an equivocal result and values to the right of the orange dotted line 
show a positive result. 
 
6.5.4 Associations between exposures and potential confounders 
 
Table 6.6 shows p values from X2 tests for the association between various 
exposures and potential confounders.  Factors with a p value of <0.2 are 
highlighted as these were subsequently considered for inclusion in multivariable 
regression models (along with age-group, gender, timing of admission and 
influenza vaccination status). 
 
6.5.5 Uni- and multivariable models from logistic regression analysis 
 
Although differences were not statistically significant, cases were more likely to 
have reported recent influenza-like illness than controls – adjusted OR 3.17 (95% 
CI 0.61 - 16.47) as well as other key respiratory illness symptoms.  There was a 
non-significant trend towards a protective effect of influenza vaccination against 
AMI – adjusted OR 0.46 (95% CI 0.19 - 1.12).  Results from the logistic regression 
analysis are summarised in table 6.7.   
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Table 6.6 p values from X2 tests of the association between respiratory illness exposures and potential confounders 
 
Factors with p values <0.2 are highlighted in bold.  These factors were considered for inclusion in multivariable models, along with age group, gender, month of 
admission (the variables used for frequency matching) and influenza vaccination status (an a priori confounder) 
Potential confounder Exposure variable 
Respiratory 
illness 
 
Influenza-
like illness 
Fever Cough Sore 
throat 
Influenza IgA 
antibodies 
Influenza 
vaccination 
Age-group 0.23 0.18 0.09 0.54 0.25 0.88 0.001 
Gender 0.98 0.22 0.15 0.79 0.88 0.60 0.06 
Month of admission 0.22 0.40 0.35 0.34 0.17 0.56 <0.001 
Ethnicity 0.83 0.91 0.76 0.63 0.92 0.59 0.63 
Smoker (questionnaire) 
Smoker (medical records) 
0.09 
0.32 
0.30 
0.85 
0.21 
0.82 
0.003 
0.25 
0.22 
0.18 
0.65 
0.57 
0.16 
0.04 
Diabetes 0.47 0.28 0.45 0.61 0.75 0.59 0.50 
Hypertension 0.57 0.95 0.98 0.56 0.08 0.77 0.03 
Hypercholesterolaemia 0.81 0.56 0.56 0.50 0.03 0.92 0.05 
Personal history of AMI 0.26 0.07 0.02 0.03 0.26 0.11 0.02 
Personal history of stroke 0.23 0.46 0.42 0.21 0.37 0.08 0.46 
Family history of AMI 0.28 0.08 0.09 0.13 0.40 0.77 0.81 
Family history of stroke 0.64 0.32 0.04 0.28 0.63 0.08 0.92 
BMI category 0.25 0.28 0.26 0.47 0.89 0.20 0.64 
Influenza vaccination 
status 
0.92 0.87 0.83 0.58 0.58 0.001 - 
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Table 6.7 ORs for the association between AMI and respiratory illness exposures, unadjusted and adjusted 
 
*Adjustments were made for age-group, gender, month of admission and influenza vaccination status (all exposures), family history of myocardial infarction (exposures 
2, 3, 4 & 5) and personal history of  myocardial infarction (exposures 2, 3,4 & 5) 
 
±Note that n=105 (54 cases and 51 controls) for influenza antibodies where equivocal results are excluded, compared to n=134 (70 cases and 64 controls) for all other 
exposures 
Exposure variable Prevalence – 
cases, n(%) 
Prevalence – 
controls, n(%) 
Unadjusted odds ratio 
(95% CI) 
Adjusted odds ratio* 
(95% CI) 
1. Respiratory illness 17 (24.3) 12 (18.8) 1.39 (0.60-3.19) 1.39 (0.56-3.47) 
2. Influenza-like illness 10 (14.3) 3 (4.7) 3.39 (0.89-12.92) 3.17 (0.61-16.47) 
3. Fever 11 (15.7) 4 (6.3) 2.80 (0.84-9.28) 2.42 (0.54-10.98) 
4. Cough 21 (30.0) 10 (15.6) 2.31 (0.99-5.40) 2.04 (0.76-5.47) 
5. Sore throat 10 (14.3) 8 (12.5) 1.17 (0.43-3.17) 1.43 (0.44-4.69) 
6. Influenza A IgA antibodies± 25 (46.3) 28 (54.9) 0.71 (0.33-1.53) 0.82 (0.34-2.00) 
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Although the effect of interaction terms was examined (data not shown) no 
interaction terms were fitted in final models.  It was recognised that statistical 
tests for heterogeneity between strata were likely to be underpowered to detect 
an effect in this analysis.   
 
6.5.6 Validation of questionnaire information against medical records 
 
Comparing information on several potential confounding factors – personal 
history of AMI, diabetes, hypertension, hypercholesterolaemia and smoking 
status – from questionnaires and medical records revealed very similar results for 
all except smoking status (table 6.8).  While 97.7% of those reporting themselves 
to be non-smokers had a non-smoking history in the medical notes, 45.6% of 
people described themselves as ‘ex smokers’ when the medical notes identified 
them as ‘current smokers’ and only 54.3% had a current smoking history 
according to both questionnaires and medical record.  Due to this discrepancy, 
both smoking self-report and history from medical records were tested 
separately for inclusion in models. 
 
Variable Prevalence from 
questionnaire (%) 
Prevalence from 
record (%) 
P value 
Smoker 
 No never 
 Yes current 
 Yes ex 
 
45 (33.6) 
48 (35.8) 
41 (30.6) 
 
43 (33.9) 
81 (63.8) 
3 (2.4) 
 
<0.001 
Diabetes 
 No  
 Yes 
 
108 (80.6) 
26 (19.4) 
 
104 (80.6) 
25 (19.4) 
 
0.99 
Hypertension 
 No  
 Yes 
 
71 (53.0) 
63 (47.0) 
 
68 (54.0) 
58 (46.0) 
 
0.87 
Hypercholesterolaemia 
 No  
 Yes 
 
72 (53.7) 
62 (46.3) 
 
68 (54.0) 
58 (46.0) 
 
0.97 
Personal history of AMI 
 No  
 Yes 
 
115 (85.8) 
19 (14.2) 
 
111(86.7) 
17 (13.3) 
 
0.83 
Personal history of 
stroke 
 No  
 Yes 
 
129 (96.3) 
5 (3.7) 
 
121 (94.5) 
7 (5.5) 
 
0.50 
Table 6.8 Comparison of information obtained from questionnaires and medical records 
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6.5.7 Inference of sample size needed based on season 1 of recruitment 
 
The proportion of controls exposed to recent influenza-like illness was 4.7% with 
an adjusted odds ratio of 3.17.  Using the Fleiss method the sample size needed 
was 222 cases and 222 controls to detect a result with 90% power at the 5% 
significance level (or 245 of each with a continuity correction).  Though high, the 
expected odds ratio was in keeping with incidence ratios generated through self-
controlled case series analysis in chapters 4 and 5.  Doing a similar calculation 
using the exposure respiratory illness, the proportion of exposed controls was 
18.8%.  With an adjusted odds ratio of 1.39 this resulted in a sample size 
requirement of 1154 cases and 1154 controls (or 1190 of each with a continuity 
correction).   
 
6.5.8 Decisions regarding further recruitment  
 
For reasons outside the scope of the project (maternity leave) it was not possible 
to recruit participants during the 2010/11 influenza season. A decision was taken 
following the PhD upgrade meeting and viva on 28th March 2011 to cease 
recruitment after one season, rather than to conduct the study during the 
2011/12 season.  This was because, using results from the corrected sample size 
calculations informed by season one, even at the lowest level 222 cases and 
controls would be needed (total 444 participants) for the study to be adequately 
powered.  Despite relatively high uptake, only 134 participants were recruited in 
the first season.  Without additional resources it was not possible that another 
310 participants could be recruited in a second season, especially as the 
unpredictable nature of influenza circulation meant that seasons could last for 
fewer months than expected.  During the 2009 influenza pandemic, there was a 
mismatch between age-groups infected by H1N1pdm09 and those typically 
affected by AMI which further reduced the study’s power to detect an effect. 
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6.6 Discussion  
 
6.6.1 Summary of findings 
 
The study was supportive of the hypothesis that recent respiratory illness and in 
particular influenza-like illnesses occurring during the second wave of the 2009 
influenza pandemic were more common in patients hospitalised with AMI than 
with acute surgical conditions, although differences were not statistically 
significant.  There was a (non-significant) trend towards protection against AMI 
with influenza vaccination.  Based on current ILI rates it is estimated that at least 
222 cases and 222 controls would be needed for a full scale case control study.   
 
6.6.2 Study strengths 
 
Triangulating data on influenza from several sources including symptom report, 
virus detection and antibody testing, allowed sensitivity analyses to be done using 
different influenza definitions.  The accuracy of information on admission 
diagnosis and potential medical confounding factors obtained through self-report 
was also confirmed using medical records.  The study proved successful at 
demonstrating the feasibility of recruitment from hospital wards, the 
acceptability of the study to patients and the effectiveness of questionnaire and 
database design.   
 
6.6.3 Study limitations – lack of power and missing data 
 
While I had hypothesised that more adults would be infected during the second 
pandemic wave due to the expected upwards shift in age distribution of 
infections, national ILI rates remained low throughout this period so the study 
was underpowered to detect an effect.  In addition some variables were affected 
by missing data: only 113 participants (84.3%) had a usable serum sample and 
only 105 (78.4%) samples had a definite positive or negative result on IgA ELISA.  
Some samples were missing due to patients being missed on the phlebotomist’s 
round and others due to difficulties obtaining a blood sample.  As there were no 
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substantial differences in characteristics of participants with and without missing 
laboratory data, however, this is unlikely to have significantly biased results.   
 
6.6.4 Study limitations – misclassification of exposure 
 
Using self-reported recent respiratory and influenza-like illness as exposures 
introduced the possibility of reporting or recall bias.  Nevertheless this method 
allows greater sensitivity to detect recent respiratory symptoms than relying on 
reports of medically attended illnesses, which comprise only a small minority of 
influenza cases195.  As cases and controls were frequency matched on week of 
admission, external factors such as media coverage of the influenza pandemic 
should not have had a differential effect on respiratory illness reporting.  It was 
perhaps unsurprising that none of the nasopharyngeal and throat swabs was 
positive for influenza virus given a) the low rates of infection in this age-group175 
and b) that the majority of viral shedding in influenza occurs in the first 2-3 days 
after symptom onset19 and most reported respiratory symptoms in study 
participants occurred 8-14 days before admission.   
 
Influenza serology is difficult to interpret in vaccinated participants as it not 
possible to distinguish antibody rises caused by infection from those caused by 
vaccination.  Validation of the IgA assay used suggests it has acceptable sensitivity 
and specificity to detect recent seasonal influenza A infection191 but its effect with 
H1N1pdm09 is unclear.  It has previously been noted that serological studies 
carried out during the pandemic were severely hampered by cross reactivity both 
with vaccine and with seasonal influenza strains177.  It would have been useful to 
have validated the IgA ELISA against results obtained from the more widely used 
haemagglutinin inhibition (HI) assay for IgG on paired samples, which uses the 
more standard technique of serial dilutions.  This was not done for several 
reasons: HI assays require several controls for standardisation and are time-
consuming and labour-intensive188; participants were not due to attend for 
routine follow-up during the time window in which a second blood sample was 
needed; in people with recent (rather than current) influenza it was likely that an 
antibody response would already be maximal on the first test, limiting the 
usefulness of a second sample.   
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6.6.5 Logistic issues and lessons learned  
 
From a training perspective, conducting research in a busy acute setting, 
developing clinical and laboratory collaborations, and adapting the study in 
response to changing external factors (such as the advent of the 2009 influenza 
pandemic) were all valuable lessons learned.  In future a similar study would be 
improved by having a recruitment team able to operate across multiple sites to 
maximise recruitment during the influenza season.  This would reduce the impact 
of losing potential participants before recruitment due to transfers to other 
hospitals or problems fitting recruitment around clinical care.  Having a dedicated 
study phlebotomist would have increased the number of samples obtained, 
although part of the rationale for using ward phlebotomists to take study blood 
samples at the same time as routine samples was to minimise inconvenience and 
the number of tests that patients required.    
 
The unexpected coincidence of the study start date with the 2009 influenza 
pandemic led to several issues with study design and communication.  During the 
pandemic, the hospital infection control team followed up any in-patient on 
whom a nasopharyngeal swab was taken for influenza testing.  When this came to 
light I reported details of all study participants to the team on a daily basis to 
prevent these patients from being following up as potential influenza cases.  For 
the first time, in the autumn and winter of 2009/2010 patients attending the GP 
for influenza vaccination were offered both seasonal and pandemic influenza 
vaccinations.  In the questionnaire when people said that they had been 
vaccinated ‘this year’ I did not know (and it seemed that many participants did 
not know) which vaccination they had had.  Therefore some participants labelled 
as ‘vaccinated’ may in fact have had only seasonal influenza vaccine based on the 
previous year’s circulating strains which would not have provided protection 
against pandemic strain influenza.  This highlights the need to pilot data 
collection systems and to evaluate them early in the study to incorporate changes. 
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6.6.6 Interpretation of results in context of previous studies 
 
There are no previous individual-level studies of the association between 
H1N1pdm09 and AMI that met inclusion criteria for the systematic review update 
(appendix to chapter 2).  The low rates of ILI and acute respiratory illness seen in 
hospitalised participants in our study (whose median age was 63.6 years) were in 
keeping with other studies of H1N1pdm09 suggesting that most illnesses were 
mild and typically affected younger people176.  There have been four small case 
control studies examining the association between clinically-defined ILI in AMI 
patients during periods of seasonal influenza circulation86–89.  Two of these 
studies found a significant association between AMI and recent ILI86,89.  In the 
other two studies, the point estimate tended towards an effect but results failed to 
reach statistical significance87,88.  Our results are consistent with these studies.  
Though findings should be interpreted with caution, this study supports the 
hypothesis that, as with other influenza strains, H1N1pdm09 could trigger AMI in 
vulnerable groups.  Nonetheless the population impact of H1N1pdm09 on rates of 
AMI hospitalisations and death is likely to have been relatively low given the 
mismatch between the ages of those typically affected by H1N1pdm09 and AMI as 
well as the relatively mild clinical effects of this strain. 
 
6.6.7 Future directions 
 
Studies described in this thesis have used varying clinical and laboratory 
definitions of influenza to investigate the strength, temporality, gradient and 
consistency across time periods and strains of an association between influenza 
and AMI.  Some vulnerable populations have been identified.  So far, though, the 
biological plausibility of an effect has not been investigated.  In chapter 7 I discuss 
potential biological mechanisms through which influenza could act to trigger AMI 
and describe an exploratory study of inflammatory and haemostatic markers.   
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  SUMMARY 
 A case control study was used to investigate whether patients 
hospitalised for AMI were more likely to have experienced recent ILI 
during the second wave of the 2009 influenza A H1N1 pandemic than 
patients hospitalised for a range of acute non-vascular surgical 
conditions 
 Of 134 participants, 29 (21.6%) reported recent respiratory illness of 
whom 13 (9.7%) had illnesses meeting ILI criteria 
 AMI cases were more likely to have reported ILI than controls – adjusted 
OR 3.17 (95% CI 0.64 - 16.76) – as well as other key respiratory 
symptoms but differences were not statistically significant. 
 Compared to seasonal influenza, during the pandemic the age groups 
typically affected by AMI had comparatively low rates of influenza 
infection which decreased the study’s power to detect an effect 
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7. Inflammatory and haemostatic mechanisms through which 
influenza could trigger acute myocardial infarction  
 
7.1 Description of chapter contents 
 
The first part of this chapter describes inflammatory and haemostatic 
mechanisms associated with influenza and AMI.  This provides a rationale and 
theoretical framework to underpin the exploratory study described in the second 
half of the chapter.  Section 7.2 describes acute inflammatory and haemostatic 
response to influenza and other tissue insults.  Section 7.3 outlines the roles of 
inflammation and haemostasis in atherosclerosis and AMI.  Section 7.4 discusses 
theoretical mechanisms for an interaction between the acute phase response to 
influenza and the triggering of acute cardiovascular events.  In section 7.5, several 
prominent markers of inflammation and haemostasis relevant to both influenza 
and AMI are discussed in detail.  I then describe an exploratory mechanistic study 
in sections 7.6-7.9.  Here, AMI patients admitted to the Royal Free Hospital (who 
comprise the ‘cases’ in the case control study described in chapter 6) have extra 
blood samples taken and tested for a range of cytokines and inflammatory 
markers.  Comparisons are made between levels of biomarkers in AMI patients 
with and without evidence of recent influenza infection.   
 
7.2 Inflammatory and haemostatic responses to acute tissue insults 
 
7.2.1 Acute phase inflammatory response to influenza  
 
While the innate immune response to influenza comprises a range of rapid co-
ordinated defence mechanisms including physical defences (eg mucus and cilia), 
interferons and complement, this section will focus on one of these – the acute 
inflammatory response.  An acute phase response is triggered by influenza virus 
as well as a range of tissue insults such as other infections or ischaemic injury.  It 
is characterised by rapid rises in local pulmonary levels of inflammatory 
cytokines and chemokines196.  Cytokines such as tumour necrosis factor-α (TNF-
α), interleukin -6 (IL-6) and IL-18 and chemokines such as RANTES, MIP-1a, 
monocyte chemoattractant protein-1 (MCP-1) and MCP-3 are produced from 
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influenza virus-infected monocytes and macrophages and, to a lesser extent, 
virus-infected respiratory epithelial cells197.  These pleiotropic agents mediate a 
variety of inflammatory processes in different tissues, for example acting on the 
brain to induce fever198, the liver to stimulate the secretion of acute phase 
proteins such as C-reactive protein199, and on vascular endothelium to increase 
permeability and allow leukocyte extravasation and migration to the site of 
inflammation200.  A graphical representation of this process is shown in figure 
7.1201.   
 
The resulting inflammatory milieu favours development of antiviral and T helper 
cell type 1 immune responses by the adaptive immune system designed to 
combat influenza, for example through direct attack on antigen-bearing cells by 
cytotoxic T cells202.  Humoral (or antibody-mediated) immunity - another major 
component of the adaptive immune response to influenza - is described briefly in 
chapter 6, section 6.2 in relation to the research study described.  Adaptive 
immunity will not be discussed further here. 
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LUNG TISSUE 
Influenza 
infection 
TNF-a 
IL-6 
MAC 
PMN 
phagocytosis 
BLOOD VESSEL 
PMN 
PMN 
Figure 7.1 Examples of molecular level acute inflammatory responses to influenza in lung and 
vascular tissue.  Adapted from fig 7, p20, Playfair & Chain, Immunology at a Glance201 
 
PMN = polymorphonuclear leukocyte 
MAC = macrophage 
MONO = monocyte 
TNF-α = tumour necrosis factor-α 
IL-6 = interleukin-6 
MONO 
IL-1 
tissue damage 
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7.2.2 Haemostasis after tissue injury 
 
Inflammatory and coagulation pathways are closely linked through a complex 
system of bi-directional crosstalk203,204.  Both pathways are triggered by the same 
types of stimuli such as vascular injury or infection and their effects act in concert 
in the same tissues and disease states205.  Blood coagulation, or haemostasis, is an 
intricate process involving platelet activation and aggregation, as well as a 
cascade of proteolytic reactions whereby circulating precursor proteins are 
cleaved to active products, leading ultimately to thrombin-mediated conversion 
of fibrinogen to a fibrin network206 (figure 7.2).  Key players are the endothelium, 
platelets, coagulation factors and inhibitors and the fibrinolytic system206.  
Inflammatory molecules and products interact with the coagulation pathway at 
every stage eg expression of the coagulation factor tissue factor is mostly 
dependent on the pro-inflammatory cytokine IL-6204; another prominent 
coagulation factor, thrombin, has pleiotropic anti-inflammatory actions including 
diminishing the release of IL-12 and favouring transformation of protein C to 
activated protein C (a potent inflammatory and anticoagulant molecule)207; a 
third important coagulation factor, fibrinogen, is considered to be an acute phase 
reactant205 and is genetically correlated with C-reactive protein levels via links on 
chromosomes 12 and 21208.  Powerful anti-coagulation systems regulate not only 
coagulation reactions but also inflammation204.  Finally various coagulation 
factors including tissue factor, thrombin and fibrinogen have been significantly 
implicated in diseases with an inflammatory component, such as 
atherosclerosis205.  This is discussed further in section 7.3.         
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platelet adhesion 
platelet aggregation 
fibrin  
platelet activation 
stable haemostatic plug 
platelet phospholipid 
Blood coagulation cascade 
thrombin 
Vascular injury/ 
other trauma 
Figure 7.2 Platelet and haemostatic 
responses to vascular injury or trauma. 
Adapted from fig 22.1, p164, chapter 22, 
Hoffbrand, Essential Haematology206 
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7.2.3 Detecting inflammatory and haemostatic products after influenza 
infection or vaccination in vivo 
 
It is clear that influenza infection stimulates expression or release of a wide 
variety of inflammatory molecules and cytokines (many of which are key 
mediators of atherosclerosis209 as well as interacting with coagulation pathways.  
Various studies have examined products of inflammation and haemostasis after 
influenza infection, or influenza vaccination as an inflammatory stimulus.  For 
such markers to be useful tools for epidemiological research, they must not only 
be expressed in circulating blood in response to influenza infection, but should 
have a validated, commercially available assay that is stable over time and to 
freeze-thaw cycles.  Tables 7.1 and 7.2 below are not exhaustive but give 
examples of the types and temporal profiles of molecules that are expressed and 
measurable after influenza.  Six important markers identified from these studies – 
C reactive protein, serum amyloid A, interleukin-6, tumour necrosis factor-α, P-
selectin and von Willebrand factor – are measured in the exploratory study 
described later in this chapter.  Further details on these individual markers are 
given in section 7.5. 
 
 
   
 
SUMMARY 1) 
 Influenza infection elicits acute local and systemic inflammation and 
haemostasis 
 There is extensive crosstalk between inflammatory and haemostatic 
pathways 
 Key markers of inflammation (such as CRP and SAA), cytokines (such as 
IL-6 and TNF-α) and markers of platelet activation (such as P-selectin) 
are increased in influenza and may be useful in mechanistic studies 
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Author (year) Inflammatory stimulus Methods        Results 
Lannegard 
(2003)210 
Various bacterial and viral 
infections in 98 patients 
(11 had influenza A)  
Serum SAA and CRP levels measured in 
all patients on admission and correlated 
with each other 
- Positive correlations between CRP and SAA found in both viral 
and bacterial infections 
- Mean CRP concentration = 85 in influenza patients 
- Median SAA = 980 mg/L in influenza patients 
 
Lee (2007)211 Severe influenza A virus 
infection in 39 hospitalised 
patients  
Acute and convalescent blood samples 
taken on admission and >10 days later 
and tested for a panel of 11 cytokines 
and chemokines 
- Significant increases in IL-6, IL-8, IFN-induced protein 10 and 
monokine induced by IFN-gamma seen in acute phase. 
- RANTES increased in convalescent sample only 
- No change in IFN-gamma, IL-12, TNF- α , IL-10, IL-1B and MCP-1 
  
Keller (2007)212 ILI in 54 subjects (9 had 
confirmed influenza) 
Blood taken at baseline (pre-illness) 
then within 1-3 days of illness and 14 
days later.  Haemostatic proteins 
measured at each time-point 
- VWF increased in the acute phase  
- Fibrinolysis was activated (measured by increased PAP) 
- There was no change in  plasminogen activator inhibitor or  
prothrombin fragments 
 
Kreutz (2007)213 Acute viral upper 
respiratory tract infection 
in 18 subjects compared to 
8 healthy controls 
Blood samples taken at enrolment and 6 
weeks later for ADP-induced platelet 
aggregation and platelet surface 
receptor expression (P-selectin and 
glycoprotein IIb/IIIa) as well as 
inflammatory markers 
 
- Platelet reactivity and P-selectin expression were higher during 
viral infection than in controls. Both fell significantly over time 
- CRP and TNF- α  increased during viral infection 
- No difference in soluble P-selectin, sICAM-1 and sVCAM-1 levels in 
illness compared to recovery 
 
Marchesi 
(2005)214 
Serologically confirmed 
symptomatic influenza 
infection in 10 otherwise 
healthy volunteers 
Endothelial function measured by 
brachial flow-mediated vasodilation 
(FMV), soluble ICAM-1 & VCAM-1. 
Inflammatory markers and lipid profile 
taken at 3 days and 3 months   
 
- After 3 months, FMV was increased, compared to the 
measurement taken during infection 
- CRP, white cell count and HDL cholesterol were significantly 
lower at 3 months than during infection 
- CRP changes were correlated with sICAM-1 and sVCAM-1 changes 
 
Nakayama 
(1993)199 
A range of confirmed viral 
and bacterial infections in 
288 hospitalised paediatric 
patients (25 had influenza) 
 
SAA and CRP measured on day 1 
(admission) and day 7 (convalescence) 
- SAA and CRP higher on D1 than D7 in influenza-infected patients 
- Arithmetic mean SAA concentration = 63 mg/L in influenza 
- Arithmetic mean CRP concentration = <7 mg/L in influenza 
 
Patel (2009)215 326 virus-positive URI 
episodes in 151 children 
aged 6-36 months (27 had  
influenza) 
Children healthy at enrolment, followed 
for 1 year.  Seen asap after each URI 
then again at day 3-7.  Nasopharyngeal 
samples taken at first visit for cytokine 
analysis 
- IL-1B, IL-6 and TNF- α  were all raised and correlated with each 
other 
- IL-6 concentrations were significantly higher during influenza 
- IL-1B higher during URI episodes associated with acute otitis 
media than other episodes 
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Table 7.1 Studies of inflammatory and haemostatic markers after influenza or ARI 
 
 
 
 
 
 
 
 
 
 
 
Van Wissen216 
(2011) 
ILI in 15 subjects (6 had 
confirmed influenza) 
Blood taken at baseline (pre-illness) 
then within 1 day of illness, 2-3 days 
later and 14 days later.  Haemostatic 
proteins measured at each time-point 
- Large acute rise in hs_CRP, PAP, VWF and D-dimer cf baseline 
- No change in plasminogen activator inhibitor or prothrombin 
fragments 
- Other parameters of thrombin generation showed significant 
procoagulant change during infection and in the convalescent 
phase 
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Table 7.2 Studies of inflammatory and haemostatic markers after influenza vaccination as an inflammatory stimulus 
Author (year) Inflammatory stimulus Methods        Results 
Carty (2006)196 Influenza vaccination given to 
107 men (43 with severe 
carotid artery disease) 
 
24 hour levels of cytokines measured - CRP, Il-6 and SAA relatively higher in men with carotid 
artery disease (but difference only significant for SAA) 
Lanza (2011)217 Influenza vaccination given to 
28 patients with diabetes 
Inflammatory and haemostatic markers 
were measured pre and post vaccine. 24 
hour ECG and heart rate variability were 
assessed 
 
- IL-6, CRP, platelet-monocyte aggregates and platelet-
monocyte receptor expression were increased after 
vaccination 
- Heart rate variability decreased after vaccination 
 
Liuba (2007)218 Influenza vaccination given to 8 
healthy volunteers 
Brachial artery responses to hyperaemia 
and sublingual GTN measured and carotid 
intima-media thickness assessed by 
external ultrasound before, 2 and 14 days 
after vaccination.  Plasma CRP, fibrinogen, 
cGMP and antibodies against oxidised LDL 
measured  
 
- CRP and fibrinogen elevated slightly on D2 resolved by 
D14 
- oxLDL antibody levels increased above baseline D2 and 
D14 
- Flow mediated dilatation of brachial artery decreased at 
D2 with a further decrease at D14. 
- No change in dilatory responses to GTN or carotid 
intima-medial thickness seen 
 
Tsai (2005)219 Influenza vaccination given to 
22 healthy individuals 
Plasma CRP, IL-6, MCP-1, TNF-α, IL-2 
soluble receptor-α and SAA measured pre 
vaccine and 1,3 and 7  days afterwards 
- hsCRP, IL-6 and SAA all mildly increased on D1 and 
hsCRP on D3 
- Plasma triglyceride levels decreased n D1, 3 and 7 
- No change to MCP-1, TNF-α or IL-2 soluble receptor-α 
 
Vlachopoulos 
(2011)220 
 
 
 
 
Influenza vaccination or 
placebo given to 24 HIV-
infected patients in an RCT 
Endothelial function measured by flow-
mediated dilatation (FMD) and 
inflammatory markers assessed before and 
at 8 and 48 hours post vaccine 
- FMD deteriorated after vaccination at 8 and 48 hours 
- White blood cell count was elevated at 8 and 48 hours 
- Soluble ICAM-1 decreased maximally at 48 hours 
- There were no changes in endothelial function or 
inflammatory markers in the placebo group 
Werba (2008)221 60 patients received influenza 
vaccine (26 with quiescent CHD 
and 34 with previous ACS) 
Blood taken at baseline and 48 hours after 
vaccination for CRP and SAA 
- CRP increased significantly in both groups 
- SAA increased significantly only in the group with 
previous ACS  
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7.3 Pathogenesis of atherosclerosis and AMI 
 
7.3.1 Development of atherosclerosis  
 
Atherosclerosis is a dynamic inflammatory disease, with inflammation central to 
all stages of its pathogenesis from inception and development of atherosclerotic 
lesions to end-stage thrombotic complications6.  In its earliest stages, endothelial 
dysfunction is mediated through attachment of leukocytes to the vascular cell 
wall by molecules such as vascular cell adhesion molecule-1 and members of the 
selectin family222.  Expression of cell adhesion molecules on vascular endothelium 
may be initiated by the action of cardiovascular risk factors such as smoking, 
hypertension and a high saturated fat diet6.  After adhesion, chemokines such as 
monocyte chemoattractant protein-1 direct migration of monocytes into the 
artery wall, where they differentiate into macrophages and proliferate, under the 
influence of factors such as macrophage colony-stimulating factor223.  Numerous 
coagulation factors have also been implicated in these processes207.  Activated 
macrophages engulf modified lipoprotein particles by endocytosis224.  
Macrophages accumulate intra-cytoplasmic droplets of cholesterol ester and 
become known as ‘foam cells’.  These form early atherosclerotic lesions known as 
fatty streaks52 (figure 7.3).  With continued cycles of inflammation, accumulation 
of leukocytes, migration and proliferation of smooth muscle cells and fibrosis, 
lesions enlarge and remodel7.  Complicated atherosclerotic plaques comprise a 
thrombogenic lipid core overlain by a fibrous cap7, which may protrude into the 
vessel lumen and affect blood flow (figure 7.4).  
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Figure 7.3 Formation of a fatty streak 
Figure designed by C. Warren-Gash 
Figure 7.4 Formation of a complicated atherosclerotic plaque 
Figure designed by C. Warren-Gash 
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7.3.2 Inflammation and haemostasis in AMI 
 
Coronary artery thrombosis leading to AMI usually results from plaque rupture, 
rather than a critical artery narrowing225.  The transition from stable to unstable 
(and ruptured) plaque involves disruption of the integrity of interstitial collagen 
matrix forming the plaque’s fibrous cap226.  This is mediated by fibrinolytic 
enzymes such as matrix metalloproteinases226, which are expressed by 
macrophages in response to stimulation by pro-inflammatory cytokines.  These 
cytokines also act on smooth muscle to prevent formation of new collagen fibres6.  
Platelets and the coagulation system are activated by the damaged vessel wall 
leading to thrombus formation227.  In addition, activated T lymphocytes can 
contribute to arterial thrombosis by producing CD-40L which stimulates 
macrophages to produce the highly thrombotic protein tissue factor228.  Markers 
from the haemostatic pathway such as D-dimer and von Willebrand factor have 
an independent association with myocardial infarction risk after adjusting for 
established risk factor and inflammatory markers227.  Similarly inflammatory 
markers such as CRP are associated with myocardial infarction risk independent 
of other established risk factor and haemostatic factors229.  It is evident that both 
inflammation and haemostasis contribute to the final common pathway towards 
coronary artery thrombosis and AMI.  This is reflected in the use of agents such as 
aspirin, which have pleiotropic actions including anti-platelet and anti-
inflammatory properties207, for both primary and secondary AMI prevention. 
 
 
 
 
 
 
 
 
 
 
 
SUMMARY 2) 
 Inflammation is central to the genesis of atherosclerotic plaques 
 Pro-inflammatory and pro-thrombotic molecules are instrumental in 
the transition from stable to unstable atherosclerotic disease 
 Markers of systemic inflammation (such as CRP) and haemostasis 
(such as Von Willebrand Factor) have been shown to predict AMI 
risk independent of other established risk factors  
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7.4 Possible mechanisms through which influenza could trigger AMI 
 
7.4.1 Direct effects on coronary vessels 
 
Influenza and other acute respiratory infections exert both direct local effects on 
coronary arteries and indirect systemic effects through which they might act to 
trigger AMI109.   Direct infiltration of influenza virus RNA has been found in 
human atherosclerotic plaques, although the clinical significance of this is 
unknown230.   Influenza may also lead to focal inflammatory changes within 
atherosclerotic plaques and coronary vessels231,232.  This has been demonstrated 
in a mouse model of atherosclerosis in which 24 apolipoprotein E-deficient (ApoE 
-/-) mice were injected with a lethal dose of influenza233.  Histological aortic 
specimens from infected ApoE -/- mice showed increased intimal cellularity 
compared to non-infected ApoE -/- mice.  10 infected ApoE -/- mice also had a 
significant sub-endothelial infiltrate of smooth muscle cells, lymphocytes and 
macrophages and one had a sub-occlusive platelet and fibrin-rich thrombus.  As 
well as stimulating plaque inflammation, it is proposed that the host immune 
response to infection may affect plaque composition and therefore vulnerability 
to rupture through mechanisms such as macrophage activation209. 
 
7.4.2 Indirect systemic effects  
 
Influenza infection may also generate systemic inflammation, acting through 
some of the inflammatory mediators described above.  There is increasing 
evidence that markers of systemic inflammation independently predict vascular 
risk234.  People with systemic inflammatory disorders such as rheumatoid 
arthritis are at higher risk of AMI and other acute cardiovascular events235.  
Acting in concert with systemic inflammation, haemostatic effects of influenza 
virus including endothelial dysfunction214, increased platelet reactivity and 
aggregation200, increased plasma viscosity and formation of thrombi 204 can also 
predispose to AMI.  Haemodynamic effects associated with infections include 
increased sympathetic activity, vasoconstrictive effects and changes in circulating 
blood volume55.  These can increase biomechanical stress on coronary plaques, 
potentially triggering their disruption56.  Immobility associated with bed rest as 
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well as dehydration might accompany influenza infection and potentiate these 
processes. 
 
 
 
 
 
 
 
7.5 Role of specific markers of inflammation and haemostasis 
 
7.5.1 C-reactive protein and serum amyloid A 
 
C-reactive protein is probably the best-studied circulating inflammatory marker.  
It is produced by hepatocytes during the acute phase response, under stimulation 
from inflammatory cytokines that include IL1, IL-6 and TNF-α229.  It is a highly 
sensitive but non-specific marker of events that trigger the acute phase response.  
CRP levels can rise by several orders of magnitude above baseline in response to 
major infections, inflammation, tissue damage or other stresses229.  These large 
rises in CRP should be distinguished from modest elevations above baseline (to 
levels previously considered negative or normal) that have been found to be 
associated with significant changes in vascular risk236.  It is unclear whether CRP 
plays a direct role in the pathogenesis of inflammation or whether it is simply a 
marker for inflammatory disorders.  This controversy is highlighted by studies in 
cardiovascular disease: on one hand, the finding that inherited genetic variations 
in CRP are not linked to coronary heart disease suggests that CRP may not play a 
causal role237; on the other, a number of trials of statins for both primary and 
secondary prevention of cardiovascular events, in which statin use was associated 
with major reductions in CRP as well as in serum lipids, suggest that reducing 
CRP may reduce risk of cardiovascular events238–240.   
 
Serum amyloid A (SAA) is another acute phase protein synthesised primarily in 
the liver in response to stimulation from pro-inflammatory cytokines241.  Levels 
are raised after infection, injury and other tissue damage.  SAA also correlates 
SUMMARY 3) 
 Influenza might trigger AMI either through direct action on coronary 
vessels or through indirect systemic inflammatory, haemostatic or 
haemodynamic effects 
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with cardiovascular disease242.  As with CRP, it is unclear whether SAA 
contributes causally to the development of atherosclerosis and myocardial 
infarction or simply acts as a marker of underlying disease processes241.  It is 
expressed locally at the site of atherosclerotic lesions by macrophages, smooth 
muscle cells and endothelial cells243.  Known effects of SAA include the promotion 
of thrombosis by inducing tissue factor244, stimulation of production of pro-
inflammatory cytokines244, induction of matrix metalloproteinases245 and 
promotion of chemotaxis for monocytes and neutrophils246.  Recent evidence 
suggests that SAA also modulates the anti-inflammatory function of high density 
lipoprotein247.  Though it is expressed in adipose tissue, its role there is less well 
understood. 
 
7.5.2 Interleukin-6 and tumour necrosis factor-α 
 
IL-6 is expressed and released from various cells including monocytes, 
macrophages and endothelial cells upon induction by vasoactive peptides, 
reactive oxygen species and other cytokines248.  It is an important proximal 
mediator of the acute phase response234 and has a major role in stimulating 
hepatic secretion of other acute phase proteins including CRP227 and SAA248.  It 
interacts with other inflammatory cytokines including TNF-α, IL-1 and IL-8 to 
drive inflammation248.  While many previous studies have focussed on 
downstream inflammatory mediators such as CRP as these are more stable, long-
term average levels of IL-6 have also recently been found to be independently 
associated with coronary heart disease risk234.  In addition, IL-6 levels are 
increased in AMI patients compared to healthy controls249.  As before, whether IL-
6 plays a causative role in coronary heart disease and, by extension, whether it 
could be used as a potential therapeutic target remains to be seen234.  Statin trials 
suggest a reduction in IL-6 levels250 but the pleiotropic effects of statins may 
make it difficult to disentangle the significance of this result. 
 
TNF-α is released rapidly in a preformed soluble form from cells such as 
macrophages, lymphoid cells and endothelial cells in response to inflammatory 
stimuli251.  Stimuli include infections and acute tissue injuries such as myocardial 
ischaemia or infarction.  Levels of TNF-α are increased in peripheral blood 
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samples from AMI patients compared to healthy controls249 and there may be a 
low-grade increase in concentration with age252.  TNF-α works in concert with 
other pro-inflammatory cytokines, acting on macrophages, monocytes, 
endothelial cells and vascular smooth muscle cells to promote changes such as 
increased vascular permeability, leukocyte attachment and transmigration, 
increased cholesterol uptake, formation of foam cells and increased blood 
clotting251.  In high concentrations, TNF-α may contribute to ischaemic tissue 
damage and myocardial necrosis through triggering fibrosis, apoptosis and 
hypertrophy251.  Although antibodies directed against TNF-α have been posited as 
a potential treatment for cardiovascular conditions, large randomised controlled 
trials as yet show no evidence of benefit for treatment of cardiac failure253,254, 
though it is hypothesised that this may be due to immune system redundancy.  
 
7.5.3 P-selectin and Von Willebrand factor 
 
P-selectin is a trans-membrane inflammatory cell adhesion molecule present in 
the alpha granules of platelets and Weibel-Palade bodies of endothelial cells255.  
Cell adhesion molecules belong to one of three main families – selectins, 
immunoglobulins and integrins.  In general selectins mediate rolling and binding 
of flowing blood cells on vascular endothelium, while immunoglobulins such as 
ICAM-1,2,3 and integrins such as β1-integrin and β 2-integrin, facilitate adhesion 
and extravasation of blood cells256.  After activation and rapid translocation to the 
cell surface, P-selectin initiates interactions of leukocytes and platelets with 
endothelium257,258 through its ligand at sites of inflammation and tissue injury.  It 
contributes to the pro-thrombotic environment by up-regulating tissue factor and 
other pro-coagulant molecules259.  P-selectin is also involved in platelet-platelet 
interactions that stabilise platelet aggregates260.  Both platelet-platelet and 
platelet-leukocyte interactions are important for the development of arterial 
thrombosis.   P-selectin is a marker of platelet activation in vivo and its levels are 
raised in various vascular conditions such as acute coronary syndromes, atrial 
fibrillation, stroke and peripheral vascular disease255.  Knockout mouse studies 
suggest it is also critical for the progression of atherosclerosis261.   
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Von Willebrand factor is a large plasma protein synthesised in endothelial cells 
and megakaryocytes and stored in Weibel-Palade bodies and platelet alpha 
granules262.  Levels increase markedly during acute-phase responses to systemic 
or local inflammation263 and VWF is a key player in the primary haemostatic 
response to vascular injury262.  Specific actions include promoting rapid platelet 
adhesion to exposed collagen within the subendothelium through glycoprotein 
receptors Ib and IIb/IIIa and to other platelets206.  VWF is also involved in 
carriage of factor VIII206.  It is highly correlated with other markers of both 
haemostasis and inflammation227.   A previous meta-analysis has found a 
moderate relationship between VWF and coronary heart disease, which holds 
even after adjusting for other markers of haemostasis and inflammation264.   
 
7.6 Exploratory study 
 
7.6.1 Aims & objectives 
 
Aim: To perform an exploratory study examining markers of inflammation and 
platelet activation in AMI patients. 
 
Objectives 
1. To describe laboratory markers of inflammation and platelet activation in 
a cohort of AMI patients hospitalised during the 2009 influenza pandemic 
2. To investigate whether AMI patients with evidence of recent influenza had 
higher levels of inflammatory and haemostatic markers than patients 
without evidence of recent influenza infection.  
 
7.7 Methods 
 
7.7.1 Overview of study design 
 
This single centre study was an extension of the study described in chapter 6.  The 
group of patients hospitalised with AMI during the 2009 influenza pandemic 
(who were ‘cases’ in the previous chapter) had an extra serum and plasma sample 
taken for analysis of levels of inflammatory and haemostatic markers.  In this new 
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study, the exposure was recent influenza infection (defined both clinically and by 
serological testing) and outcome variables were the various inflammatory and 
haemostatic markers.     
 
7.7.2 Setting and participants 
 
As before, the study was conducted at the Royal Free Hospital, London, UK 
between 21/09/2009 and 28/02/2010.  Participants were recruited from the 
acute cardiology ward and coronary care unit.  They were eligible for inclusion if 
aged ≥40 years and admitted with an AMI (defined as before as a rise in troponin 
T with ischaemic symptoms and/or typical ECG changes, or by angiographic 
evidence of acute coronary artery thrombosis during primary percutaneous 
coronary intervention).  Exclusion criteria were patients transferred from other 
hospitals, those unable to provide informed consent, those unable to speak 
sufficient English or those judged by the treating clinician to be too unwell to take 
part.  The recruitment and consent processes are described in section 6.4.3. 
 
7.7.3 Data sources and management 
 
Demographic and clinical data on the admission, cardiovascular risk factors, 
symptoms of respiratory illness and influenza vaccination status were obtained 
through a questionnaire and verified where possible through medical records – 
see table 6.1 for further details. 
 
For this study in addition to the serum sample taken for determination of the 
concentration of influenza A IgA antibodies by ELISA, another 5ml serum sample 
and a 5ml plasma EDTA sample were collected.  These were taken to the virology 
laboratory for storage at -80°C prior to batch testing for a range of inflammatory 
and haemostatic markers using commercially available assays described below.   
 
7.7.3i Influenza A IgA antibodies 
Assays for influenza antibodies were performed by staff in the Virology 
Department at the Royal Free Hospital.  Antibodies were quantified using a 
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commercially obtained ELISA kit (Biosupply UK, cat no. RE56501), described in 
detail in section 6.4.5. 
 
7.7.3ii C-reactive protein and serum amyloid A 
CRP was measured by staff in the Biochemistry Department at the Royal Free 
Hospital using a high sensitivity automated microparticle enhanced latex 
turbidimetric immunoassay (COBAS MIRA; Roche Diagnostics GmbH) and SAA 
was measured by latex nephelometry (BNII autoanalyser; Dade Behring, Marburg, 
Germany)265.  Standardisation of CRP and SAA assays was based on the respective 
WHO International Reference Standards266,267.  Results were reported in mg/L. 
 
7.7.3iii Quantitative analysis of cytokines and haemostatic markers 
Concentrations of IL-6, TNF-α and soluble P-selectin were measured by staff in 
the Virology Department at the Royal Free Hospital using immunoassay kits (R&D 
Systems, cat no’s D6050, DTA00C & BBE6) and VWF collagen binding activity 
(CBA) was quantified using a Technozym VWF: CBA ELISA (Technoclone Ltd, cat 
no. 5450301).  All tests were based on the quantitative sandwich enzyme 
immunoassay technique.  Here, a specific monoclonal antibody against the 
molecule of interest was pre-coated onto a microplate.  Standards and samples 
were pipetted into wells allowing the molecule to bind to the antibody.  Washes 
were done to remove unbound substrate and then an enzyme-linked polyclonal 
antibody specific to the desired molecule was added.  After further washes a 
substrate solution was added to wells and colour developed in proportion to the 
amount of bound molecule present.  The optical density of colour was measured 
within a standard time frame and the equivalent concentration of the molecule 
read from a standard curve.  Minimum detectable doses of IL-6, TNF-α and 
soluble P-selectin were <0.7pg/ml, 1.6pg/ml and <0.5ng/ml respectively.  The 
collagen binding activity of VWF was measured rather than VWF concentration as 
this corresponds better to the physiological function of VWF in vivo.  
 
7.7.4 Data management and statistical methods 
 
Categories for demographic and clinical factors were generated as described in 
section 6.4.8.  ‘Influenza’ was classified clinically as presence or absence of recent 
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respiratory illness and presence or absence of recent ILI.  Influenza antibody 
concentrations were initially explored as a continuous outcome variable before 
being grouped by standard thresholds (‘positive’ >12U/ml, ‘equivocal’ = 8-12 
U/ml and ‘negative’ <8 U/ml), with equivocal results dropped to leave a binary 
variable for analysis.  
 
Inflammatory and haemostatic marker outcomes were initially explored as 
continuous variables with a natural log transformation done to enhance 
normality of the data distribution.  Histograms, ranges and the geometric mean 
concentration of each marker were described across all study participants and 
then stratified by presence or absence of recent influenza.  p values were 
presented from t tests of the difference in means of the log of the inflammatory or 
haemostatic marker concentrations in those with and without evidence of recent 
influenza.  For SAA, the only marker for which log transformation did not produce 
a standard normal distribution, non-parametric Wilcoxon rank sum tests were 
also used to test the difference in means.   
 
Univariable linear regression analysis was used to correlate the natural log of 
each inflammatory or haemostatic marker against each influenza variable as well 
as against potential confounding factors such as age-group, gender, troponin level 
(as a marker of the extent of cardiac damage) and type of infarction (STEMI or 
NSTEMI).  As in chapter 6, binary influenza variables were regressed against 
potential confounding factors using univariable logistic regression analysis.  Any 
factors with Wald test values of p<0.2 for their association with both outcome 
(inflammatory or haemostatic marker) and exposure (influenza) were considered 
for inclusion in multivariable linear regression models with the main outcome 
and exposure.  Factors were examined in a backwards stepwise procedure using 
likelihood ratio tests to test the effect of removing each factor sequentially from 
the model.  P values were considered significant at 0.05.  As this was a small study 
it was recognised that there was unlikely to be sufficient power to detect 
interactions.   
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7.8 Results 
 
7.8.1 Characteristics of AMI patients 
 
70 patients with AMI were enrolled in the original case control study, of whom 58 
had a usable serum or plasma sample for measurement of markers of 
inflammation and haemostasis.  Characteristics of AMI patients with and without 
laboratory data are shown in table 7.3.  
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Table 7.3 Characteristics of participants with and without missing laboratory data, n=70 
 
7.8.2 Description of inflammatory and haemostatic markers 
All samples contained detectable amounts of inflammatory and haemostatic 
markers.  Ranges and geometric mean concentrations of markers for the 58 AMI 
patients with laboratory data are given in table 7.4.  Results are not presented for 
Von Willebrand factor collagen binding activity: although levels were detectable 
in all samples, the assay was insufficiently sensitive to distinguish concentrations 
Characteristic of participant Laboratory data 
not missing, n (%) 
Laboratory data 
missing, n (%) 
P value 
Age-group 
 40-49 
 50-59 
 60-69 
 70-79 
 80+ 
 
7 (12.1) 
15 (25.9) 
16 (27.6) 
14 (24.1) 
6 (10.3) 
 
1 (8.3) 
4 (33.3) 
3 (250) 
3 (25.0) 
1 (8.3) 
 
0.98 
Gender 
 Male 
 Female 
 
47 (81.0) 
11 (19.0) 
 
10 (83.3) 
2 (16.7) 
 
0.85 
Smoker (questionnaire data) 
 No never 
 Yes current 
 Yes ex 
 
19 (32.8) 
23 (39.7) 
16 (27.6) 
 
3 (25.0) 
4 (33.3) 
4 (41.7) 
 
0.62 
 
 
Diabetes 
 No 
 Yes  
 
46 (79.3) 
12 (20.7) 
 
10 (83.3) 
2 (16.7) 
 
0.75 
 
Hypertension 
 No 
 Yes  
 
24 (41.4) 
34 (58.6) 
 
9 (75.0) 
3 (25.0) 
 
0.03 
 
Hypercholesterolaemia 
 No 
 Yes  
 
30 (51.7) 
28 (48.3) 
 
6 (50.0) 
6 (50.0) 
 
0.91 
 
Personal history of AMI 
 No 
 Yes 
 
46 (79.3) 
12 (20.7) 
 
10 (83.3) 
2 (16.7) 
 
0.75 
Family history of AMI 
 No 
 Yes 
 
22 (37.9) 
36 (62.1) 
 
5 (41.7) 
7 (58.3) 
 
0.81 
Type of AMI 
 STEMI 
 NSTEMI  
 Unclear 
 
41 (70.7) 
14 (24.1) 
3 (5.2) 
 
7 (58.3) 
3 (25.0) 
2 (16.7) 
 
0.36 
Influenza vaccination status 
  Vaccinated 
  Unvaccinated 
 
32 (55.2) 
26 (44.8) 
 
8 (66.7) 
4 (33.3) 
 
0.46 
Respiratory illness 
  No 
  Yes 
 
46 (79.3) 
12 (20.7) 
 
7 (58.3) 
5 (41.7) 
 
0.12 
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above 2 U/ml (and for 43/58 samples the concentration was given as >2U/ml).  
The histograms below (figures 7.5-7.9) show distributions of outcome variables 
after log transformation, roughly corresponding to the Normal distribution.   
 
Figure 7.5 Histogram of log of hsCRP concentration (mg/L) 
 
 
Figure 7.6 Histogram of log of SAA concentration (mg/L) 
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Figure 7.7 Histogram of log of IL-6 concentration (pg/L) 
 
Figure 7.8 Histogram of log of TNF-α concentration (pg/L) 
 
Figure 7.9 Histogram of log of soluble P-selectin concentration (ng/ml) 
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7.8.3 Univariable associations between inflammatory or haemostatic 
markers and influenza 
 
Associations between geometric mean concentrations of serum inflammatory and 
haemostatic markers in AMI patients with and without evidence of recent 
influenza are shown in table 7.5.  For most markers, concentrations were not 
significantly associated with influenza exposures.  An exception was TNF-α, 
where there was weak evidence that patients with recent respiratory illness 
(p=0.035) or ILI (p=0.08) had higher TNF-α concentrations.  There was similarly 
weak evidence that patients with influenza IgA antibodies in serum had lower 
SAA concentrations, both by t test (p=0.07) and Wilcoxon rank sum test (p=0.08).
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                                         Table 7.4 Ranges and geometric mean concentrations of inflammatory and haemostatic markers 
 
 
Influenza exposure 
variable 
Inflammatory or haemostatic marker outcome variable 
hsCRP  
mean  (95% CI) 
 
P 
value 
 
 
SAA 
mean  (95% CI) 
 
P 
value 
 
IL-6 mean  
(95% CI) 
 
P 
value 
 
TNF-α 
mean  (95% CI) 
 
P 
value 
 
P-selectin 
mean  (95% CI) 
 
P 
value 
 
Recent respiratory 
illness 
  Yes 
  No 
 
 
14.7 (7.18-30.2) 
15.9 (10.0-17.0) 
 
0.87 
 
42.1 (13.5-131.2) 
46.2 (26.3-80.8) 
 
0.88 
 
2.2 (1.3-3.6) 
2.3 (1.8-3.0) 
 
0.76 
 
16.7 (15.0-18.8) 
14.9 (14.3-15.7) 
 
0.035 
 
67.0 (44.6-100.5) 
56.5 (48.0-66.5) 
 
0.36 
Influenza like illness 
  Yes 
  No 
 
 
15.0 (6.4-35.4) 
15.7 (10.2-24.2) 
 
0.94 
 
33.9 (8.0-143.6) 
47.1 (27.6-80.5) 
 
0.67 
 
1.8 (1.0-3.3) 
2.4 (1.9-3.0) 
 
0.41 
 
17.0 (14.2-20.3) 
15.0 (14.4-15.8) 
 
0.08 
 
71.1 (34.3-147.7) 
57.0 (49.0-66.3) 
 
0.34 
Presence of influenza IgA 
antibodies 
  Yes 
  No 
 
 
 
10.7 (5.6-20.3) 
19.6 (11.4-33.7) 
 
 
0.14 
 
 
26.7 (12.0-59.7) 
68.4 (35.0-134.0) 
 
 
0.07 
 
 
2.1 (1.5-2.9) 
2.6 (1.9-3.5) 
 
 
0.36 
 
 
15.2 (14.1-16.3) 
15.6 (14.7-16.6) 
 
 
0.56 
 
 
57.0 (45.1-71.9) 
60.6 (48.5-75.6) 
 
 
0.70 
Table 7.5 Geometric mean concentrations of inflammatory and haemostatic markers stratified by recent ARI, ILI and influenza IgA antibodies. P values shown from t 
test for difference in mean log concentrations  
Result hsCRP (mg/L) 
 
SAA (mg/L) IL-6 (pg/ml)* TNF-a* (pg/ml) P-selectin* (ng/ml) 
Range             
(min-max) 
0.3-293 2.6-1260 0.6-20.7 10.2-22.6 13.6-204.2 
Geometric 
mean (95% CI) 
15.6 (10.6 -23.0) 45.3 (27.8-73.9) 2.3 (1.9-2.8) 15.3 (14.6-16.0) 58.5 (50.4-68.0) 
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7.8.4 Associations between outcomes and potential confounders 
 
Table 7.6 shows p values for the strength of association between logs of 
inflammatory or haemostatic marker concentrations (outcomes) and potential 
confounding factors.  Age group was associated with all five outcome variables.  
Gender and diabetes were associated with three, month of admission, smoking 
status and peak troponin were associated with two, while personal history of 
myocardial infarction, family history of stroke and influenza vaccination status 
were associated with one each.  Although personal history of stroke appeared to 
be associated with four outcome variables, this was based on very small numbers. 
 
Potential confounder Inflammatory or haemostatic marker outcome variable 
hsCRP 
 
SAA IL-6 TNF-α P-selectin 
Agegroup 
 
0.14 0.11 0.05 0.03 0.16 
Gender 
 
0.004 0.03 0.03 0.73 0.69 
Month of admission 
 
0.88 0.74 0.78 0.03 0.12 
Ethnicity 
 
0.98 0.83 0.48 0.55 0.72 
Smoker (questionnaire) 
 
0.06 0.03 0.22 0.88 0.41 
Smoker (medical records) 
 
0.24 0.10 0.76 0.75 0.46 
Diabetes 
 
0.16 0.08 0.33 0.008 0.65 
Hypertension 
 
0.97 1.00 0.38 0.34 0.78 
Hypercholesterolaemia 
 
0.32 0.40 0.26 0.91 0.67 
Personal history of AMI 
 
0.19 0.32 0.30 0.37 0.87 
Personal history of stroke 
 
0.19 0.15 0.05 0.02 0.28 
Family history of AMI 
 
0.27 0.16 0.42 0.88 0.50 
Family history of stroke 
 
0.74 0.97 0.65 0.59 0.09 
BMI category 
 
0.77 0.32 0.99 0.52 0.23 
Influenza vaccination 
status 
 
Peak troponin 
 
Type of AMI 
 
0.60 
 
 
0.13 
 
0.96 
0.41 
 
 
0.06 
 
0.84 
0.97 
 
 
0.67 
 
0.59 
0.69 
 
 
0.98 
 
0.23 
0.017 
 
 
0.47 
 
0.91 
Table 7.6 p values for associations between inflammatory or haemostatic marker outcomes and 
potential confounders.   
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Factors with a p value <0.2 are shown in bold and were considered for inclusion in multivariable 
models.   
 
7.8.5 Associations between influenza exposures and potential confounders 
 
Table 7.7 (below) shows p values for the strength of associations between four 
influenza exposures and potential confounding factors.  Age group, smoking 
status, influenza vaccination status and peak troponin were associated with two 
influenza exposures each while gender, month of admission, personal history of 
AMI, personal history of stroke, family history of AMI and body mass index were 
each associated with one influenza exposure. 
 
Potential confounder Influenza exposure 
Respiratory 
illness 
Influenza-like 
illness 
Presence of 
antibodies 
Antibody 
concentration 
Agegroup 
 
0.09 0.12 0.81 0.50 
Gender 
 
0.31 0.74 0.46 0.16 
Month of admission 
 
0.24 0.37 0.80 0.13 
Ethnicity 
 
0.57 0.91 0.30 0.36 
Smoker (questionnaire) 
 
0.97 0.19 0.27 0.06 
Smoker (medical records) 
 
0.73 0.41 0.13 0.07 
Diabetes 
 
0.68 0.59 0.72 0.88 
Hypertension 
 
0.53 0.47 0.85 0.57 
Hypercholesterolaemia 
 
0.89 0.62 0.79 0.73 
Personal history of AMI 
 
0.68 0.59 0.06 0.44 
Personal history of stroke 
 
- - - 0.005* 
Family history of AMI 
 
0.10 - 0.21 0.70 
Family history of stroke 
 
0.83 0.43 - 0.28 
BMI category 
 
0.82 0.53 0.13 0.92 
Influenza vaccination status 
 
Peak troponin 
 
Type of AMI 
 
0.69 
 
0.04 
 
0.72 
0.91 
 
0.15 
 
0.77 
0.009 
 
0.30 
 
0.77 
0.018 
 
0.90 
 
0.20 
Table 7.7 p values for associations between influenza exposures and potential confounders   
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Factors with a p value <0.2 are shown in bold and were considered for inclusion in multivariable 
models. 
 
7.8.6 Regression models 
 
7.8.6.i CRP 
Linear regression models exploring the association between log hs-CRP 
concentration and four influenza exposures are shown in table 7.8.  In univariable 
analysis there was no association between recent respiratory illness, recent ILI or 
concentration of influenza IgA antibodies and log hsCRP concentration, and only a 
trend towards a negative association between influenza IgA seropositivity and log 
hs-CRP concentration (p=0.14).  In multivariable models, there was a significant 
negative association between influenza IgA seropositivity and log hs-CRP 
concentration after adjusting for age group, gender and smoking status (p=0.012). 
 
7.8.6.ii SAA 
Similar models exploring the association between log SAA concentration and four 
influenza exposures are shown in table 7.9.  As before, in univariable analysis 
there was no association between recent respiratory illness, recent ILI or 
concentration of influenza IgA antibodies and log SAA concentration, and only a 
trend towards a negative association between influenza IgA seropositivity and log 
SAA concentration (p=0.07).  In multivariable models, however, there was a 
significant negative association between influenza IgA seropositivity and log SAA 
concentration after adjusting for age group, gender and smoking status (p=0.004). 
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Table 7.8 Uni- and multivariable models for the association between log hs-CRP concentration and influenza exposures.  Multivariable models adjusted for gender (a), 
gender and smoking status (b & d) and age group, gender and smoking status (c).  
 
 
 
 
 
 
 
 
 
 
 
Table 7.9 Uni- and multivariable models for the association between log SAA concentration and influenza exposures.  Multivariable models adjusted for age group, 
gender and smoking status (b & c) and gender and smoking status (d).  
 
 
 
Influenza exposure Coefficient (95% CIs) 
from univariable 
analysis  
P 
value 
Coefficient (95% CIs) 
from multivariable 
analysis 
P 
value 
a) Respiratory illness 
 
-0.08 (-1.04-0.89) 0.87 -0.27 (-1.18-0.64) 0.56 
b) Influenza-like illness 
 
-0.04 (-1.24-1.15) 0.94 -0.09 (-1.17-0.99) 0.87 
c) Influenza A IgA seropositivity 
 
-0.61 (-1.42-0.21) 0.14 -0.90 (-1.59—0.21) 0.012 
d) Influenza antibody concentration 
 
0.01 (-0.02-0.03) 0.45 0.00 (-0.03-0.02) 0.71 
Influenza exposure Coefficient (95% CIs) 
from univariable 
analysis  
P 
value 
Coefficient (95% CIs) 
from multivariable 
analysis 
P 
value 
a) Respiratory illness 
 
-0.09 (-1.31-1.13) 0.88 As before  
b) Influenza-like illness 
 
-0.33 (-1.84-1.19) 0.67 -0.20 (-1.58-1.17) 0.77 
c) Influenza A IgA seropositivity 
 
-0.94 (-1.96-0.07) 0.07 -1.31 (-2.18—0.45) 0.004 
d) Influenza antibody concentration 
 
0.01 (-0.03-0.04) 0.67 -0.01 (-0.04-0.02) 0.48 
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7.8.6.iii IL-6 
Table 7.10 shows uni- and multivariable linear regression models of the 
association between the log of IL-6 concentration and four influenza exposures.  
There were no significant associations. 
 
7.8.6.iv TNF-α 
Similar uni- and multivariable models are shown in table 7.11 for the outcome log 
TNF-α concentration and the same influenza exposures.  Significantly increased 
TNF-α concentrations were seen for participants with evidence of recent 
respiratory illness (p=0.04 after adjusting for age group and month) and for those 
with recent ILI (p=0.04 after adjusting for age group and month).  There was no 
association between influenza IgA antibodies (either seropositivity or 
concentration) and log TNF-α concentration. 
 
7.8.6.v P-selectin 
Univariable linear regression models for associations between the final outcome, 
log P-selectin concentration, and influenza exposures are shown in table 7.12.  
There were no significant associations in univariable analysis and no potential 
confounders were significantly associated with both outcome and exposure so 
multivariable models were not constructed. 
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Table 7.10 Uni- and multivariable models for the association between log IL-6 concentration and influenza exposures.  Multivariable models adjusted for age group and 
gender (a, b & c), and gender (d).  
 
 
 
 
 
 
 
 
 
 
 
 
Table 7.11 Uni- and multivariable models for the association between log TNF-a concentration and influenza exposures.  Multivariable models adjusted for age group 
and month (a, b & c) and age group, month and stroke history (d).  
 
 
 
 
Influenza exposure Coefficient (95% CIs) 
from univariable 
analysis  
P 
value 
Coefficient (95% CIs) 
from multivariable 
analysis 
P 
value 
a) Respiratory illness 
 
-0.08 (-0.61-0.45) 0.76 -0.10 (-0.61-0.41) 0.70 
b) Influenza-like illness 
 
-0.27 (-0.93-0.38) 0.41 -0.23 (-0.86-0.39) 0.46 
c) Influenza A IgA seropositivity 
 
-0.21 (-0.67-0.25) 0.36 -0.22 (-0.65-0.21) 0.31 
d) Influenza antibody concentration 
 
0.01 (0.00-0.02) 0.18 0.01 (-0.01-0.02) 0.33 
Influenza exposure Coefficient (95% CIs) 
from univariable 
analysis  
P 
value 
Coefficient (95% CIs) 
from multivariable 
analysis 
P 
value 
a) Respiratory illness 
 
0.11 (0.01-0.22) 0.035 0.11 (0.01-0.21) 0.04 
b) Influenza-like illness 
 
0.12 (-0.01-0.25) 0.08 0.12 (0.01-0.25) 0.04 
c) Influenza A IgA seropositivity 
 
-0.03 (-0.12-0.07) 0.56 -0.01 (-0.09-0.08) 0.91 
d) Influenza antibody concentration 
 
0.001 (-0.002-0.003) 0.71 0.000 (-0.003-0.002) 0.97 
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Influenza exposure Coefficient (95% CIs) 
from univariable 
analysis  
P 
value 
Coefficient (95% CIs) 
from multivariable 
analysis 
P 
value 
a) Respiratory illness 
 
0.17 (-0.20-0.54) 0.36 As before  
b) Influenza-like illness 
 
0.22 (-0.24-0.68) 0.34 As before  
c) Influenza A IgA seropositivity 
 
-0.06 (-0.38-0.25) 0.70 As before  
d) Influenza antibody concentration 
 
-0.01 (-0.01-0.00) 0.26 As before  
 
Table 7.12 Uni- and multivariable models for the association between log P-selectin concentration and influenza exposures.  No multivariable models were generated. 
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7.9 Discussion 
 
7.9.1 Summary of main findings 
 
This exploratory study of the effect of recent influenza on concentrations of 
various prominent inflammatory and haemostatic markers in AMI patients 
showed several interesting results: first, participants with recent respiratory 
illness or ILI had higher levels of TNF-α than those without influenza; second, 
there was a negative association between seropositivity for influenza A IgA and 
hs-CRP levels; third, there was a similar negative association between influenza A 
IgA seropositivity and SAA levels, all after adjustment for relevant confounders.  
Nevertheless findings should be interpreted with caution given the small study 
size. 
 
7.9.2 Study strengths 
 
Laboratory outcome measures were robust: freshly frozen samples were 
prepared in an ideal way; assays generated plausible results within specified 
reference ranges and all samples yielded a result.  The commercial immunoassays 
for IL-6, TNF-α and P-selectin are well-validated and have been used extensively 
in previous studies268–270.  Measuring recent influenza was done (as in chapter 6) 
using both clinical and laboratory definitions to maximise available data.  The 
feasibility of this approach to collecting and testing blood samples for 
inflammatory and haemostatic markers has been demonstrated. 
 
7.9.3. Study weaknesses – roles of chance, bias and confounding  
 
This was an exploratory study nested within the case control study described in 
chapter 6, so the outcomes used here – levels of inflammatory and haemostatic 
markers – were not primary outcomes.  Therefore the study was underpowered 
to detect differences in these secondary outcomes between those with and 
without evidence of recent influenza.  Although use of several measures of 
influenza exposure was potentially a strength, each measure had potentially for 
inaccuracy – eg there was a potential risk of recall bias for recent respiratory 
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illness (though it seems unlikely that this would differ by inflammatory or 
haemostatic marker status) and there was uncertainty as to whether presence of 
influenza A IgA antibodies represented recent infection or recent vaccination.  
While data were collected on a range of potential confounders, the presence of 
chronic conditions was not fully explored in questionnaires.  For example, chronic 
conditions tend to be associated with more severe cases and complications of 
influenza and chronic inflammatory conditions or their treatments could 
plausibly affect levels of inflammatory and haemostatic markers. 
 
7.9.4 Interpretation of results 
 
Assuming that significant results were not due to factors described above then 
they represent something of a paradox.  On one hand, the raised levels of TNF-α 
seen in those with recent respiratory or influenza-like illness are to be expected, 
given the direct triggering effect of respiratory illnesses on acute inflammatory 
pathways that stimulate production of cytokines such as TNF-α.  On the other, it is 
surprising that this association is not reflected in other inflammatory and 
haemostatic markers (although given that most reported respiratory symptoms 
occurred 8-14 days previously and that some inflammatory markers such as IL-6 
have a very short half-life in vivo, this may not be so surprising).  In fact there is 
an inverse association between presence of influenza A IgA antibodies and levels 
of two inflammatory markers hs-CRP and SAA.  This is also counter-intuitive as it 
would be expected that recent influenza would produce higher levels of 
inflammation.  Even influenza vaccine acts as a small inflammatory stimulus so 
antibody production as the result of vaccination does not explain this result.  
 
Few previous studies have examined inflammatory and haemostatic markers in 
AMI patients in the context of influenza infection.  One case control study of AMI 
patients and outpatient controls in a Chinese population demonstrated higher 
levels of a panel of pro-inflammatory cytokines in AMI patients compared to 
control subjects249.  AMI patients were also more likely to have serum IgG 
antibodies to influenza A and B than controls.  No direct investigation was done 
between influenza and cytokine levels in AMI patients, however, and as both 
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influenza and AMI are independently associated with inflammation it is difficult 
to draw valid conclusions from these findings. 
 
7.9.5 Future directions 
 
Further basic science studies are needed to establish molecular mechanisms 
between influenza and AMI.  In practice this type of study has been limited by the 
lack of suitable animal models: ApoE and LDL receptor deficient mice are useful 
models of chronic atherosclerosis but plaque rupture rarely occurs209.  While 
clinical mechanistic studies might be technically more feasible, interpretation of 
results remains a challenge.  To aid understanding, it would be helpful to compare 
with results of serial measurements of inflammatory and haemostatic markers in 
patients infected with confirmed influenza.  This type of study may be difficult: 
biased results would be obtained from patients hospitalised with severe 
influenza; identifying patients with influenza in the community is difficult and 
time-consuming.  Volunteer challenge studies, in which patients are deliberately 
infected with viruses such as influenza under controlled conditions, are carried 
out regularly in the UK and might assist in elucidating mechanisms.  Randomised 
controlled trials of the effect of anti-inflammatory and antiviral medications in 
patients with influenza on AMI would provide further indirect evidence for some 
of the mechanistic pathways described above. 
 
  SUMMARY 
 Influenza could theoretically trigger AMI either through direct infection 
or inflammation on coronary vessels or by acting through indirect 
systemic inflammatory, haemostatic or haemodynamic mechanisms 
 An exploratory study was carried out to measure CRP, SAA, TNF-α, IL-6, 
P-selectin and Von Willebrand factor collagen binding activity  in serum 
and plasma samples provided by 58 AMI patients from the case control 
study described in the previous chapter 
 Though AMI patients with recent respiratory or influenza-like illness 
had higher levels of TNF-α than those without recent ARI, results should 
be interpreted with caution given the study size. 
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8. Discussion, conclusions, recommendations 
 
8.1 Description of chapter contents 
 
In this chapter I summarise the background to the hypothesis that influenza and 
acute respiratory infections can trigger acute cardiovascular events and review 
the rationale for work in this thesis.  I draw together findings from this body of 
research and previous studies, consider key methodological strengths and 
limitations and assess the level of evidence generated.  I explore implications for 
clinical and public health policy and practice and highlight future research needs. 
 
8.2 Summary of research undertaken 
 
8.2.1 Background and rationale 
 
AMI is a leading cause of death worldwide.  Management of AMI remains a key 
challenge, especially as AMI risk is incompletely explained by traditional vascular 
risk factors4.  There is now widespread recognition of the role of inflammation in 
the pathogenesis of atherosclerosis and AMI7.  The contribution of inflammatory 
triggers such as acute respiratory infections, however, remains poorly 
understood.  Influenza may lead to cardiovascular complications, either through 
direct infection or inflammation of myocardial tissues or through indirect 
systemic inflammatory and haemodynamic effects109.  Some cardiac 
complications of influenza such as myocarditis are well-recognised, but the 
relationship with AMI is less clear.  Improved understanding of this relationship 
will help to inform seasonal and pandemic influenza planning as well as strategies 
for AMI prevention.   
 
My work in this thesis aimed to investigate the relationship between acute 
respiratory infections – particularly influenza – and AMI, building on previous 
studies to address some earlier methodological limitations such as inadequate 
control for environmental confounders in population level studies and lack of 
specificity for influenza in individual-level studies.  
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8.2.2 Summary of methods and results 
 
Findings from a systematic literature review (chapter 2) tended to support the 
hypothesis that acute respiratory infections – and influenza in particular – could 
trigger AMI, with more limited evidence for an association with cardiovascular 
death.  An ecological time series study (chapter 3) showed associations between 
seasonal influenza circulation and AMI after adjusting for temporal and 
environmental confounders in England & Wales and Hong Kong.  Self-controlled 
case series studies using electronic health records from the GPRD (chapter 4) and 
linked records in GPRD, MINAP and HES (chapter 5) found a substantially 
increased AMI risk after consultation for acute respiratory infection.   
In the linked database study AMI risk was greatest for infections judged most 
likely to be due to influenza.  An association between recent ILI and AMI was seen 
in a hospital-based case control study (chapter 6) conducted during the 2009 
influenza A H1N1 pandemic.  Potential biological mechanisms were investigated 
through an exploratory study of cytokines and inflammatory markers in AMI 
patients with and without recent acute respiratory infection (chapter 7).   
 
As supported by publications listed on p5, this work has contributed substantially 
to the evidence that acute respiratory infections and influenza in particular are 
important contributors to AMI.  Key findings are highlighted below, placed in the 
context of previous literature and major strengths and limitations of approaches 
used are discussed.  
 
8.3 Key findings  
 
 
 
8.3.1i Supporting evidence 
i. In the present self-controlled case series study in GPRD there was a 3.65- 
fold increased risk of AMI in the first three days after GP consultation for 
1. Acute respiratory infections trigger AMI 
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acute respiratory infection.  This tapered over time suggesting that the 
increased AMI risk was transient. 
ii. Repeating the study using linked MINAP data to classify and time cardiac 
events more accurately revealed a more pronounced risk with a 4.19-fold 
increase in AMI risk immediately following consultation for acute 
respiratory infection. 
iii. Five of seven previous observational studies (six case control studies78–83 
and one self-controlled case series study84) reported statistically significant 
associations between occurrence of recent respiratory symptoms and AMI, 
with effect sizes ranging from a 2-fold to nearly 5-fold increase in risk.  The 
two remaining studies did not demonstrate an effect, although one noted an 
association of fever with AMI82 and the other suggested that several GP 
visits for ARI (but not one visit) were associated with AMI risk79. 
iv. Overall these studies provide good evidence to support the hypothesis that 
acute respiratory infections can act as triggers of AMI. 
 
8.3.1ii Strengths and limitations  
v. Some previous studies were limited by lack of power, risks of recall bias 
(when recent respiratory symptoms were self-reported) and selection bias 
when using control groups selected for convenience such as people 
attending or admitted to hospital for conditions other than AMI.   
vi. Using the GPRD conferred some major strengths to my work: it is the largest 
computerised database of longitudinal primary care records worldwide so 
analyses were well powered; records are from an unselected sample of 8% 
of the UK population so results should be generalisable to UK residents; data 
are high quality and diagnoses well-validated which reduced the risk of 
misclassification error; in particular, respiratory symptoms are recorded by 
the GP at consultation, rendering recall by participants unnecessary. 
vii. A further strength was the addition of linked MINAP and HES data allowing 
information on accuracy, specificity and timing of an AMI diagnosis to be 
improved.  MINAP provides near complete coverage of hospitalised AMI 
cases in England & Wales and detailed information is available on timing of 
symptom onset, investigations and diagnoses.  Having accurate data on 
timing was particularly important for self-controlled case series analysis 
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using short risk periods in which delayed recording of AMI would bias 
results towards the null.  
viii. Use of the self-controlled case series method (compared to the case control 
design selected for many earlier studies) had the advantages of eliminating 
fixed between-person confounding as well as reducing the risk of residual 
biases due to lack of suitable control subjects.  These are both important 
considerations when using primary care data originally collected for clinical 
rather than research purposes. 
ix. Despite the many advantages to using a large primary care dataset such 
work is limited to acute respiratory infections for which medical attention is 
sought.  These cases form only the ‘tip of the iceberg’ of the community 
burden of disease, and my results may not therefore be generalisable to all 
respiratory infections.  In studies using other observational designs, under-
ascertainment of ARI would tend to bias results towards the null through 
non-differential misclassification of exposure.  This is less of an issue though 
for self-controlled case series in which every patient is required to have 
both an exposure and outcome event.  
 
 
 
8.3.2i Supporting evidence 
i. In weekly time series analysis, there were strong associations between 
influenza circulation and AMI hospitalisations and deaths in a subtropical 
(Hong Kong) and temperate climate (England & Wales) after controlling for 
temporal and environmental factors 
ii. At least 20 previous ecological studies dating from 1932 until 2012 have 
noted an association between circulating influenza and the broader 
outcome cardiovascular death (which includes AMI) – see chapter 2 –
although effect sizes were not easily compared across studies due to 
widely varying time periods (and therefore different influenza strains), 
populations, case definitions and statistical methods used. 
iii. At individual level one previous case control study found a significant 
association between the presence of IgG antibodies to influenza in an 
unvaccinated population and AMI91, which would tend to support our 
2. Seasonal influenza triggers AMI 
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finding of a particular effect of influenza.  Three other small early case 
control studies using antibody tests for influenza in paired sera, however, 
found no association with AMI87–89. 
iv. Four small case control studies compared the odds of recent ILI in AMI 
patients with controls86–89.  Results were somewhat mixed with two 
studies reporting significant effects and two reporting slight positive but 
not significant associations. 
v. Overall there is consistent ecological evidence for an association between 
influenza circulation, ILI and cardiovascular mortality but at individual 
level the evidence for a specific effect of influenza is less clear. 
 
8.3.2ii Strengths and limitations 
vi. Few previous ecological studies adjusted appropriately (or at all) for 
potential environmental confounders.  The risk of ecological bias, where 
findings at population level fail to reflect individual level associations, was 
inherent to these studies.  Individual level studies were generally small and 
those using an ILI definition alone lacked specificity for influenza. 
vii. The England & Wales/ Hong Kong study extends previous work by taking a 
more robust approach to controlling for environmental variables, in 
particular adjusting for weekly mean temperature using flexible natural 
cubic spline functions, rather than either omitting temperature control or 
comparing effects in cold versus warm periods, as was done in some 
earlier studies.   
viii. In addition, using data from two geographically distinct settings 
characterised by differing populations, climates and patterns of influenza 
circulation reduced the risk that associations may be attributed to residual 
confounding from environmental factors. 
ix. Although the risk of ecological bias could not be overcome in this time 
series study, triangulation with individual-level results presented in the 
rest of the thesis helped to ensure that results were robust. 
x. Laboratory PCR data on influenza were used in this study (as primary 
exposure in Hong Kong and in sensitivity analysis in England & Wales – 
data not shown) to enhance specificity compared to some previous work 
based on either antibody detection or clinical definitions alone. 
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xi. One puzzling aspect to this time series analysis was the inconsistent lag 
times seen between influenza and AMI outcomes in the different settings.  
It is unclear whether these reflect differences in speed of health-seeking 
behaviour or reporting delays in surveillance data, and further studies 
would be needed to disentangle the effect. 
 
 
 
8.3.3i Supporting evidence 
i. In my self-controlled case series study using linked databases, infections 
occurring when influenza was circulating and those coded as ILI were 
associated with consistently higher incidence ratios for AMI, suggesting 
that a triggering effect might be stronger for influenza than other infections 
ii. As described in key findings 1 and 2, there is clear evidence for a triggering 
effect of general acute respiratory infections on AMI and some evidence for 
a particular effect of influenza.  Nonetheless, no previous study has directly 
compared the magnitude and strength of the effect of influenza with that of 
other acute respiratory infections. 
iii. Overall further evidence is needed to confirm whether there is a stronger 
effect of influenza compared to other respiratory infections, ideally using 
laboratory confirmation of diagnosis. 
 
8.3.3ii Strengths and limitations 
iv. Strengths of my analysis included using three complementary methods 
(levels of circulating influenza, medical codes used to classify infections 
and influenza vaccination status) to judge which infections were most 
likely to be due to influenza.  The most powerful method – harnessing the 
high positive predictive value of acute respiratory infections, in particular 
ILI, for influenza during peak times of influenza circulation – demonstrated 
the most convincing differential effect.  
v. A limitation to using GPRD data to identify acute respiratory infections was 
that I relied upon GPs’ diagnoses based on clinical symptoms and did not 
have microbiological confirmation of influenza.  Although inferences could 
3. A triggering effect on AMI may be greater for influenza 
than for other respiratory infections 
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be made about which infections were more or less likely to be due to 
influenza, some misclassification would be inevitable.  This is likely to have 
been non-differential, reducing the size of the apparent effect of influenza 
on AMI compared to other respiratory infections.  
 
 
 
 
8.3.4i Supporting evidence  
i. In both of the present self-controlled case series a gradient of AMI risk was 
evident after ARI.  Risks were highest in the first three days and tapered 
over time to reach baseline by 28 days. 
ii. One previous self-controlled case series study in GPRD found a similar 
gradation of AMI risk after consultation for systemic acute respiratory 
infection84.  In this study there was a 5-fold increase in risk at days 1-3, 
with some increase above baseline persisting for up to 28 days.   
iii. Two other large primary care database studies using case control designs 
support the finding of a graded risk of acute respiratory infection on AMI, 
strongest immediately after GP consultation, with the highest risk seen for 
days 1-5 in one study80 and days 1-7 in the other83. 
iv. A case crossover study of AMI patients with recent ILI showed that the 
relative probability of an AMI happening on the first rather than the 
seventh day after infection onset was around 2.585. 
v. Literature on biological mechanisms suggests that a triggering effect is 
likely to be transient, given that acute respiratory infections result in a 
variety of short-lived local and systemic inflammatory and haemodynamic 
responses that may contribute to atherosclerotic plaque destabilisation209. 
vi. Although the duration of effects varied, the general finding that increased 
risks are transient is likely to be robust as it is both biologically plausible 
and consistent across all studies that used graded risk periods. 
 
8.3.4ii Strengths and limitations 
vii. Previous studies have used different designs and risk periods after ARI so 
effect sizes and durations are not directly comparable between studies.   
4. AMI risk is highest in the first three days after acute respiratory 
infection and persists for around a month 
225 
 
viii. A strength of my study was the use of self-controlled case series analysis 
with the same graded risk periods after acute infection as a previous 
similarly designed study, to allow direct comparisons to be made.  Self-
controlled case series also allowed easy manipulation of time periods: I 
was also able to exclude the period from ARI consultation up to 14 days 
before from baseline time, as an AMI occurring in that time window may 
affect subsequent likelihood of attending the GP (and thereby artificially 
inflate AMI incidence in baseline periods). 
ix. One potential limitation is that I did not have the onset date of ARI but 
instead used the date of GP consultation.  As this is likely to be some time 
after the onset of respiratory symptoms the true effect on AMI risk may be 
even greater than that observed, and may last for longer (although this 
needs further investigation). 
 
  
 
8.3.5i Supporting evidence 
i. In my case control study, patients hospitalised with AMI during the second 
wave of the 2009 influenza A H1N1 pandemic were more likely than acute 
surgical controls to have experienced recent ILI and other key respiratory 
illness symptoms, although differences were not statistically significant. 
ii. There have been no similar analytical studies conducted in the pandemic.  
Descriptive studies including individual case reports and case series have 
reported cardiac complications of H1N1pdm09 such as myocarditis and 
AMI178,179.  One modelling study estimated that globally there were 83,300 
deaths from cardiovascular causes attributed to influenza during the first 
12 months of the 2009 influenza pandemic121.   
iii. It is therefore likely that, as with other influenza strains, H1N1pdm09 may 
be able to trigger AMI, but further adequately powered evidence from 
studies conducted in a range of populations is needed. 
 
 
 
5. A triggering effect on AMI is also seen for pandemic H1N1 influenza  
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8.3.5ii Strengths and limitations 
iv. Previous descriptive studies have not compared with control groups and 
case reports/ case series tend to be subject to publication bias, so it is 
difficult to draw conclusions based on these findings. 
v. My study was underpowered to detect an effect, as there was a mismatch 
between age groups typically affected by AMI and those infected with 
H1N1pdm09.  This would not have been the case for seasonal influenza 
strains which were circulating when this study was designed. 
vi. Although I collected laboratory data, which was potentially a strength, 
serology results in this study were difficult to interpret, partly due to 
difficulty distinguishing rises in antibody titres caused by infection from 
those caused by vaccination as well as lack of validation of the IgA assay 
used against the pandemic influenza strain.  The ideal would have been 
acute and convalescent sera for IgG but this was not practical within 
resource constrains.   
 
 
 
 
 
8.3.6i Supporting evidence 
i. In my time series study the proportion of AMI-associated deaths attributed 
to influenza ranged from 3.9-5.6% in Hong Kong and 3.1-3.4% in England 
& Wales depending on the model of seasonality used.  Figures for AMI 
hospitalisations were lower in both settings.  During the most active 
periods of influenza virus circulation, up to 13% of AMI deaths and 8% of 
AMI hospitalisations were attributable to influenza. 
ii. One ecological study from Colombia estimated that rates of cardiovascular 
mortality were 8% higher in times of peak influenza circulation than in 
other periods119, which accords with these findings. 
iii. Other previous ecological studies have tended to estimate the proportion 
of excess influenza mortality attributed to cardiovascular disease rather 
than looking specifically at the proportion of AMI deaths associated with 
influenza so it is not possible to compare figures. 
6. The proportion of AMI deaths due to seasonal influenza ranges 
from 3-5%, rising to 13% in periods of highest influenza circulation 
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iv. Overall our estimated proportions were similar across sensitivity analyses 
using different methods to model seasonality and suggest that a small but 
significant proportion of AMI burden may be attributed to influenza.  
Nonetheless further work is needed in different settings to establish a 
likely normal range for this proportion. 
 
8.3.6ii Strengths and limitations 
v. A strength of this estimate was that it provided a more meaningful and 
specific measure of population impact of influenza on AMI than previous 
estimates based on proportions of influenza excess mortality due to 
cardiovascular diseases 
vi. Nevertheless only two settings and one 10-year time period were 
investigated and it is recognised that figures are likely to vary depending 
on setting, time period and circulating influenza strains.  
vii. It was also not possible to determine population attributable risk in my 
individual-level studies due to under-ascertainment of ARI in primary care 
data. 
 
 
 
 
8.3.7i Supporting evidence 
i. In both self-controlled case series analyses AMI risks increased with age 
and were greatest in people aged ≥80 years. 
ii. In my time series analysis, incidence rate ratios for AMI were highest in 
those aged ≥80 years in England & Wales and in Hong Kong. 
iii. While a lower age limit of eg 40 years has been imposed in several 
previous individual-level studies, none has stratified the effect of acute 
respiratory infection on AMI by age.  In five earlier ecological studies using 
age-specific data30,65,71,73,77, the strongest associations between AMI and 
CVD death were noted in the oldest age-groups. 
iv. From studies of biological mechanisms, low-grade inflammation is a 
hallmark of the ageing process271.  Therefore if influenza acts through 
inflammatory mechanisms to trigger AMI it is plausible that effects might 
7. The relative risk of AMI after acute respiratory infection is 
highest in the elderly 
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be greater in elderly populations where pro-inflammatory phenotypes are 
already apparent. 
v. Overall a consistent age gradient in the effect of acute respiratory 
infections and influenza on AMI has been demonstrated across many 
population-level and two individual-level studies, suggesting that risks are 
highest in the elderly. 
 
8.3.7ii Strengths and limitations 
vi. There is a lack of age-specific data from previous individual-level studies. 
vii. A strength of my GPRD-based studies was the use of robust measures of 
age: age checks were conducted as part of a suite of quality control 
measures before patient records were deemed acceptable for use in 
research. 
viii. A limitation of my time series study was that I did not have access to age-
specific data on influenza or ILI so based stratifications on age at AMI.  
Although this might have enhanced the risk of ecological bias (if much 
circulating influenza was present in younger age groups), the consistency 
in findings between this and other studies reduces the risk that the effect 
was due to bias. 
 
 
 
 
 
8.3.8i Supporting evidence 
i. There was a trend towards a protective effect of influenza vaccination 
against AMI in my pandemic case control study although this was not 
statistically significant.  
ii. In the updated meta-analysis of three previous small RCTs of influenza 
vaccination in patients with existing vascular disease102,105,126 there was a 
33% reduction in AMI and a 54% reduction in cardiovascular death in 
vaccinated subjects, with effects just failing to reach statistical significance.  
If this level of effect were true, it would signify both that influenza 
vaccination as secondary prevention compared highly favourably with 
8. Influenza vaccine protects against AMI 
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other risk reduction strategies and that in people with prior cardiovascular 
disease influenza was responsible for a high proportion of AMI.  
iii. Previous observational vaccine studies have shown mixed results.  Of 12 
studies using cohort, case control or self-controlled case series designs, six 
demonstrated a protective effect92,93,97,122,124,125, one showed a protective 
effect that just failed to reach significance96 and five found no effect of 
influenza vaccination81,84,94,95,123 against a range of cardiac outcomes. 
iv. Overall, based mainly on findings from the meta-analysis of RCT data, it is 
likely that influenza vaccination is effective as secondary prevention 
against cardiovascular death and AMI.  Further evidence is needed on the 
cardioprotective effects of influenza vaccination in populations without 
evidence of existing cardiovascular disease. 
 
8.3.8ii Strengths and limitations 
v. Previous randomised controlled trials have been small and conducted only 
in populations with existing cardiovascular disease.  Previous 
observational studies have been limited by the risk of ‘healthy user’ bias.   
vi. None of my studies aimed to elucidate the protective effect of influenza 
vaccination against AMI as a primary aim.  Although I examined this 
question in my pandemic case control study, influenza vaccination was a 
secondary exposure and the study was therefore not powered to detect an 
effect.  In this study there was also a risk of misclassification of exposure as 
influenza vaccine status was determined by self-report. 
 
8.3.9 Summary of evidence generated 
 
Overall there was good evidence for a transient triggering effect of acute 
respiratory infections, including influenza, on AMI.  This was greatest in the first 
few days following ARI onset and highest in the elderly.  A small but important 
proportion of AMIs was due to influenza.  There was some evidence that influenza 
vaccination is effective at protecting against cardiovascular death and AMI in 
people with existing vascular disease.  The variety of research methods and 
influenza definitions used in this thesis allowed results to be triangulated across 
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different data sources, populations and influenza strains.  Results were broadly 
consistent across studies, enhancing their reliability.  
 
 
8.4 Implications for clinical and public health policy and practice 
 
8.4.1 General 
 
i. Interventions targeted either at preventing acute respiratory infections 
and influenza in established risk groups or at reducing cardiovascular 
complications associated with these infections would mitigate the acute 
triggering effect on AMI and cardiovascular deaths in vulnerable 
populations. 
ii. General non-pharmaceutical measures, such as practising good hand and 
respiratory hygiene and social distancing measures for people who are ill, 
may help to reduce the burden of acute respiratory infections in 
populations272.  Such non-specific and untargeted measures are, however, 
likely to have little impact on ARI-associated AMI. 
 
8.4.2 Influenza vaccination 
 
iii. Influenza vaccination offers more specific protection against AMI triggered 
by influenza rather than by general acute respiratory infections, although 
its effectiveness at preventing infections is limited to 60-80% in healthy 
adults39 and is lower in the elderly.  It may also reduce the incidence of 
severe complications in individuals who become infected with influenza40.   
iv. Two types of policy are relevant to use of influenza vaccine to prevent 
influenza-associated AMI.  First, seasonal and pandemic influenza plans, 
both at national and international levels recommend that high risk 
individuals including people aged over 65 as well as those with chronic 
cardiac conditions and diabetes receive annual influenza vaccination40,113.  
Second, some national policies relating to secondary prevention of AMI 
such as the American Heart Association/ American College of Cardiology 
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Foundation guideline recommend that all patients with cardiovascular 
disease should have an annual influenza vaccination114.   
v. In the UK, however, this recommendation is not included in National 
Institute for Health and Clinical Excellence (NICE) clinical guideline on 
secondary prevention of myocardial infarction273 (due to be updated in 
November 2013) nor the Scottish Intercollegiate Guidelines Network 
(SIGN) guidelines on management of acute coronary syndrome274 or risk 
estimation and prevention of cardiovascular disease275.  
vi. Evidence from this thesis suggests that this disparity should be addressed 
to improve patient management and streamline international standards.   
vii. My research findings also highlight the need to encourage influenza 
vaccination uptake in the elderly and those with existing cardiovascular 
disease: in England influenza vaccine uptake was 74.0% for people aged 
65 years and over in the 2011/12 winter season and only 51.6% in people 
aged 6 months to 65 years in high risk groups41.   
viii. It remains unclear whether influenza vaccination should be used as 
primary prevention from AMI in people who are at increased 
cardiovascular risk but fall outside current priority groups for vaccination.  
Further trials in ‘healthy’ populations are needed.  These could lead to 
adoption of a risk-based approach for influenza vaccination similar to that 
used for other preventive therapies for AMI, such as statins, where 
eligibility is determined by long-term cardiovascular event risk. 
 
8.4.3 Antiviral drugs 
 
ix. Antiviral drugs such as oseltamavir could in theory reduce the risk of 
influenza-associated AMI either by preventing influenza or by lessening its 
severity.  Antiviral drugs are not available for other common respiratory 
infections.   
x. Currently NICE and the Department of Health recommend that antiviral 
medications are available as treatment for patients at risk of complications 
who present within 48 hours of ILI onset115.  These include all those 
eligible to receive influenza vaccination as well as patients outside these 
groups deemed at high risk of complications40.  Seasonal influenza plans 
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do not include the use of antiviral medications as prevention but this may 
differ in the event of an influenza pandemic.   
xi. In England there is no standardised method to monitor antiviral uptake 
during ILI.  Research evidence suggests that community uptake of 
antivirals is extremely low even in times of heightened awareness and 
wider prescription such as the 2009 influenza pandemic276. 
xii. The effectiveness of antiviral drugs at reducing AMI and cardiovascular 
complications associated with influenza and other acute respiratory 
infections is also not known. 
xiii. Additional research is needed before the likely impact of antiviral drugs on 
influenza-associated AMI can be assessed.   
 
8.4.4 Anti-thrombotic treatments during acute respiratory infections 
 
xiv. Interventions to reduce AMI risk are typically prescribed according to 
estimates of long-term (eg 10-year) cardiovascular risk based on 
algorithms that incorporate traditional demographic, behavioural and 
biological risk factors48,49.  Pharmacological agents including aspirin, beta-
blockers, ACE inhibitors and statins have proven benefits in terms of 
cardiovascular risk reduction277 which are likely to apply equally to 
influenza-associated cardiovascular events.    
xv. This thesis provides evidence that short-term cardiovascular risk 
fluctuates in response to external stimuli such as influenza, with AMI risk 
greatest in the first 3 days after infection onset and increased risk 
persisting for around a month.   
xvi. There is currently no policy recommending short-term use of anti-
thrombotic agents such as aspirin or statins to reduce the occurrence of 
acute vascular events at such times of heightened risk278. 
xvii. Existing studies examining the effectiveness of prophylactic statin and 
beta-blocker therapy during the peri-operative period (a time of short-
term increased vascular risk) are inconclusive279,280. 
xviii. Further research is needed into effectiveness, cost effectiveness and safety 
before such an approach could be adopted.   
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8.4.5 Public and health professional awareness of symptoms 
 
xix. Effective management of AMI requires prompt recognition of cardinal 
symptoms and a rapid primary and secondary care response. 
xx. Studies in this thesis have highlighted particular risk periods for AMI such 
as during times of influenza circulation and following onset of acute 
respiratory symptoms.  Elderly people have also been identified as a high 
risk population for AMI associated with acute respiratory infection or 
influenza. 
xxi. This suggests that future public health campaigns aimed at increasing 
cardiac symptom recognition might be most effective when timed to 
coincide with periods of highest risk and targeted to populations at highest 
risk such as the elderly and their carers.  
 
8.5 Future research directions  
 
i. While studies in this thesis have identified the elderly as a risk group for 
AMI associated with acute respiratory infection and influenza, the 
magnitude of increased risk in other groups such as people with individual 
cardiovascular risk factors remains unclear.  Adequately powered 
stratified analyses using large datasets from different populations are 
needed to identify other high risk groups. 
ii. Linking laboratory data (eg from the HPA’s ‘Lab base’) on positive 
specimens to general practice datasets would allow the relative effects of 
influenza versus other respiratory infections to be better delineated. 
iii. Further vaccine trials are needed to assess the protective effect of 
influenza vaccination against AMI and cardiovascular death in people 
without existing cardiovascular disease but with vascular risk factors and 
in the general population. 
iv. Research is required into methods to increase influenza vaccine uptake in 
established risk groups, perhaps using findings from this thesis as part of 
an educational intervention.  
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v. More evidence is needed, ideally from RCTs, on the effectiveness, risks, 
benefits and safety of using antiviral drugs to reduce AMI and 
cardiovascular complications during acute respiratory viral infection 
vi. Information is also needed on the use of short-term antithrombotic 
therapies during infections to answer questions such as which patients 
would benefit and the optimal choice, dose and timing of therapy. 
vii. Further basic science studies would help to elucidate underlying biological 
mechanisms and aid identification of novel therapeutic targets.  Use of 
several experimental influenza strains including H1N1pdm09 would 
clarify whether triggering actions are similar across influenza strains. 
viii. Finally there is already a small body of literature suggesting that influenza 
and acute respiratory infection may trigger acute ischaemic stroke.  
Studies of whether this effect extends to other acute vascular events such 
as ruptured aortic aneurysm or acute limb ischaemia would help to guide 
prescription of prophylactic measures for high risk patients. 
 
8.6 Conclusions 
 
Work from this thesis has contributed substantially to understanding the 
relationship between influenza and AMI with important clinical and public health 
implications.  Overall, there was good evidence for a transient triggering effect of 
acute respiratory infections, including influenza, on AMI especially in elderly 
populations.  The effect may be stronger for influenza than for other respiratory 
infections although it is unclear whether this relates to specific biological 
mechanisms associated with influenza or is a more general effect of illness 
severity.  A protective effect of influenza vaccination against adverse cardiac 
outcomes has been demonstrated in randomised controlled trials.  This suggests 
that, regardless of underlying mechanism, efforts focussed on reducing the 
population burden of influenza and its complications would benefit 
cardiovascular health.  Questions remain about which populations would derive 
most benefit from this strategy as well as the optimal type and delivery of 
interventions.  
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10. Appendices 
 
10.1 Technical appendices 
 
10.1.1 Data extraction specification for GPRD patient records (chapter 4) 
 
Data-set specification - protocol no. 09_034 
 
Authors: R Williams, Dr. T Williams GPRD, MHRA, UK 
Distribution: Dr. C Warren-Gash, UCL Centre for Infectious Disease Epidemiology 
 
Description of cohort as defined in the protocol 
The baseline population will consist of all acceptable patients registered with 
GPRD practices.  
 
Patients will: 
a) be registered with a GPRD UTS practice during the study period 
(01/01/1999 to 31/12/2008) 
b) have a record of incident myocardial infarction (MI) that occurs both 
within their registration period and the study period 
c) have at least six months between their registration date and the date of 
the incident MI 
 
Incident MI will be defined by the list of the Read/OXMIS codes provided by the 
researcher and agreed with the GPRD research team (Annex I).  If more than 
100,000 patients are identified, a sample will be selected, restricted first to those 
patients registered at MINAP-linked practices and secondly in order of calendar 
year of MI (backwards sequentially). 
 
Gprd medcode Description 
203615 ECG: myocardial infarction 
207058 Acute transmural myocardial infarction of unspecified site 
207059 Other acute myocardial infarction 
207064 Atrial septal defect/current complication following acute myocardial infarct 
207065 Ventricular septal defect/current complication following acute myocardial infarction 
207066 Postoperative transmural myocardial infarction other sites 
211073 MYOCARDIAL INFARCT WITH HYPERTENSION 
211078 MYOCARDIAL THROMBOSIS 
211079 
212602 
SUBENDOCARDIAL INFARCTION 
ECG: posterior/inferior infarct 
216008 Cardiac rupture following myocardial infarction (MI) 
216009 Posterior myocardial infarction NOS 
216010 Inferior myocardial infarction NOS 
216011 Acute septal infarction 
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216012 Microinfarction of heart 
216018 THROMBOSIS ATRIUM,AURIC APPEND&VENT/CURR COMP FOLL ACUTE MI 
225084 Acute subendocardial infarction 
225085 Acute atrial infarction 
225097 Subsequent myocardial infarction 
225098 Haemopericardium/current complication following acute myocardial infarct 
234219 Lateral myocardial infarction NOS 
234226 Subsequent myocardial infarction of inferior wall 
234227 Certain current complication follow acute myocardial infarct 
234228 Rupture chordae tendinae/current complication following acute myocardial infarct 
234229 Rupture papillary muscle/current complication following acute myocardial infarct 
243246 Attack – heart 
243247 Coronary thrombosis 
243248 MI - acute myocardial infarction 
243249 Acute anterolateral infarction 
243255 Postoperative myocardial infarction 
252390 Acute infer-olateral infarction 
252391 Acute infero-posterior infarction 
252395 Subsequent myocardial infarction of unspecified site 
252468 [X]Subsequent myocardial infarction of unspecified site 
258148 ECG: subendocardial infarct 
259269 PERCUT TRANSLUMINAL CORONARY THROMBOLYSIS WITH STREPTOKINASE 
261622 Other specified anterior myocardial infarction 
261623 Acute antero-apical infarction 
261624 Other acute myocardial infarction NOS 
261696 [X]Subsequent myocardial infarction of other sites 
265787 THROMBOSIS CORONARY WITH HYPERTENSION 
270887 Silent myocardial infarction 
270888 Acute antero-septal infarction 
270889 Acute papillary muscle infarction 
270894 RUPTUR CARDIAC WALL W'OUT HAEMOPERICARD/CUR COMP FOL AC MI 
270896 Postoperative transmural myocardial infarction anterior wall 
270897 Postoperative subendocardial myocardial infarction 
270983 [X]Acute transmural myocardial infarction of unspecified site 
276474 ECG: antero-septal infarct. 
276475 ECG: lateral infarction 
279940 Thrombosis - coronary 
279944 Subsequent myocardial infarction of other sites 
279945 Postoperative transmural myocardial infarction inferior wall 
279946 Postoperative transmural myocardial infarction unspecified site 
286731 PERCUT TRANSLUM CORONARY THROMBOLYTIC THERAPY- STREPTOKINASE 
289040 Heart attack 
289041 True posterior myocardial infarction 
289148 [X]Other current complications following acute myocardial infarct 
294781 ECG: myocardial infarct NOS 
298318 Acute myocardial infarction 
298319 Anterior myocardial infarction NOS 
298320 Acute myocardial infarction NOS 
298329 Subsequent myocardial infarction of anterior wall 
298330 Postoperative myocardial infarction, unspecified 
303765 MYOCARDIAL INFARCT ACUTE WITH HYPERTENSION 
303768 MYOCARDIAL INFARCT 
303769 MYOCARDIAL INFARCT ACUTE 
303770 INFARCT HEART 
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303771 THROMBOSIS CORONARY 
306424 CORONARY INFARCTION 
306459 HEART ATTACK 
307878 Acute non-Q wave infarction 
308452 Diabetes mellitus insulin-glucose infusion acute myocardial infarct 
309266 Acute Q-wave infarct 
339896 Acute non-ST segment elevation myocardial infarction 
341510 Acute ST segment elevation myocardial infarction 
344390 Acute postero-lateral myocardial infarction 
Annex I: List of Read/OXMIS codes as evidence of incident MI 
 
10.1.2 AMI codes in MINAP (chapter 5) 
 
Code Label Definition 
1 Myocardial infarction 
(STEMI) 
There will normally be a history consistent with the diagnosis. 
The diagnosis requires the presence of cardiographic changes 
of ST elevation consistent with infarction of =>2mm in 
contiguous chest leads and/or ST elevation of =>1 mm ST 
elevation in 2 or more standard leads. (New LBBB is included; 
although ST elevation is usually apparent in the presence of 
LBBB). There must be enzyme or troponin elevation. Where 
CK is used the peak value should exceed twice the upper limit 
of the reference range. Where troponin assay is used the 
locally accepted cut off value should be used. (See Threatened 
MI) This group includes all patients with STEMI regardless of 
whether typical changes were evident on the admission ECG 
or developed subsequently. 
 
3 Threatened MI After early reperfusion treatment there may be rapid 
resolution of existing ST elevation associated with a CK rise 
less than twice the upper limit of normal or a small troponin 
release. If only troponin has been measured and is elevated; it 
is a local decision whether this is recorded as 'Definite 
infarction' or 'Threatened infarction'. 
 
4 Acute coronary 
syndrome (troponin 
positive)/ NSTEMI 
ACS troponin positive includes all those patients previously 
defined as nSTEMI. There must be symptoms consistent with 
cardiac ischaemia and there will normally be cardiographic 
changes consistent with this diagnosis. Troponon elevation 
above locally determined reference level is mandatory. 
 
7 Myocardial infarction 
(unconfirmed) 
This diagnosis must only be applied to patients who die in 
hospital before biochemical confirmation of infarction can be 
confirmed. 
 
50 MI (NSTEMI) Old code (no longer in use) 
 
51 ACS (troponin 
unspecified)* 
Old code (no longer in use) 
Annex 2 List of codes in the MINAP discharge diagnosis field considered as AMI 
*This code was only considered to denote an AMI when there was separate evidence of a positive 
cardiac marker result 
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10.1.3 ARI codes in GPRD (chapter 5) 
 
Codelist 1 Acute respiratory infection codes with a systemic component 
Medcode Description (Read term) 
68 Chest infection 
312 Acute bronchitis 
556 Influenza 
572 Pneumonia due to unspecified organism 
763 Whooping cough 
886 Bronchopneumonia due to unspecified organism 
1019 Acute bronchiolitis 
1142 Croup 
1257 Acute tracheitis 
1285 Laryngotracheitis 
1382 Acute viral bronchitis unspecified 
1576 Pneumonia due to mycoplasma pneumoniae 
1849 Lobar (pneumococcal) pneumonia 
2157 Flu like illness 
2476 Chest cold 
2581 Chest infection NOS 
3358 Lower resp tract infection 
3683 Basal pneumonia due to unspecified organism 
3842 Bordetella pertussis 
4899 Recurrent chest infection 
5202 Viral pneumonia 
5324 Atypical pneumonia 
5612 Pneumonia due to staphylococcus 
5947 Influenza like illness 
5978 Acute wheezy bronchitis 
6094 Pneumonia or influenza NOS 
6124 Acute lower respiratory tract infection 
7267 Notification of whooping cough 
8318 Lung consolidation 
8980 Influenza-like symptoms 
9043 Acute pneumococcal bronchitis 
9389 Chest infection - viral pneumonia 
9639 Lobar pneumonia due to unspecified organism 
9953 Tuberculous pneumonia 
10086 Pneumonia and influenza 
10087 Acute laryngotracheitis 
10093 Tracheopharyngitis 
11072 Acute purulent bronchitis 
11101 Acute tracheobronchitis 
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11849 Other specified pneumonia or influenza 
12061 Pneumonia - Legionella 
12423 Pneumonia due to streptococcus 
12476 Acute tracheitis without obstruction 
13573 Influenza with bronchopneumonia 
14791 Influenza with gastrointestinal tract involvement 
14976 Viral pneumonia NOS 
15761 Bordetella parapertussis 
15774 Influenza with laryngitis 
15912 Influenza with pneumonia 
16120 Acute laryngitis and tracheitis NOS 
16287 Chest infection - unspecified bronchopneumonia 
16313 Acute tracheitis NOS 
16388 Influenza NOS 
17025 Chlamydial pneumonia 
17185 Acute bronchiolitis with bronchospasm 
17359 Chest infection - unspecified bronchitis 
17917 Acute bronchiolitis NOS 
18451 Acute bronchiolitis due to respiratory syncytial virus 
19400 Chest infection - pnemonia due to unspecified organism 
19431 Croup 
20198 Acute bronchitis NOS 
21061 COPD with acute lower respiratory infection 
21145 Acute croupous bronchitis 
21415 Pharyngotracheitis 
21492 Acute haemophilus influenzae bronchitis 
22009 Streptococ pneumon/cause/disease classified/oth chapters 
22795 Chest infection - other bacterial pneumonia 
22835 Bronchiolitis obliterans organising pneumonia 
23095 Bacterial pneumonia NOS 
23333 Hypostatic pneumonia 
23488 Influenza with respiratory manifestations NOS 
23546 Pneumonia due to klebsiella pneumoniae 
23726 Pneumonia with varicella 
24316 Chest infection with infectious disease EC 
24356 Hypostatic bronchopneumonia 
24471 Acute laryngotracheitis NOS 
24800 Acute bacterial bronchitis unspecified 
25259 Acute laryngotracheitis without obstruction 
25462 Varicella pneumonitis 
25694 Pneumonia due to other specified organisms 
27519 Pneumonia with pneumocystis carinii 
27641 HIV disease resulting in Pneumocystis carinii pneumonia 
28634 Other bacterial pneumonia 
29166 Chest infection - pneumococcal pneumonia 
29273 Acute bronchitis due to parainfluenza virus 
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29457 Chest infection - influenza with pneumonia 
29617 Influenza with pharyngitis 
29669 Acute bronchitis and bronchiolitis 
30437 Pneumonia with whooping cough 
30509 Post operative chest infection 
30591 Pneumonia due to pseudomonas 
30653 Chest infection - pneumonia organism OS 
31024 Mycoplasma pneumoniae [PPLO] cause/dis classifd/oth chaptr 
31269 Pneumonia due to respiratory syncytial virus 
31363 Influenza with other manifestations NOS 
31603 Staphylococcal pleurisy 
31689 Bacterial pleurisy with effusion 
31886 Acute bronchitis due to mycoplasma pneumoniae 
32172 Postmeasles pneumonia 
32818 Pneumococcal pleurisy 
33478 Viral pneumonia NEC 
34251 Pneumonia due to specified organism NOS 
34274 Pneumonia with aspergillosis 
34300 Postoperative pneumonia 
35082 Pneumonia with pertussis 
35189 Abscess of lung with pneumonia 
35220 Pneumocystosis 
35745 Influenza with pneumonia NOS 
36675 Pneumonia due to parainfluenza virus 
37447 Acute lower respiratory tract infection 
37881 Pneumonia due to haemophilus influenzae 
40299 Pneumonia - candidal 
40498 Pneumonia with infectious diseases EC 
41034 Pneumonia with measles 
41137 Acute bronchitis or bronchiolitis NOS 
41324 Acute laryngitis and tracheitis 
41404 Primary pulmonary blastomycosis 
42548 Whooping cough NOS 
43286 Pneumonia with cytomegalic inclusion disease 
43345 Pneumococcal pleurisy with effusion 
43362 Acute streptococcal bronchitis 
43625 Influenza with other respiratory manifestation 
43884 Pneumonia due to bacteria NOS 
44842 Bacterial pleurisy with effusion NOS 
45072 Cytomegaloviral pneumonitis 
45425 Pneumonia due to proteus 
46052 Severe acute respiratory syndrome 
46157 Influenza with encephalopathy 
47295 Pneumonic plague, unspecified 
47472 Influenza with other manifestations 
47973 Herpes simplex pneumonia 
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48593 Acute bronchitis due to respiratory syncytial virus 
48804 Pneumonia due to haemophilus influenzae 
49398 Pneumonia with typhoid fever 
49794 Acute neisseria catarrhalis bronchitis 
50396 Acute fibrinous bronchitis 
50408 Ornithosis with pneumonia 
50867 Pneumonia due to other specified bacteria 
51398 Pleuropneumonia-like organism (PPLO) infection 
52071 Pneumonia with candidiasis 
52384 Pneumonia due to other aerobic gram-negative bacteria 
52520 [X]Other viral pneumonia 
53753 [X]Other pneumonia, organism unspecified 
53897 Whooping cough - other specified organism 
53947 [X]Pneumonia in viral diseases classified elsewhere 
53969 Pneumonia with systemic mycosis NOS 
54533 Acute capillary bronchiolitis 
54540 Primary pulmonary coccidioidomycosis 
54906 Pulmonary cryptococcosis 
55646 Acute myocarditis - influenzal 
56762 Toxoplasma pneumonitis 
57667 Gangrenous pneumonia 
58896 Salmonella pneumonia 
59951 Pulmonary histoplasmosis 
60119 Pneumonia due to Eaton's agent 
60299 E.coli pneumonia 
60482 Pneumonia with Q-fever 
61359 Eaton's agent infection 
61623 Pneumonia with actinomycosis 
62623 Pneumonia with ornithosis 
62632 Influenza with pneumonia, influenza virus identified 
63697 Avian influenza virus nucleic acid detection 
63763 [X]Other bacterial pneumonia 
63858 Pneumonia due to streptococcus, group B 
64286 Other whooping cough NOS 
64306 Pulmonary actinomycosis 
64890 Acute bronchitis due to rhinovirus 
65419 Pneumonia due to escherichia coli 
65916 Acute bronchitis due to echovirus 
66228 Acute bronchiolitis due to other specified organisms 
66362 Pneumonia with infectious diseases EC NOS 
66397 [X]Other acute lower respiratory infections 
67836 Pneumonia due to adenovirus 
67901 Pneumonia with nocardiasis 
68867 Acute tracheitis with obstruction 
69192 Acute exudative bronchiolitis 
69352 Streptococcal pleurisy 
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69782 Pneumonia with other infectious diseases EC 
69898 Acute laryngotracheitis with obstruction 
70559 Pneumonia with other infectious diseases EC NOS 
70710 Primary pneumonic plague 
71370 Acute pseudomembranous bronchitis 
72182 Pneumonia with salmonellosis 
73100 [X]Acute bronchitis due to other specified organisms 
73340 Pulmonary nocardiosis 
73735 Pneumonia due to pleuropneumonia like organisms 
91123 Parainfluenza type 3 nucleic acid detection 
91481 Acute pulmonary histoplasmosis capsulati 
93010 Staphylococcal pleurisy with effusion 
93153 Acute bronchitis due to coxsackievirus 
94130 Parainfluenza type 1 nucleic acid detection 
94858 Parainfluenza type 2 nucleic acid detection 
94930 Avian influenza 
96017 Influenza B virus detected 
96018 Influenza H3 virus detected 
96019 Influenza H1 virus detected 
96059 Mycoplasma pneumoniae detected 
96286 Human parainfluenza virus detected 
97062 Influenza A virus, other or untyped strain detected 
97279 [X]Influenza+other manifestations, virus not identified 
97605 [X]Influenza+oth respiratory manifestatns,virus not identifd 
97936 [X]Influenza+other manifestations,influenza virus identified 
98102 Influenza A (H1N1) swine flu 
98103 Possible influenza A virus H1N1 subtype 
98115 Suspected swine influenza 
98125 Suspected influenza A virus subtype H1N1 infection 
98129 Influenza due to Influenza A virus subtype H1N1 
98143 Influenza A virus H1N1 subtype detected 
98156 Influenza H5 virus detected 
98257 [X]Flu+oth respiratory manifestations,'flu virus identified 
98381 [X]Pneumonia due to other specified infectious organisms 
98782 Pneumonia with toxoplasmosis 
99214 [X]Acute bronchiolitis due to other specified organisms 
100943 [X]Whooping cough, unspecified 
101292 Histoplasma duboisii with pneumonia 
101507 Histoplasma capsulatum with pneumonia 
101775 Acute membranous bronchitis 
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Codelist 2 As list 1 but minus non influenza organism-specific codes (used to 
extract episodes where underlying diagnosis could plausibly be influenza) 
 
Medcode Description (Read term) 
68 Chest infection 
312 Acute bronchitis 
556 Influenza 
572 Pneumonia due to unspecified organism 
886 Bronchopneumonia due to unspecified organism 
1019 Acute bronchiolitis 
1142 Croup 
1257 Acute tracheitis 
1285 Laryngotracheitis 
1382 Acute viral bronchitis unspecified 
2157 Flu like illness 
2476 Chest cold 
2581 Chest infection NOS 
3358 Lower resp tract infection 
3683 Basal pneumonia due to unspecified organism 
4899 Recurrent chest infection 
5202 Viral pneumonia 
5324 Atypical pneumonia 
5947 Influenza like illness 
5978 Acute wheezy bronchitis 
6094 Pneumonia or influenza NOS 
6124 Acute lower respiratory tract infection 
8318 Lung consolidation 
8980 Influenza-like symptoms 
9389 Chest infection - viral pneumonia 
9639 Lobar pneumonia due to unspecified organism 
10086 Pneumonia and influenza 
10087 Acute laryngotracheitis 
10093 Tracheopharyngitis 
11072 Acute purulent bronchitis 
11101 Acute tracheobronchitis 
11849 Other specified pneumonia or influenza 
12476 Acute tracheitis without obstruction 
13573 Influenza with bronchopneumonia 
14791 Influenza with gastrointestinal tract involvement 
14976 Viral pneumonia NOS 
15774 Influenza with laryngitis 
15912 Influenza with pneumonia 
16120 Acute laryngitis and tracheitis NOS 
16287 Chest infection - unspecified bronchopneumonia 
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16313 Acute tracheitis NOS 
16388 Influenza NOS 
17185 Acute bronchiolitis with bronchospasm 
17359 Chest infection - unspecified bronchitis 
17917 Acute bronchiolitis NOS 
19400 Chest infection - pnemonia due to unspecified organism 
19431 Croup 
20198 Acute bronchitis NOS 
21061 Chronic obstruct pulmonary dis with acute lower resp infectn 
21145 Acute croupous bronchitis 
21415 Pharyngotracheitis 
22835 Bronchiolitis obliterans organising pneumonia 
23333 Hypostatic pneumonia 
23488 Influenza with respiratory manifestations NOS 
24316 Chest infection with infectious disease EC 
24356 Hypostatic bronchopneumonia 
24471 Acute laryngotracheitis NOS 
25259 Acute laryngotracheitis without obstruction 
29457 Chest infection - influenza with pneumonia 
29617 Influenza with pharyngitis 
29669 Acute bronchitis and bronchiolitis 
30509 Post operative chest infection 
31363 Influenza with other manifestations NOS 
33478 Viral pneumonia NEC 
34300 Postoperative pneumonia 
35189 Abscess of lung with pneumonia 
35745 Influenza with pneumonia NOS 
37447 Acute lower respiratory tract infection 
40498 Pneumonia with infectious diseases EC 
41137 Acute bronchitis or bronchiolitis NOS 
41324 Acute laryngitis and tracheitis 
43625 Influenza with other respiratory manifestation 
46157 Influenza with encephalopathy 
47472 Influenza with other manifestations 
50396 Acute fibrinous bronchitis 
52520 [X]Other viral pneumonia 
53753 [X]Other pneumonia, organism unspecified 
53947 [X]Pneumonia in viral diseases classified elsewhere 
54533 Acute capillary bronchiolitis 
55646 Acute myocarditis - influenzal 
57667 Gangrenous pneumonia 
62632 Influenza with pneumonia, influenza virus identified 
63697 Avian influenza virus nucleic acid detection 
66362 Pneumonia with infectious diseases EC NOS 
66397 [X]Other acute lower respiratory infections 
68867 Acute tracheitis with obstruction 
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69192 Acute exudative bronchiolitis 
69782 Pneumonia with other infectious diseases EC 
69898 Acute laryngotracheitis with obstruction 
70559 Pneumonia with other infectious diseases EC NOS 
71370 Acute pseudomembranous bronchitis 
94930 Avian influenza 
96017 Influenza B virus detected 
96018 Influenza H3 virus detected 
96019 Influenza H1 virus detected 
97062 Influenza A virus, other or untyped strain detected 
97279 [X]Influenza+other manifestations, virus not identified 
97605 [X]Influenza+oth respiratory manifestatns,virus not identifd 
97936 [X]Influenza+other manifestations,influenza virus identified 
98102 Influenza A (H1N1) swine flu 
98103 Possible influenza A virus H1N1 subtype 
98115 Suspected swine influenza 
98125 Suspected influenza A virus subtype H1N1 infection 
98129 Influenza due to Influenza A virus subtype H1N1 
98143 Influenza A virus H1N1 subtype detected 
98156 Influenza H5 virus detected 
98257 [X]Flu+oth respiratory manifestations,'flu virus identified 
101775 Acute membranous bronchitis 
 
Codelist 3 Influenza-like illness codes 
Medcode Description (Read term) 
556 Influenza 
2157 Flu like illness 
5947 Influenza like illness 
6094 Pneumonia or influenza NOS 
8980 Influenza-like symptoms 
11849 Other specified pneumonia or influenza 
13573 Influenza with bronchopneumonia 
14791 Influenza with gastrointestinal tract involvement 
15774 Influenza with laryngitis 
15912 Influenza with pneumonia 
16388 Influenza NOS 
23488 Influenza with respiratory manifestations NOS 
29457 Chest infection - influenza with pneumonia 
29617 Influenza with pharyngitis 
31363 Influenza with other manifestations NOS 
35745 Influenza with pneumonia NOS 
43625 Influenza with other respiratory manifestation 
46157 Influenza with encephalopathy 
47472 Influenza with other manifestations 
55646 Acute myocarditis - influenzal 
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62632 Influenza with pneumonia, influenza virus identified 
63697 Avian influenza virus nucleic acid detection 
94930 Avian influenza 
96017 Influenza B virus detected 
96018 Influenza H3 virus detected 
96019 Influenza H1 virus detected 
97062 Influenza A virus, other or untyped strain detected 
97279 [X]Influenza+other manifestations, virus not identified 
97605 [X]Influenza+oth respiratory manifestatns,virus not identifd 
97936 [X]Influenza+other manifestations,influenza virus identified 
98102 Influenza A (H1N1) swine flu 
98103 Possible influenza A virus H1N1 subtype 
98115 Suspected swine influenza 
98125 Suspected influenza A virus subtype H1N1 infection 
98129 Influenza due to Influenza A virus subtype H1N1 
98143 Influenza A virus H1N1 subtype detected 
98156 Influenza H5 virus detected 
98257 [X]Flu+oth respiratory manifestations,'flu virus identified 
 
Codelist 4 As list 1 but minus influenza-like illness codes (for comparison with 
list 3) 
 
Medcode Description (Read term) 
68 Chest infection 
312 Acute bronchitis 
572 Pneumonia due to unspecified organism 
763 Whooping cough 
886 Bronchopneumonia due to unspecified organism 
1019 Acute bronchiolitis 
1142 Croup 
1257 Acute tracheitis 
1285 Laryngotracheitis 
1382 Acute viral bronchitis unspecified 
1576 Pneumonia due to mycoplasma pneumoniae 
1849 Lobar (pneumococcal) pneumonia 
2476 Chest cold 
2581 Chest infection NOS 
3358 Lower resp tract infection 
3683 Basal pneumonia due to unspecified organism 
3842 Bordetella pertussis 
4899 Recurrent chest infection 
5202 Viral pneumonia 
5324 Atypical pneumonia 
5612 Pneumonia due to staphylococcus 
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5978 Acute wheezy bronchitis 
6124 Acute lower respiratory tract infection 
7267 Notification of whooping cough 
8318 Lung consolidation 
9043 Acute pneumococcal bronchitis 
9389 Chest infection - viral pneumonia 
9639 Lobar pneumonia due to unspecified organism 
9953 Tuberculous pneumonia 
10086 Pneumonia and influenza 
10087 Acute laryngotracheitis 
10093 Tracheopharyngitis 
11072 Acute purulent bronchitis 
11101 Acute tracheobronchitis 
12061 Pneumonia - Legionella 
12423 Pneumonia due to streptococcus 
12476 Acute tracheitis without obstruction 
14976 Viral pneumonia NOS 
15761 Bordetella parapertussis 
16120 Acute laryngitis and tracheitis NOS 
16287 Chest infection - unspecified bronchopneumonia 
16313 Acute tracheitis NOS 
17025 Chlamydial pneumonia 
17185 Acute bronchiolitis with bronchospasm 
17359 Chest infection - unspecified bronchitis 
17917 Acute bronchiolitis NOS 
18451 Acute bronchiolitis due to respiratory syncytial virus 
19400 Chest infection - pnemonia due to unspecified organism 
19431 Croup 
20198 Acute bronchitis NOS 
21061 Chronic obstruct pulmonary dis with acute lower resp infectn 
21145 Acute croupous bronchitis 
21415 Pharyngotracheitis 
21492 Acute haemophilus influenzae bronchitis 
22009 Streptococ pneumon/cause/disease classified/oth chapters 
22795 Chest infection - other bacterial pneumonia 
22835 Bronchiolitis obliterans organising pneumonia 
23095 Bacterial pneumonia NOS 
23333 Hypostatic pneumonia 
23546 Pneumonia due to klebsiella pneumoniae 
23726 Pneumonia with varicella 
24316 Chest infection with infectious disease EC 
24356 Hypostatic bronchopneumonia 
24471 Acute laryngotracheitis NOS 
24800 Acute bacterial bronchitis unspecified 
25259 Acute laryngotracheitis without obstruction 
25462 Varicella pneumonitis 
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25694 Pneumonia due to other specified organisms 
27519 Pneumonia with pneumocystis carinii 
27641 HIV disease resulting in Pneumocystis carinii pneumonia 
28634 Other bacterial pneumonia 
29166 Chest infection - pneumococcal pneumonia 
29273 Acute bronchitis due to parainfluenza virus 
29669 Acute bronchitis and bronchiolitis 
30437 Pneumonia with whooping cough 
30509 Post operative chest infection 
30591 Pneumonia due to pseudomonas 
30653 Chest infection - pneumonia organism OS 
31024 Mycoplasma pneumoniae [PPLO] cause/dis classifd/oth chaptr 
31269 Pneumonia due to respiratory syncytial virus 
31603 Staphylococcal pleurisy 
31689 Bacterial pleurisy with effusion 
31886 Acute bronchitis due to mycoplasma pneumoniae 
32172 Postmeasles pneumonia 
32818 Pneumococcal pleurisy 
33478 Viral pneumonia NEC 
34251 Pneumonia due to specified organism NOS 
34274 Pneumonia with aspergillosis 
34300 Postoperative pneumonia 
35082 Pneumonia with pertussis 
35189 Abscess of lung with pneumonia 
35220 Pneumocystosis 
36675 Pneumonia due to parainfluenza virus 
37447 Acute lower respiratory tract infection 
37881 Pneumonia due to haemophilus influenzae 
40299 Pneumonia - candidal 
40498 Pneumonia with infectious diseases EC 
41034 Pneumonia with measles 
41137 Acute bronchitis or bronchiolitis NOS 
41324 Acute laryngitis and tracheitis 
41404 Primary pulmonary blastomycosis 
42548 Whooping cough NOS 
43286 Pneumonia with cytomegalic inclusion disease 
43345 Pneumococcal pleurisy with effusion 
43362 Acute streptococcal bronchitis 
43884 Pneumonia due to bacteria NOS 
44842 Bacterial pleurisy with effusion NOS 
45072 Cytomegaloviral pneumonitis 
45425 Pneumonia due to proteus 
46052 Severe acute respiratory syndrome 
47295 Pneumonic plague, unspecified 
47973 Herpes simplex pneumonia 
48593 Acute bronchitis due to respiratory syncytial virus 
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48804 Pneumonia due to haemophilus influenzae 
49398 Pneumonia with typhoid fever 
49794 Acute neisseria catarrhalis bronchitis 
50396 Acute fibrinous bronchitis 
50408 Ornithosis with pneumonia 
50867 Pneumonia due to other specified bacteria 
51398 Pleuropneumonia-like organism (PPLO) infection 
52071 Pneumonia with candidiasis 
52384 Pneumonia due to other aerobic gram-negative bacteria 
52520 [X]Other viral pneumonia 
53753 [X]Other pneumonia, organism unspecified 
53897 Whooping cough - other specified organism 
53947 [X]Pneumonia in viral diseases classified elsewhere 
53969 Pneumonia with systemic mycosis NOS 
54533 Acute capillary bronchiolitis 
54540 Primary pulmonary coccidioidomycosis 
54906 Pulmonary cryptococcosis 
56762 Toxoplasma pneumonitis 
57667 Gangrenous pneumonia 
58896 Salmonella pneumonia 
59951 Pulmonary histoplasmosis 
60119 Pneumonia due to Eaton's agent 
60299 E.coli pneumonia 
60482 Pneumonia with Q-fever 
61359 Eaton's agent infection 
61623 Pneumonia with actinomycosis 
62623 Pneumonia with ornithosis 
63763 [X]Other bacterial pneumonia 
63858 Pneumonia due to streptococcus, group B 
64286 Other whooping cough NOS 
64306 Pulmonary actinomycosis 
64890 Acute bronchitis due to rhinovirus 
65419 Pneumonia due to escherichia coli 
65916 Acute bronchitis due to echovirus 
66228 Acute bronchiolitis due to other specified organisms 
66362 Pneumonia with infectious diseases EC NOS 
66397 [X]Other acute lower respiratory infections 
67836 Pneumonia due to adenovirus 
67901 Pneumonia with nocardiasis 
68867 Acute tracheitis with obstruction 
69192 Acute exudative bronchiolitis 
69352 Streptococcal pleurisy 
69782 Pneumonia with other infectious diseases EC 
69898 Acute laryngotracheitis with obstruction 
70559 Pneumonia with other infectious diseases EC NOS 
70710 Primary pneumonic plague 
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71370 Acute pseudomembranous bronchitis 
72182 Pneumonia with salmonellosis 
73100 [X]Acute bronchitis due to other specified organisms 
73340 Pulmonary nocardiosis 
73735 Pneumonia due to pleuropneumonia like organisms 
91123 Parainfluenza type 3 nucleic acid detection 
91481 Acute pulmonary histoplasmosis capsulati 
93010 Staphylococcal pleurisy with effusion 
93153 Acute bronchitis due to coxsackievirus 
94130 Parainfluenza type 1 nucleic acid detection 
94858 Parainfluenza type 2 nucleic acid detection 
96059 Mycoplasma pneumoniae detected 
96286 Human parainfluenza virus detected 
98381 [X]Pneumonia due to other specified infectious organisms 
98782 Pneumonia with toxoplasmosis 
99214 [X]Acute bronchiolitis due to other specified organisms 
100943 [X]Whooping cough, unspecified 
101292 Histoplasma duboisii with pneumonia 
101507 Histoplasma capsulatum with pneumonia 
101775 Acute membranous bronchitis 
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10.1.4 Participant information sheet and consent form (chapter 6) 
 
Example participant information sheet (cases) 
 
      
 
Study title: The role of influenza as a trigger for acute myocardial infarction 
(heart attack) 
 
We would like to invite you to take part in a research study, which is being 
done by Dr Charlotte Warren-Gash as part of a PhD.  Before you decide, you 
need to understand why the research is being done and what it would involve 
for you. Please take time to read the following information carefully. Talk to 
others about the study if you wish. Ask us if there is anything that is not clear 
or if you would like more information. Take time to decide whether or not you 
wish to take part. 
 
What is the purpose of the study? 
We are interested in whether infections such as influenza (flu) can trigger heart 
attacks.  Some research suggests that recent infections are more common in 
people who have had heart attacks. If true, this would help healthcare 
professionals to reduce the risk of heart attacks by vaccinating people against 
infections or treating infections promptly when they do occur. 
 
Why have I been invited to take part? 
You have been invited to take part because you have had a heart attack. The 
research team aims to compare the recent experience of infections in people 
who have had heart attacks compared to people who have not had a heart 
attack.  
 
Do I have to take part? 
It is up to you to decide. We will describe the study and answer any questions 
that you might have after reading this information sheet. If you agree to take 
part we will then ask you to sign a consent form. You are free to withdraw at 
any time, without giving a reason. This would not affect the quality of care you 
receive. 
 
What will happen to me if I take part? 
If you take part, the study will involve the following: 
 
1) A short interview with the researcher, which should take no more than 
10 minutes.  Questions will be asked about recent cough, sore throat or 
other symptoms of infection, whether you have had a flu vaccination 
and some questions about your medical history eg. whether you have 
diabetes.  
 
2) A nasal swab to check for influenza virus.   
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3) A blood test to check for influenza antibodies and for signs of 
inflammation.   
 
4) Giving the researcher permission to look in your medical records to find 
out more about your heart attack eg. what treatment you have had. 
 
5) For some people who are due to come back to clinic, we will ask 
whether you would mind having a second blood test then (to do a 
different test for influenza antibodies). 
 
We will also ask your permission to store your blood sample (whether or not it 
is positive for influenza) for possible future research into heart attacks or 
influenza and other respiratory infections.  
 
PTO 
What are the possible disadvantages and risks of taking part? 
There are few risks to taking part in this study. Taking time to answer 
questions on recent symptoms of infection might be slightly inconvenient, but 
the interview should last no more than 10 minutes. Having an extra blood test 
taken might be slightly uncomfortable. However if possible we will aim to take 
this blood sample at the same time as your normal blood tests to minimise 
inconvenience. 
 
What are the possible benefits of taking part? 
We cannot promise that the study will help you, but information we get from 
this study may help to prevent others from having heart attacks in future. 
 
Will my taking part in the study be kept confidential? 
All information which is collected about you during the course of the research 
will be kept strictly confidential. You will be given a unique ‘participant 
identification number’.  Answers to your interview questions, blood test results 
and any information collected from your medical records will be stored under 
that number. You will not be identifiable when results of the study are 
published. 
 
What will happen if I don’t want to carry on with the study? 
You are free to withdraw at any time. If you do withdraw from the study, we will 
destroy all your identifiable samples, but we will need to use data collected up 
to your withdrawal. 
 
What if there is a problem? 
If you have a concern about any aspect of this study, you should ask to speak 
to the researchers who will do their best to answer your questions. If you 
remain unhappy and wish to complain formally, you can do this through the 
NHS Complaints Procedure. Details can be obtained from the hospital. 
 
What will happen to the results of the research study?  
We plan to write to each participant to give them the results of their antibody 
tests for flu.  If the results show that you have had flu, this will not require any 
medical treatment. We can also provide you with a short summary of findings 
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from the study.  We hope to publish the results of this study in a scientific 
journal.    
 
Further information and contact details 
Chief investigator: Dr Charlotte Warren-Gash, MRC Clinical Research Training 
Fellow, UCL Centre for Infectious Disease Epidemiology.  
E-mail: c.warren-gash@pcps.ucl.ac.uk   Tel: 020 7830 2239 x36720 
 
Supervisors: Dr Andrew Hayward, Senior Lecturer in Infectious Disease 
Epidemiology, UCL and Professor Liam Smeeth, Professor of Epidemiology, 
London School of Hygiene & Tropical Medicine 
 
Collaborators: Dr Anna Maria Geretti, Consultant Virologist; Professor George 
Hamilton, Professor of Vascular Surgery and Dr Roby Rakhit, Consultant 
Cardiologist (all at the Royal Free Hospital). 
 
If you would like a large print or audio version of this 
information, please ask a member of staff. 
 
© UCL Centre for Infectious Disease Epidemiology 2009 
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Study Number: 7848 
 
CONSENT FORM  
 
Title of Project: The role of influenza as a trigger for acute myocardial infarction 
(heart attack) 
 
Name of Researcher: Dr Charlotte Warren-Gash/ Dr Andrew Hayward 
 
 
Please initial box  
 
 
1. I confirm that I have read and understand the information sheet dated 04-
08-09 (version 3) for the above study.   I have had the opportunity to consider 
the information, ask questions and have had these answered satisfactorily.  
 
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving any reason, without my medical care or legal rights 
being affected.  
 
3. I understand that relevant sections of my medical notes may be looked at by 
the researcher. I give permission for the researcher to have access to my 
records.   
 
4. I agree to my blood sample being stored for possible future research into 
heart attacks or influenza and other respiratory infections  
 
 
5. I agree to take part in the above study. 
 
 
 
 
___________________ ________________ ___________________  
Name of Participant                Date                        Signature  
 
 
___________________ ________________ ___________________  
Name of Person                     Date                        Signature  
taking consent  
 
 
When completed, 1 for participant; 1 for researcher site file; 1 (original) to be 
kept in medical notes  
 
 
